CH617774A5 - - Google Patents

Download PDF

Info

Publication number
CH617774A5
CH617774A5 CH1621671A CH1621671A CH617774A5 CH 617774 A5 CH617774 A5 CH 617774A5 CH 1621671 A CH1621671 A CH 1621671A CH 1621671 A CH1621671 A CH 1621671A CH 617774 A5 CH617774 A5 CH 617774A5
Authority
CH
Switzerland
Prior art keywords
enzyme
cellulose
added
determination
testosterone
Prior art date
Application number
CH1621671A
Other languages
German (de)
Inventor
Antonius Hermanus W M Schuurs
Bauke Klaas Van Weemen
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of CH617774A5 publication Critical patent/CH617774A5/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/964Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808Automated or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Description

617 774 617 774

2 2nd

PATENTANSPRÜCHE PATENT CLAIMS

1. Verfahren zur qualitativen und quantitativen Bestimmung von einem Hapten oder einem entsprechenden Antikörper, dadurch gekennzeichnet, dass man einer Flüssigkeitsprobe, welche die zu bestimmende Verbindungen enthält, eine vorbestimmte, bekannte Menge des Kupplungsproduktes des Haptens mit einem Enzym und eine vorbestimmte, bekannte Menge des Haptens bzw. dessen Antikörpers in Form eines unlöslichen Präparates zusetzt, wobei eine Reaktion des Haptens mit dem Antikörper stattfindet, worauf die flüssige Phase von der festen Phase getrennt wird und die Enzymaktivität in einer dieser Phasen qualitativ bestimmt wird, welche Aktivität ein Mass für die Menge der zu bestimmenden Verbindung ist. 1. A method for the qualitative and quantitative determination of a hapten or a corresponding antibody, characterized in that a liquid sample containing the compounds to be determined, a predetermined, known amount of the coupling product of the hapten with an enzyme and a predetermined, known amount of Haptens or its antibody is added in the form of an insoluble preparation, a reaction of the hapten with the antibody taking place, whereupon the liquid phase is separated from the solid phase and the enzyme activity in one of these phases is qualitatively determined, which activity is a measure of the amount the connection to be determined.

2. Verfahren nach Patentanspruch 1, dadurch gekennzeichnet, dass das Hapten ein Vitamin oder Hormon ist. 2. The method according to claim 1, characterized in that the hapten is a vitamin or hormone.

3. Verfahren nach Patentanspruch 1 oder 2, dadurch gekennzeichnet, dass eine Oxidoreduktase als Enzym verwendet wird. 3. The method according to claim 1 or 2, characterized in that an oxidoreductase is used as an enzyme.

4. Testpackung zur Durchführung des Verfahrens nach Patentanspruch 1, gekennzeichnet durch einen Gehalt an 4. Test pack for performing the method according to claim 1, characterized by a content of

(a) einer vorbestimmten Menge des Kupplungsproduktes des Haptens mit einem Enzym, (a) a predetermined amount of the coupling product of the hapten with an enzyme,

(b) einer vorbestimmten Menge einer Kompomente des Reaktionssystems in unlöslicher Form, (b) a predetermined amount of components of the reaction system in insoluble form,

(c) einem Substrat zur Bestimmung der Aktivität des verwendeten Enzyms. (c) a substrate for determining the activity of the enzyme used.

Zum Nachweis und zur Bestimmung niedermolekularer Substanzen, die in geringen Konzentrationen vorliegen, wie Steroidhormonen in Körperflüssigkeiten, wurden Verfahren entwickelt, bei denen Proteine verwendet werden, die fähig sind, die nachzuweisende Substanz spezifisch zu binden. Diese Verfahren beruhen auf der Konkurrenz zwischen der nachzuweisenden Substanz in der Probe und einer bekannten Menge dergleichen Substanz, die radioaktiv markiert ist, mit einer begrenzten Menge des spezifischen bindenden Proteins. Durch die unbekannte Menge der bindungsfähigen Substanz wird bestimmt, welcher Anteil der radioaktiv markierten Substanz an das spezifische bindende Protein gebunden wird. For the detection and determination of low-molecular substances, which are present in low concentrations, such as steroid hormones in body fluids, methods have been developed which use proteins which are capable of specifically binding the substance to be detected. These methods rely on competition between the substance to be detected in the sample and a known amount of the same substance, which is radiolabelled, with a limited amount of the specific binding protein. The unknown amount of the bindable substance determines which portion of the radioactively labeled substance is bound to the specific binding protein.

Es ist auch möglich, mit Hilfe dieser Verfahren, eine unbekannte Menge eines spezifischen bindende Proteins durch Umsetzung einer Probe, die eine unbekannte Menge des spezifischen bindenden Proteins enthält, mit einer bestimmten Menge einer bindungsfähigen radioaktiv markierten Substanz zu bestimmen. It is also possible to use these methods to determine an unknown amount of a specific binding protein by reacting a sample containing an unknown amount of the specific binding protein with a certain amount of a bindable radiolabeled substance.

In der Literatur ist es üblich, diese Bestimmungsverfahren je nach der Art des verwendeten spezifischen bindenden Proteins < zu unterscheiden, obwohl das grundlegende Prinzip all dieser Bestimmungen das gleiche ist. So wird z.B. von «konkurrierenden Protein-Bindungsversuchen» («competitive protein binding assays») gesprochen, wenn Rezeptor- oder Transportproteine verwendet werden, die im Körper vorkommen und von «radio- 5 immunologischen Bestimmungen», wenn Antisubstanzen verwendet werden. It is common in the literature to distinguish these methods of determination depending on the type of specific binding protein used, although the basic principle of all of these determinations is the same. For example, spoken of “competitive protein binding assays” when using receptor or transport proteins that are found in the body and “radio-immunological determinations” when using anti-substances.

Für beide Arten von Bestimmungen sind radioaktiv markierte Substanzen erforderlich. Das Arbeiten mit diesen Substanzen erfordert das Vorhandensein präziser Messvorrichtun- ( gen, gut ausgerüstete Laboratorien und ein qualifiziertes Personal. Diese hohen Anforderungen machen eine allgemeine Anwendung dieser Bestimmungsverfahren besonders in kleineren Laboratorien unmöglich. Radioactively labeled substances are required for both types of determinations. Working with these substances requires the presence of precise measuring devices (well-equipped laboratories and qualified personnel). These high requirements make it impossible to use these determination methods in general, especially in smaller laboratories.

Es wurde nun ein Verfahren gefunden zur qualitativen und quantitativen Bestimmung von einem Hapten oder einem entsprechenden Antikörper. Haptene können als eine spezielle Gruppe niedermolekularer Verbindungen betrachtet werden. A method has now been found for the qualitative and quantitative determination of a hapten or a corresponding antibody. Haptens can be viewed as a special group of small molecules.

Haptene und ihre Antikörper treten meist in geringen Konzentrationen auf. Nach der Definition von K. Landsteiner sind Haptene proteinfreie Substanzen, deren chemische Konfiguration so ist, dass sie nicht mit spezifischen Antikörpern reagieren ■- können, jedoch auch nicht so, dass sie zur Bildung von Antikörpern führen können. Um jedoch trotzdem Antikörper zu Haptenen bilden zu können, müssen die Haptene, bevor sie dem Testtier injiziert werden, an Polypeptide gekuppelt werden. Bei der Bestimmung einer niedermolekularen Verbindung konkur-I» deren die zu bestimmende Substanz und deren Kupplungsprodukt mit einem Enzyn um eine bestimmte Menge des unlöslichen spezifisch bindenden Proteins. Je mehr der niedermolekularen Verbindung die Probe enthält, um so geringer ist die Chance für das Kopplungsprodukt aus dem löslichen Enzym i * und der Verbindung, sich mit dem unlöslichen spezifischen bindenden Protein zu verbinden und um so mehr des Kopplungsproduktes bleibt in der flüssigen Phase zurück, in der die Enzymaktivität auf einfache Weise gemessen werden kann. Haptens and their antibodies mostly occur in low concentrations. According to the definition by K. Landsteiner, haptens are protein-free substances whose chemical configuration is such that they cannot react with specific antibodies, but also not so that they can lead to the formation of antibodies. However, in order to still be able to form antibodies to haptens, the haptens must be coupled to polypeptides before they are injected into the test animal. When determining a low molecular weight compound konkur-I »its the substance to be determined and its coupling product with an enzyme for a certain amount of the insoluble specific binding protein. The more of the low-molecular compound the sample contains, the less the chance for the coupling product from the soluble enzyme i * and the compound to combine with the insoluble specific binding protein and the more of the coupling product remains in the liquid phase, in which the enzyme activity can be measured easily.

Das Verfahren ist dadurch gekennzeichnet, dass man einer Flüssigkeitsprobe, welche die zu bestimmende Verbindungen enthält, eine vorbestimmte, bekannte Menge des Kupplungsproduktes des Haptens mit einem Enzym und eine vorbestimmte, bekannte Menge des Haptens bzw. dessen Antikörpers in Form eines unlöslichen Präparates zusetzt, wobei eine Reaktion des Haptens mit dem Antikörper stattfindet, worauf die flüssige Phase von der festen Phase getrennt wird und die Enzymaktivität in einer dieser Phasen qualitativ oder quantitativ bestimmt wird, welche Aktivität ein Mass für die Menge der ,,, zu bestimmenden Verbindung ist. The method is characterized in that a predetermined, known amount of the coupling product of the hapten with an enzyme and a predetermined, known amount of the hapten or its antibody in the form of an insoluble preparation are added to a liquid sample which contains the compounds to be determined, whereby a reaction of the hapten with the antibody takes place, whereupon the liquid phase is separated from the solid phase and the enzyme activity in one of these phases is determined qualitatively or quantitatively, which activity is a measure of the amount of the compound to be determined.

Bei der Bestimmung eines spezifischen bindenden Proteins mit den gleichen Reagenzien treten das zu bestimmende lösliche Protein und das unlösliche Protein in Konkurrenz, um eine bestimmte Menge des Kopplungsproduktes des Haptens mit dem Enzym zu bilden. Wenn der Gehalt an spezifischem bindenden Protein in der Probe höher ist wird das unlösliche Protein weniger von dem Enzym-Kopplungsprodukt binden und folglich bleibt mehr Enzym in der flüssigen Phase zurück. When determining a specific binding protein with the same reagents, the soluble protein to be determined and the insoluble protein compete to form a certain amount of the coupling product of the hapten with the enzyme. If the level of specific binding protein in the sample is higher, the insoluble protein will bind less of the enzyme coupling product and, consequently, more enzyme will remain in the liquid phase.

Ein spezifisches bindendes Protein mit zwei oder mehr bindenden Stellen kann ebenfalls nach dem erfindungsgemässen Verfahren nachgewiesen und bestimmt werden, d.h. mit dem Enzym-Kopplungsprodukt und dem Haptenpräparat in unlöslicher Form. Die flüssige Phase des Reaktionsgemisches kann dann das Kopplungsprodukt an das spezifische bindende Protein gebunden enthalten und in der festen Phase kann der Komplex aus Enzym-Kopplungsprodukt und spezifischem bindenden Protein und dem in Wasser unlöslichen Haptenpräparat enthalten sein. Je mehr des zu bestimmenden Proteins in der Probe enthalten ist, umso mehr Enzymaktivität besitzt die flüs-50 sige Phase. A specific binding protein with two or more binding sites can also be detected and determined by the method according to the invention, i.e. with the enzyme coupling product and the hapten preparation in insoluble form. The liquid phase of the reaction mixture can then contain the coupling product bound to the specific binding protein and the complex of the enzyme coupling product and specific binding protein and the water-insoluble hapten preparation can be contained in the solid phase. The more of the protein to be determined is contained in the sample, the more enzyme activity the liquid phase has.

Mit Hilfe einer Bestimmungskurve für ein bestimmtes System, bei dem der zunehmende Gehalt an der zu bestimmenden Substanz gegen die gefundene Enzymaktivität, vorzugsweise in der flüssigen Phase, aufgetragen ist, kann die Menge 55 der in der Probe enthaltenen zu bestimmenden Substanz für den gefundenen Wert für die Enzymaktivität abgelesen werden. With the aid of a determination curve for a specific system, in which the increasing content of the substance to be determined is plotted against the enzyme activity found, preferably in the liquid phase, the amount 55 of the substance to be determined contained in the sample can be determined for the value found for the enzyme activity can be read.

Das wichtigste Reagens für dieses Bestimmungsverfahren ist das Kopplungsprodukt aus dem Hapten und einem Enzym, im folgenden auch Enzym-Kopplumgsprodukt genannt, das einer-seits mit dem spezifischen bindenden Protein über die Hapten-komponente reagieren kann und andererseits Enzymaktivität besitzt. Dieses Reagens kann nach einem für ähnliche Produkte beschriebenen Verfahren hergestellt werden. Das zweite Reagens, die unlösliche Komponente in dem Reaktionssystem dient (,5 zur Erleichterung der Trennung der verschiedenen enzymhalti-gen Fraktionen des Reaktionsgemisches. Die Zugabe dieses Reagens führt zur Bildung einer festen Phase neben einer flüssigen Phase. The most important reagent for this determination method is the coupling product from the hapten and an enzyme, hereinafter also called enzyme coupling product, which on the one hand can react with the specific binding protein via the hapten component and on the other hand has enzyme activity. This reagent can be prepared by a method described for similar products. The second reagent, the insoluble component in the reaction system, serves to facilitate the separation of the various enzyme-containing fractions of the reaction mixture. The addition of this reagent leads to the formation of a solid phase in addition to a liquid phase.

3 3rd

617 774 617 774

Die Enzymaktivität einer Fraktion des Reaktionsgemisches wird im allgemeinen gezeigt oder gemessen, indem diese Fraktion mit einem Substrat und anderen Substanzen zur Durchführung einer Enzymreaktion inkubiert wird. Vorzugsweise wird eine Reaktion angewandt, bei der eine gegärbte Verbindung gebildet oder entfernt wird, deren Absorption auch leicht quantitativ gemessen werden kann. The enzyme activity of a fraction of the reaction mixture is generally shown or measured by incubating that fraction with a substrate and other substances to carry out an enzyme reaction. A reaction is preferably used in which a colored compound is formed or removed, the absorption of which can also be easily measured quantitatively.

Niedermolekulare Substanzen, die nach dem neuen Verfahren nachgewiesen werden können und ein Molekulargewicht bis zu ungefähr 1500 besitzen, sind zum Beispiel Steroide, Vitamin B12, Folinsäure, Thyroxin und Trijodothyronin, releasing fac-tors, Histamin, Serotonin und andere biogene Amine, Digoxin, Digitoxin, Prostaglandine, Adrenalin, Nor-Adrenalin, pflanzliche Hormone, wie Auxin, Kinetin, Giberellinsäure und Antibiotika, wie Penicillin. Low molecular weight substances that can be detected using the new method and have a molecular weight of up to approximately 1500 are, for example, steroids, vitamin B12, folinic acid, thyroxine and triiodothyronine, releasing factors, histamine, serotonin and other biogenic amines, digoxin, digitoxin , Prostaglandins, adrenaline, nor-adrenaline, herbal hormones such as auxin, kinetin, giberellic acid and antibiotics such as penicillin.

Das Verfahren zum Nachweis spezifischer bindender Proteine für niedermolekulare Substanzen kann angewandt werden, z.B. zur Bestimmung von Antigenen gegen Penicillin oder zur Bestimmung des Intrinsik-Faktors. The method for the detection of specific binding proteins for low molecular weight substances can be used, e.g. for the determination of antigens against penicillin or for the determination of the intrinsic factor.

Die Herstellung von Kopplungsprodukten von Enzymen und Haptenen kann auf verschiedene Weise durchgeführt werden. Einige niedermolekulare Substanzen können schon Gruppen besitzen, die mit reaktionsfähigen Gruppen an der Oberfläche des Enzyms vernetzt werden können, während andere Substanzen erst derartige Gruppen durch chemische Reaktionen erhalten müssen. Es ist selbstverständlich, dass die ursprünglichen Bindungseigenschaften der niedermolekularen Verbindung und die Aktivität des Enzyms während dieses Verfahrens nicht wesentlich geändert werden können. Die Gruppen des Enzyms, die besonders geeignet sind für Kopplungsreaktionen sind Amino- und Carboxylgruppen. Wenn die modifizierte oder nicht-modifizierte niedermolekulare Substanz ebenfalls derartige Gruppen besitzt, kann die Kopplung z.B. durch Reaktionen, wie sie aus der Peptidsynthese bekannt sind, durchgeführt werden. Darüberhinaus können solche Substanzen, wie Glu-taraldehyd,Difluordinitrodiphenylsulfon,Tolui!diisocyanat, Di-und Trichlor-s-triazin für Kopplungsreaktion verwendet werden. The production of coupling products of enzymes and haptens can be carried out in various ways. Some low molecular weight substances can already have groups which can be crosslinked with reactive groups on the surface of the enzyme, while other substances first have to obtain such groups through chemical reactions. It goes without saying that the original binding properties of the low molecular compound and the activity of the enzyme cannot be changed significantly during this process. The groups of the enzyme that are particularly suitable for coupling reactions are amino and carboxyl groups. If the modified or unmodified low molecular weight substance also has such groups, the coupling e.g. by reactions as are known from peptide synthesis. In addition, such substances as glu-taraldehyde, difluoronitrodiphenyl sulfone, tolui diisocyanate, di- and trichloro-s-triazine can be used for the coupling reaction.

Spezielle Beispiele für die Kopplung von Haptenen mit Proteinen sind z.B. in Methods in Immunology and Immuno-chemistry, Band 1, beschrieben. Die dort beschriebenen Verfahren werden angewandt zur Herstellung von Kopplungsprodukten zur Immunisierung sie können jedoch auch zur Herstellung von Kopplungsprokukten der Haptene und eines Enzyms angewand werden, die für das erfindungsgemässe Verfahren wichtig sind. Specific examples of the coupling of haptens with proteins are e.g. in Methods in Immunology and Immuno-chemistry, Volume 1. The methods described there are used for the production of coupling products for immunization, but they can also be used for the production of coupling products of the haptens and an enzyme which are important for the method according to the invention.

Die Wahl des Enzyms, das eine Komponente für das Kopplungssystem (Hapten und Enzym) ist, hängt ab von Eigenschaften wie der spezifischen Aktivität (eine hohe Umwandlungsrate vergrössert die Empfindlichkeit des Testsystems) und der Einfachheit der Bestimmung des Enzyms. Die Bestimmung eines Enzyms, das eine Umwandlung katalysiert, bei der gefärbte Produkte entstehen oder verschwinden, ist einfach. Derartige colorimetrische Bestimmungen können auf einfache Weise automatisiert werden. The choice of the enzyme, which is a component for the coupling system (hapten and enzyme), depends on properties such as the specific activity (a high conversion rate increases the sensitivity of the test system) and the ease of determination of the enzyme. Determining an enzyme that catalyzes a conversion in which colored products form or disappear is easy. Such colorimetric determinations can be automated easily.

Es ist auch möglich, Enzyme zu verwenden, die Umwandlungen katalysieren, bei denen Komponenten auftreten oder verschwinden, die spektrophotometrisch oder fluorimetrisch bestimmt werden können. Diese Bestimmungen können ebenfalls automatisiert werden. It is also possible to use enzymes that catalyze transformations in which components occur or disappear, which can be determined spectrophotometrically or fluorimetrically. These provisions can also be automated.

Für die Herstellung der Kopplungsprodukte werden Enzyme, wie Katalase, Peroxidase, ß-Glukuronidase, ß-D-Glo-kosidase, ß-D-Galactosidase, Urease, Glukoseoxidase und Galactoseoxidase bevorzugt, besonders die Gruppe der Oxido-reduktasen. For the production of the coupling products, enzymes such as catalase, peroxidase, β-glucuronidase, β-D-glocosidase, β-D-galactosidase, urease, glucose oxidase and galactose oxidase are preferred, especially the group of oxido-reductases.

Das unlösliche Haptenpräparat, das im erfindungsgemässen Verfahren verwendet wird, kann auf bekannte Weise, z.B. The insoluble hapten preparation used in the process according to the invention can be used in a known manner, e.g.

durch Vernetzung mit Chlorameisensäureäthylester, durch kovalente Bindung mit unlöslichen Trägern, wie Agarose, Vernetzung mit Dextran oder Filterpapier oder durch physikalische Kopplung an unlösliche Träger, wie Kunststoffe, hergestellt s werden. by crosslinking with ethyl chloroformate, by covalent bonding with insoluble carriers, such as agarose, crosslinking with dextran or filter paper, or by physical coupling to insoluble carriers, such as plastics.

Die Form, in der die Reagenzien verwendet werden können, ist vielfältig. Die Komponente des Reaktionssystems, die mit einem Enzym gekoppelt ist, kann gefriergetrocknet oder in einem Puffer gelöst sein. Darüber hinaus kann ein festerTräger, z.B. ein Papierstreifen, der mit dem Kopplungsprodukt imprägniert ist, verwendet werden. The form in which the reagents can be used is varied. The component of the reaction system that is coupled to an enzyme can be freeze-dried or dissolved in a buffer. In addition, a solid support, e.g. a paper strip impregnated with the coupling product can be used.

Das unlösliche Präparat kann in Form von Teilchen verschiedener Form, wie Körper, Kugeln und Stäbchen oder in ]s Form eines Streifens des einen oder anderen Trägermaterials gebracht werden. The insoluble preparation can be brought in the form of particles of various shapes, such as bodies, spheres and rods or in the form of a strip of one or the other carrier material.

Zur Durchführung des erfindungsgemässen Verfahrens wird vorzugsweise eine Testpackung verwendet, die gekennzeichnet ist durch einen Gehalt an A test pack, which is characterized by a content of, is preferably used to carry out the method according to the invention

(a) einer vorbestimmten Menge des Kopplungsproduktes des Haptens mit einem Enzym; (a) a predetermined amount of the coupling product of the hapten with an enzyme;

(b) einer vorbestimmten Menge einer der Komponenten des Reaktionssystems in unlöslicher Form; (b) a predetermined amount of one of the components of the reaction system in insoluble form;

(c) einem Substrat zur Bestimmung der Aktivität des ver-wendeten Enzyms. (c) a substrate for determining the activity of the enzyme used.

Wenn erwünscht, kann die Testpackung auch die notwendigen Hilfsmittel zur Herstellung einer Verdünnungsreihe der zu untersuchenden Probe für eine quantitative Bestimmung, wie Reagenzgläser, Pipetten und Kolben mit Verdünnungsmittel, 111 enthalten. If desired, the test pack can also contain the necessary aids for the preparation of a dilution series of the sample to be examined for a quantitative determination, such as test tubes, pipettes and flasks with diluent 111.

Beispiel / Example /

Bestimmung von Testosteron Determination of testosterone

A) Hersteilung von Testosteron-3-HRP A) Production of testosterone-3-HRP

100 mgTestosteron-3-(0-carboxymethyl)-oxim und 0,143 ml Tri-n-butylamin wurden in 5 ml Dioxan gelöst. Die Lösung wurde auf 2° C abgekühlt und dann wurden 0,03 ml Isobutyl-chlorcarbonat zugegeben. Nach 30 min wurde die Lösung zu 100 mg HRP(Meerrettichperoxidase) in einem Gemisch von 9 4,1 ml Wasser und 6 ml Dioxan zugegeben und mit 0,1 n NaOH auf einen pH-Wert von 9 eingestellt. Diese Lösung wurde 4 h bei 2° C gerührt und über Nacht dialysiert. Der Niederschlag, der nach Einstellung des Dialysats auf einen pH-Wert von 4,6 erhalten worden war, wurde, nachdem er über Nacht stehenge-45 lassen worden war, zentrifugiert, in 10 ml Wasser suspendiert und mit Hilfe von Natronlauge gelöst. Das Material wurde dreimal mit 15 ml Aceton bei einem pH-Wert von 4,5 ausgefällt, in 15 ml Wasser, das mit Natriumhydroxid-Lösung auf einen pH-Wert von 7,8 eingestellt war, gelöst, dialysiert und so schliesslich lyophilisiert. 100 mg testosterone-3- (0-carboxymethyl) oxime and 0.143 ml tri-n-butylamine were dissolved in 5 ml dioxane. The solution was cooled to 2 ° C and then 0.03 ml of isobutyl chlorocarbonate was added. After 30 minutes, the solution was added to 100 mg of HRP (horseradish peroxidase) in a mixture of 9, 4.1 ml of water and 6 ml of dioxane, and the pH was adjusted to 9 with 0.1N NaOH. This solution was stirred at 2 ° C for 4 h and dialyzed overnight. The precipitate, which was obtained after the dialysate had been adjusted to a pH of 4.6, was centrifuged after being left to stand overnight, suspended in 10 ml of water and dissolved with the aid of sodium hydroxide solution. The material was precipitated three times with 15 ml of acetone at a pH of 4.5, dissolved in 15 ml of water which had been adjusted to a pH of 7.8 with sodium hydroxide solution, dialyzed and finally lyophilized.

B) Herstellung von Testosteron-3-BSA B) Preparation of Testosterone-3-BSA

Dieses Kopplungsprodukt wurde auf die gleiche Weise wie das Testosteron-3-HRP hergestellt, wobei jedoch als Ausgangs-55 material 50 mgTestosteron-3-(0-carboxymethyl)-oxim und 150 mg BSA(Rinderserumalbumin) verwendet wurden. This coupling product was prepared in the same manner as testosterone-3-HRP, except that 50 mg of testosterone-3- (0-carboxymethyl) oxime and 150 mg of BSA (bovine serum albumin) were used as the starting material.

C) Herstellung von Antikörpern gegen Testosteron-3-BSA C) Production of antibodies against testosterone-3-BSA

5 Kaninchen wurden intramuskulär zunehmende Dosen von Testosteron-3-BSA in vollständigem Freund'schen Adjuvans (0,5,1 und 2 mg) in Intervallen von 3 Wochen injiziert. Zwei Wochen nach der letzten Injektion wurden den Tieren intravenös 2 mg Antigen in physiologischer Kochsalzlösung injiziert. Eine Woche danach wurde den Tieren Blut abgenommen. Die gegen BSA gebildeten Antikörper wurden entfernt, indem das Serum anteilweise mit BSA-m-aminobenzyloxymethylcellulose, die nach dem Verfahren von Gurvich (siehe D) hergestellt worden war, behandelt wurde. Five rabbits were injected with intramuscularly increasing doses of testosterone-3-BSA in Freund's complete adjuvant (0.5, 1 and 2 mg) at 3 week intervals. Two weeks after the last injection, the animals were intravenously injected with 2 mg of antigen in physiological saline. Blood was drawn from the animals a week later. The antibodies raised against BSA were removed by partially treating the serum with BSA-m-aminobenzyloxymethyl cellulose prepared by the Gurvich method (see D).

617 774 617 774

4 4th

D) Herstellung von Antitestosteroncellulose D) Preparation of antitestosterone cellulose

Diese Substanz wurde entsprechend dem von Gurvich in Biokhimiya 26, 934 (1961) beschriebenen Verfahren hergestellt. This substance was prepared according to the method described by Gurvich in Biokhimiya 26, 934 (1961).

1. Herstellung von «Aminocellulose»: 1. Production of «aminocellulose»:

50 g Whatman Cellulose, die mehrfach gewaschen und dekantiert worden war, wurden in 100 ml einer 0,7-prozentigen Natriumacetatlösung suspendiert, die 2 g N(m-Nitrobenzoxy)-methyl-pyridin enthielt. Das Gemisch wurde bei 60 bis 80° C getrocknet und 40 min auf 125° C erhitzt! Das entstehende Produkt wurde gründlich mit destilliertem Wasser gewaschen, bei 80° C getrocknet, mit Benzol gewaschen und erneut getrocknet. 50 g des getrockneten Produktes wurden durch Suspension in 300 ml einer 15-prozentigen Na2S204-Lösung reduziert und 30 min bei 50 bis 60° C gerührt. Das Produkt wurde filtriert und nacheinander mit destilliertem Wasser, 30-prozentiger Essigsäure und wieder mit destilliertem Wasser gewaschen. 50 g of Whatman cellulose, which had been washed and decanted several times, was suspended in 100 ml of a 0.7% sodium acetate solution containing 2 g of N (m-nitrobenzoxy) methyl pyridine. The mixture was dried at 60 to 80 ° C and heated to 125 ° C for 40 min! The resulting product was washed thoroughly with distilled water, dried at 80 ° C, washed with benzene and dried again. 50 g of the dried product were reduced by suspension in 300 ml of a 15 percent Na2S204 solution and stirred at 50 to 60 ° C. for 30 minutes. The product was filtered and washed successively with distilled water, 30 percent acetic acid and again with distilled water.

2. Behandlung mit ammoniakalischer Kupferlösung: 2. Treatment with ammoniacal copper solution:

40 ml 10-prozentiger Schwefelsäure, 20 ml 50-prozentiger Salpetersäure und 140 ml destilliertes Wasser wurden unter Rühren auf 90° C erhitzt. Anschliessend wurden 5,9 g CuO in kleinen Anteilen zugegeben. Die Lösung wurde 2 h zum Sieden erhitzt und mit destilliertem Wasser auf 500 ml aufgefüllt. 80 ml dieser Lösung wurden in ein Eisbad gegeben und unter Rühren zu 160 ml kalter 4 n NaOH zugegeben. Nach 30-minütigem Rühren wurde der Niederschlag zweimal mit destilliertem Wasser gewaschen und in 80 ml 25-prozentigem Ammoniak gelöst. Zu dieser Lösung wurde nach und nach 1 g «Aminocellulose» zugegeben. Das Gemisch wurde Vhh gerührt und anschliessend wurden 40 ml siedendes Wasser zugegeben und die Lösung schnell auf 0° C abgekühlt. Die Lösung wurde mit 10-prozenti-ger Schwefelsäure neutralisiert, worauf die Aminocellulose ausflockte. Sie wurde mit kaltem destillierten Wasser gewaschen. 40 ml of 10 percent sulfuric acid, 20 ml of 50 percent nitric acid and 140 ml of distilled water were heated to 90 ° C. with stirring. Then 5.9 g of CuO were added in small portions. The solution was heated to boiling for 2 hours and made up to 500 ml with distilled water. 80 ml of this solution were placed in an ice bath and added to 160 ml of cold 4N NaOH with stirring. After stirring for 30 minutes, the precipitate was washed twice with distilled water and dissolved in 80 ml of 25 percent ammonia. 1 g of "aminocellulose" was gradually added to this solution. The mixture was stirred for half an hour and then 40 ml of boiling water were added and the solution was rapidly cooled to 0.degree. The solution was neutralized with 10 percent sulfuric acid, whereupon the aminocellulose flocculated. It was washed with cold distilled water.

3. Herstellung von y-Globulin: 3. Production of y-globulin:

Zu Kaninchen Antitestosteronserum wurden 180 mg Na2S04 pro ml Serum zugegeben. Das Gemisch wurde 1 h bei Raumtemperatur gerührt und der entstehende Niederschlag zentrifugiert, zweimal mit einer 18-prozentigen Na2S04-Lösung gewaschen und in so viel 0,05 m Natriumborat mit einem pH-Wert von 8,6 aufgenommen, dass die Proteinkonzentration ungefähr 10 mg/ml betrug. To rabbit antitestosterone serum 180 mg Na2S04 were added per ml serum. The mixture was stirred at room temperature for 1 h and the resulting precipitate was centrifuged, washed twice with an 18% Na2S04 solution and taken up in 0.05 M sodium borate with a pH of 8.6 such that the protein concentration was approximately 10 mg / ml was.

4. Bindung des 7-Globulins an Aminocellulose: 4. Binding of 7-globulin to aminocellulose:

350 mg «Aminocellulose» wurden in 50 ml destilliertem Wasser suspendiert. Die Suspension wurde auf 0° C abgekühlt. 10 ml 36-prozentige Salzsäure wurden zugegegeben und anschliessend 10 ml 10-prozentige NaN02-Lösung zugetropft. Die Suspension wurde zentrifugiert, mit kaltem destillierten Wasser und anschliessend mit 0,05 m Natriumborat mit einem pH-Wert von 8,6 gewaschen. Die Cellulose wurde in 43 ml 0,05 m Natriumborat mit einem pH-Wert von 8,6 suspendiert. Zu dieser Suspension wurden 7 ml der wie oben hergestellten y-Globulinlösung zugegeben. Das Gemisch wurde 26 h bei 4° C gerührt, zentrifugiert und mit 0,02 m Phosphatpuffer mit einem pH-Wert von 6,0 gewaschen. Von dem Antiserum jedes der 5 immunisierten Kaninchen wurde eine Cellulosesuspension hergestellt (A bis E). 350 mg of "aminocellulose" was suspended in 50 ml of distilled water. The suspension was cooled to 0 ° C. 10 ml of 36 percent hydrochloric acid were added and then 10 ml of 10 percent NaN02 solution was added dropwise. The suspension was centrifuged, washed with cold distilled water and then with 0.05 M sodium borate with a pH of 8.6. The cellulose was suspended in 43 ml of 0.05 M sodium borate with a pH of 8.6. 7 ml of the y-globulin solution prepared as above were added to this suspension. The mixture was stirred at 4 ° C for 26 h, centrifuged and washed with 0.02 M phosphate buffer with a pH of 6.0. A cellulose suspension was prepared from the antiserum of each of the 5 immunized rabbits (A to E).

E) Bestimmung von Testosteron mit Hilfe von Testosteron-3-HRP und Antitestosteroncellulose E) Determination of testosterone using testosterone-3-HRP and antitestosterone cellulose

I) Immunreaktion I) Immune response

0,5 ml einer Probe, enthaltend Testosteron, 0,2 ml Testoste-ron-3-HRP (100 mg/ml) und 0,3 ml einer Antitestosteroncellu-lose-Suspension wurden 2 h bei Raumtemperatur rotiert und dann 5 min mit 1000 g zentrifugiert. 0.5 ml of a sample containing testosterone, 0.2 ml of testosterone-3-HRP (100 mg / ml) and 0.3 ml of an antitestosterone cellulose suspension were rotated at room temperature for 2 h and then at 1000 for 5 min g centrifuged.

Die Immunreaktion fand in 0,02 m Phosphatpuffer bei einem pH-Wert von 6,0, enthaltend 2% Schafserum, statt. The immune reaction took place in 0.02 m phosphate buffer at a pH value of 6.0, containing 2% sheep serum.

II) Enzymreaktion II) Enzyme reaction

0,5 ml der überstehenden Flüssigkeit wurden bei Raumtemperatur mit 1,5 ml Substrat 30 min inkubiert. Die Extinktion wurde bei 460 nm gemessen. 0.5 ml of the supernatant liquid was incubated at room temperature with 1.5 ml of substrate for 30 minutes. The absorbance was measured at 460 nm.

Das Enzymsubstrat enthielt 10 |il, 30-prozentiges Wasserstoffperoxid und 20 mg 5-Aminosalicylsäure in 150 ml 0,02 m Phosphatpuffer mit einem pH-Wert von 6,2. The enzyme substrate contained 10 ml, 30% hydrogen peroxide and 20 mg 5-aminosalicylic acid in 150 ml 0.02 M phosphate buffer with a pH of 6.2.

Die Fig. 1 zeigt Messwerte, bei denen Testosteron-3-HRP an die Antitestosteroncellulose-Zubereitungen gebunden worin den ist. In diesem Falle wurde nur Puffer als Probe in dem Testsystem zugegeben. Wenn Cellulose anstelle von Antitestosteroncellulose zugegeben wird, bleiben mehr als 95 % der Enzymaktivität in der überstehenden Flüssigkeit enthalten. Die Zubereitungen B, D und E zeigten, dass fast kein Testosteron- 3-1 s HRP gebunden worden war, jedoch bei den Zubereitungen A und C. 1 shows measured values in which testosterone-3-HRP is bound to the antitestosterone cellulose preparations in which it is. In this case only buffer was added as a sample in the test system. If cellulose is added instead of antitestosterone cellulose, more than 95% of the enzyme activity remains in the supernatant. Preparations B, D and E showed that almost no testosterone 3-1 s HRP had been bound, but with preparations A and C.

Fig. 2 zeigt die Ergebnisse der Inkubation einer Testoste-ronverdünnungsreihe mit Testosteron-3-HRP bei vier verschiedenen Konzentrationen von Antitestosteroncellulose C. ;ci 1 mg/ml (I), 2 mg/ml (II), 4 mg/ml (III) und 16 mg/ml (IV). Es ist offensichtlich, dass mit diesem System eine Menge von ungefähr 10 ng Testosteron gezeigt werden kann. 2 shows the results of the incubation of a testosterone dilution series with testosterone-3-HRP at four different concentrations of antitestosterone cellulose C.; ci 1 mg / ml (I), 2 mg / ml (II), 4 mg / ml (III ) and 16 mg / ml (IV). It is apparent that an amount of approximately 10ng testosterone can be shown with this system.

Beispiel 2 Example 2

Bestimmung von östradiol Determination of estradiol

A) Östradiol-17-succinyl-HRP wurde hergestellt durch die in Beispiel 1 A) beschriebene gemischte Anhydrid-Methode, wobei 50 mg Östradiol- 17-hemisuccinat und 50 mg HRP als Ausgangsmaterialien verwendet wurden. ,,, B) Östradiol-17-succinyl-BSA wurde nach der in Beispiel 1 A) beschriebenen gemischten Anhydrid-Methode hergestellt, wobei 100 mg ÖstradioI-17-hemisuccinat und 150 mg BSA als Ausgangsmaterialien verwendet wurden. A) Oestradiol-17-succinyl-HRP was prepared by the mixed anhydride method described in Example 1A), using 50 mg of estradiol-17-hemisuccinate and 50 mg of HRP as starting materials. ,,, B) Oestradiol-17-succinyl-BSA was prepared according to the mixed anhydride method described in Example 1A), using 100 mg of oestradioI-17-hemisuccinate and 150 mg of BSA as starting materials.

C) Zur Herstellung der Antikörper gegen Östradiol-17-is succinyl-BSA wurden 5 Kaninchen nach dem in Beispiel 1 C) C) To produce the antibodies against estradiol-17-is succinyl-BSA, 5 rabbits according to the method described in Example 1 C)

beschriebenen Schema immunisiert. Die Sera wurden mit BS A-m-Aminobenzyloxymethylcellulose absorbiert. immunized scheme described. The sera were absorbed with BS A-m-aminobenzyloxymethyl cellulose.

D) Antiöstradiolcellulose wude auf die in Beispiel 1 D) für Antitestosteroncellulose beschriebene Weise hergestellt. Von D) Antiestradiol cellulose was prepared in the manner described in Example 1D) for antitestosterone cellulose. From

4ii jedem der immunisierten Kaninchen wurde eine Cellulose-Zubereitung hergestellt, die mit 16 bis einschliesslich 20 numeriert wurden. 4ii Each of the immunized rabbits was made with a cellulose preparation numbered 16 to 20 inclusive.

E) Die Untersuchung wurde analog derjenigen für Testosteron in Beispiel 1E) durchgeführt. E) The test was carried out analogously to that for testosterone in Example 1E).

4_, Die Fig. 3 und 4 zeigen einige Ergebnisse. Die Fig. 3 zeigt, dass drei verwendbare Antisera durch die Immunisierung erhalten wurden, von denen 17 den höchsten Titel besitzt. Die Fig. 4 zeigt das Testsystem, bei dem Antiöstradiolcellulose 17 in einer Konzentration von 8 mg/ml verwendet wurde. Das System 5(, unterscheidet nicht zwischen Östron und 17a-östradiol. 17a Östradiol, besonders Östriol, zeigen eine geringere Kreuzreaktion. Testosteron und Progesteron beeinflussen das System nur in sehr hohen Konzentrationen 4_, Figs. 3 and 4 show some results. Figure 3 shows that three useful antisera were obtained by immunization, 17 of which had the highest title. 4 shows the test system in which anti-oestradiol cellulose 17 was used in a concentration of 8 mg / ml. System 5 (, does not differentiate between estrone and 17a-estradiol. 17a estradiol, especially estriol, show a lower cross-reaction. Testosterone and progesterone only influence the system in very high concentrations

5; Beispiel 3 5; Example 3

Bestimmung von Antikörpern gegen Penicillin Penicilloyl-Katalase Determination of antibodies against penicillin penicilloyl catalase

30 mg Benzylpenicillinsäure wurden in 5 ml 96-prozentigem Äthanol gelöst und zu 200 mg Katalase in 45 ml 0,1 m Phos-M1 phatpuffer mit einem pH-Wert von 7,5 zugetropft. Die Reaktion wurde 2 h fortgesetzt, wobei der pH-Wert mit 0,5 n NaOH zwischen 7,2 und 8,2 gehalten wurde. Das Reaktionsgemisch wurde gegen 6X310,02 m Phosphatpuffer mit einem pH-Wert von 7,0 dialysiert. 30 mg of benzylpenicillinic acid were dissolved in 5 ml of 96 percent ethanol and added dropwise to 200 mg of catalase in 45 ml of 0.1 M Phos-M1 phate buffer with a pH of 7.5. The reaction was continued for 2 hours, keeping the pH between 7.2 and 8.2 with 0.5N NaOH. The reaction mixture was dialyzed against 6X310.02 M phosphate buffer with a pH of 7.0.

h< Auf die gleiche Weise wurden 250 mg Benzylpenicillinsäure an 5 g m-Aminobenzyloxymethylcellulose, die nach dem Verfahren von Gurvich (Biokhimiya 26,934 (1961)) hergestellt worden war, gekoppelt. Das Kopplungsprodukt wurde jedoch h <In the same way, 250 mg of benzylpenicillic acid were coupled to 5 g of m-aminobenzyloxymethyl cellulose, which had been prepared by the method of Gurvich (Biokhimiya 26, 934 (1961)). The coupling product, however, was

nicht dialysiert, sondern auf einem Glasfilter gewaschen. not dialyzed, but washed on a glass filter.

Eine Überempfindlichkeit von Menschen gegenüber Penicillin konnte auf folgende Weise gezeigt werden: Hypersensitivity to penicillin has been demonstrated in the following ways:

0,2 ml einer Probe von nicht-hömolysiertem Serum wurden mit 0,5 ml einer Lösung von Penicillol-Katalase (1:800) vermischt. Nach 30 min wurden 10 mg Penicilloyl-m-amino.ben-zyloxymethylcellulose zugegeben. Das Gemisch wurde 30 min rotiert und anschliessend die Enzymaktivität in der überstehenden Flüssigkeit bestimmt, indem 0,02 ml dieser Flüssigkeit zu 2,8 ml 0, 05 m Phosphatpuffer mit einem pH-Wert von 6,8 zugegeben wurden, der 1,2 |il 30-prozentiges H202 enthielt und anschliessend die Abnahme der Extinktion bei 240 nm gemessen wurde. Im Serum von Patienten, die gegenüber Penicillin überempfindlich waren, wurde eine geringere Enzymaktivität in der Flüssigkeit gefunden als bei Kaninchenserum. Die Werte für Menschen, die nicht überempfindlich waren, wichen nicht wesentlich' von denjenigen mit Kaninchenserum ab. 0.2 ml of a sample of non-hemolyzed serum was mixed with 0.5 ml of a solution of penicillol catalase (1: 800). After 30 minutes, 10 mg of penicilloyl-m-amino.benzyloxymethylcellulose were added. The mixture was rotated for 30 min and then the enzyme activity in the supernatant liquid was determined by adding 0.02 ml of this liquid to 2.8 ml of 0.05 m phosphate buffer with a pH of 6.8, the 1.2 | Contained 30 percent H202 and then the decrease in absorbance at 240 nm was measured. In the serum of patients who were hypersensitive to penicillin, less enzyme activity was found in the liquid than in rabbit serum. The values for people who were not hypersensitive did not differ significantly from those with rabbit serum.

Beispiel 4 Bestimmung von Folinsäure Example 4 Determination of folic acid

A) Herstellung von Folatglukoseoxidase A) Production of folate glucose oxidase

200 mg Glukoseoxidase (140 IU/mg) wurden in 10 mg PBS (mit Phosphat gepufferte Salzlösung, eine phosphathaltige physiologische Kochsalzlösung) mit einem pH-Wert von 7,0 gelöst. 30 mg l-Cyclohexyl-3-(2-morpholinoäthyl)-carbodiimid (MCDI) wurden zugegeben und anschliessend 24 mg Folinsäure. Die Reaktion dauerte 2 h und anschliessend wurde eine sorgfältige Dialyse gegen PBS mit einem pH-Wert von 7,0 durchgeführt. 200 mg glucose oxidase (140 IU / mg) was dissolved in 10 mg PBS (with phosphate buffered saline, a phosphate-containing physiological saline) with a pH of 7.0. 30 mg of l-cyclohexyl-3- (2-morpholinoethyl) carbodiimide (MCDI) were added and then 24 mg of folic acid. The reaction lasted 2 hours and then careful dialysis against PBS with a pH of 7.0 was carried out.

B) Herstellung von Folat-MBSA(methyliertes Rinderserumalbumin) B) Preparation of Folate MBSA (Methylated Bovine Serum Albumin)

Folat-MBSA wurde hergestellt nach dem von Ricker und Stollar beschriebenen Verfahren (Biochemistry 6, 2001 (1967)). 25 mg MCDI wurden zu 50 mg BSA in 50 ml Wasser zugegeben und anschliessend 20 mg Folinsäure. 2 h später hatte sich ein gelber Niederschlag gebildet. Schliesslich wurde das ganze Reaktionsgemisch eine beträchtliche Zeit gegen physiologische Kochsalzlösung dialysiert. Folate MBSA was produced by the method described by Ricker and Stollar (Biochemistry 6, 2001 (1967)). 25 mg MCDI was added to 50 mg BSA in 50 ml water and then 20 mg folic acid. A yellow precipitate had formed 2 hours later. Finally the whole reaction mixture was dialyzed against physiological saline for a considerable time.

C) Herstellung von Antiserum gegen Folat-MBSA C) Preparation of antiserum against folate MBSA

Am Tage 0, 21 und 42 wurden jeweils 4 Kaninchen intramuskulär 2 mg Folat-MBSA in vollständigem Freund'schen Adjuvans und am Tage 35 intravenös 3 mg Folant-MBSA in physiologischer Kochsalzlösung injiziert. Am Tage 49 wurde den Tieren Blut abgenommen. On days 0, 21 and 42, 4 rabbits were injected intramuscularly with 2 mg of folate-MBSA in Freund's complete adjuvant and on day 35 with 3 mg of folant-MBSA intravenously in physiological saline. Blood was drawn from the animals on day 49.

D) Antifolatcellulose wurde entsprechend dem in Beispiel 1 D) beschriebenen Verfahren hergestellt. D) Antifolate cellulose was prepared according to the procedure described in Example 1 D).

E) Bestimmung von Folinsäure E) Determination of folic acid

100 |il der zu untersuchenden Probe und 700 (il einer Anti-folatcellulose-Suspension wurden 3 h rotiert. 200 fil Folatglukoseoxidase (1:1500) wurden zugegeben. Das Gemisch wurde nochmals 3 h rotiert und zentrifugiert und anschliessend die Enzymaktivität in der überstehenden Flüssigkeit bestimmt. Diese Bestimmung wurde durchgeführt durch Vermischen von 0,5 ml der überstehenden Flüssigkeit mit einer Lösung von 50 mg Glulose, 10 [ig HRP und 1 mg 5-Aminosalicylsäure in 2,5 ml 0,05 n Phosphatpuffer mit einem pH-Wert von 6,0 und Messung der Extinktion nach 30 min bei 460 nm. 100 ml of the sample to be examined and 700 ml of an anti-folate cellulose suspension were rotated for 3 hours. 200 ml of folate glucose oxidase (1: 1500) were added. The mixture was rotated again for 3 hours and centrifuged, and then the enzyme activity in the supernatant liquid This determination was carried out by mixing 0.5 ml of the supernatant liquid with a solution of 50 mg of glulose, 10 [ig HRP and 1 mg of 5-aminosalicylic acid in 2.5 ml of 0.05 N phosphate buffer with a pH of 6.0 and measurement of the absorbance after 30 min at 460 nm.

Fig. 5 zeigt den Prozentsatz des gebundenen Enzyms gegen die Konzentration der Antifolatcellulose. Figure 5 shows the percentage of bound enzyme against the concentration of antifolate cellulose.

Fig. 6 zeigt die Empfindlichkeit des Testssystems in einer Antifolatcellulose-Konzentration von 2 mg/ml und die Wirkung von Glycin, Asparagin, Alanin, und Glutaminsäure. Fig. 6 shows the sensitivity of the test system in an antifolate cellulose concentration of 2 mg / ml and the effect of glycine, asparagine, alanine, and glutamic acid.

Beispiel 5 Example 5

Bestimmung von Digoxin A) Herstellung von Digoxin -HRP Determination of digoxin A) Production of digoxin -HRP

Zu 22 mg Digoxin, in 1 ml abs. Äthanol suspendiert, wurde unter Rühren 1 ml 0,1 m Natriummetaperjodat zugetropft. To 22 mg digoxin, in 1 ml abs. Suspended ethanol, 1 ml of 0.1 M sodium metaperiodate was added dropwise with stirring.

Nach 25 min wurden 0,3 ml 0,1 m Äthylenglykol zugegeben. 5 After 25 minutes, 0.3 ml of 0.1 M ethylene glycol was added. 5

617 774 617 774

min später wurde dieses Gemisch unter Rühren zu einer Lösung von 32 mg Meerrettichperoxidase (HRP) in 1 ml destilliertem Wasser zugetropft, das mit 5-prozentiger K2C03-Lösung auf einen pH-Wert von 9,5 eingestellt war. Während der Reaktion wurde der pH-Wert durch Zugabe 5-prozentiger K2C03-Lösung auf 9 bis 9,5 gehalten. Als der pH-Wert stabil war, wurden 15 mg NaBH4 in 1 ml destilliertem Wasser zugegeben. Nach 3 h wurde der pH-Wert mit 1 m Ameisensäure auf 6,5 eingestellt. 1 h später wurde 1 m NH4OH zugegeben, bis ein pH-Wert von 8,5 erreicht war. Das Gemisch wurde über Nacht gegen kaltes fliessendes Wasser dialysiert. Schliesslich wurde der pH-Wert mit 0,1 n Salzsäure auf 4,5 eingestellt. Das Gemisch wurde 1 h bei Raumtemperatur und 4 h bei 4° C stehengelassen, um einen Niederschlag zu erhalten, der 1 h bei 1000 g zentrifugiert wurde. Der Niederschlag wurde in 5 ml 0,1 m NaHC03 gelöst, gründlich dialysiert und gefriergetrocknet. Min later, this mixture was added dropwise with stirring to a solution of 32 mg of horseradish peroxidase (HRP) in 1 ml of distilled water, which was adjusted to a pH of 9.5 with 5% K2C03 solution. During the reaction, the pH was kept at 9 to 9.5 by adding 5% K2C03 solution. When the pH was stable, 15 mg NaBH4 in 1 ml distilled water was added. After 3 h the pH was adjusted to 6.5 with 1 M formic acid. 1 h later, 1 M NH4OH was added until a pH of 8.5 was reached. The mixture was dialyzed against cold running water overnight. Finally, the pH was adjusted to 4.5 with 0.1N hydrochloric acid. The mixture was left at room temperature for 1 hour and at 4 ° C. for 4 hours to obtain a precipitate, which was centrifuged at 1,000 g for 1 hour. The precipitate was dissolved in 5 ml of 0.1 M NaHC03, dialyzed thoroughly and freeze-dried.

B) Herstellung von Digoxin-BSA Digoxin-Rinderserumalbumin (BSA) wurde auf die gleiche B) Production of Digoxin-BSA Digoxin bovine serum albumin (BSA) was the same

Weise, wie sie oben für Digoxin-HRP angegeben ist, hergestellt, wobei jedoch von 436 mg Digoxin und 560 mg BSA ausgegangen wurde und die Mengen der anderen Reagenzen in gleichem Verhältnis erhöht wurden wie das Dioxin. Prepared as described above for Digoxin-HRP, but starting from 436 mg digoxin and 560 mg BSA and increasing the amounts of the other reagents in the same ratio as the dioxin.

C) Herstellung von Antikörpern gegen Digoxin C) Production of antibodies against digoxin

5 Kaninchen wurden 400, 800 bzw. 1600 [ig Dioxin-BSA im Abstand von 14 Tagen injiziert. Das Immunogen wurde mit vollständigem Freund'schen Adjuvans vermischt und intramuskulär verabreicht. 14 Tage nach der letzten Injektion wurde den Tieren intravenös 800 [ig Digoxin-BSA in physiologischer Kochsalzlösung injiziert. 10 Tage später wurde den Tieren das Blut entnommen. Das Serum wurde mit BSA-m-Aminbenzyl-oxymethylcellulose adsorbiert. Five rabbits were injected with 400, 800 and 1600 [ig dioxin-BSA every 14 days. The immunogen was mixed with Freund's complete adjuvant and administered intramuscularly. 14 days after the last injection, the animals were intravenously injected with 800 [digoxin-BSA in physiological saline. Blood was drawn from the animals 10 days later. The serum was adsorbed with BSA-m-aminbenzyl-oxymethyl cellulose.

D) Herstellung von Antidigoxincellulose Antidigoxincellulose wurde nach dem Gurvich-Verfahren, D) Production of Antidigoxin Cellulose Antidigoxin cellulose was prepared using the Gurvich process,

wie unter 1 D) beschrieben, hergestellt. as described under 1 D).

E) Bestimmung von Digoxin E) Determination of digoxin

Eine Verdünnungsreihe wurde mit Digoxin in 0,1 m Phosphatpuffer mit einem pH-Wert von 7,5 herghestellt, enthaltend 0,9 % NaCl, 0,5% Tween-20 und 1,0% BSA. Die Verdünnungsreihe ging von 0,1 bis 100 ng/ml. 1 ml einer Digoxin-Lösung wurde mit 0,1 ml Digoxin-HRP in einer geeigneten Verdünnung vermischt und anschliessend wurden 2 mg Antidigoxincellulose, die in 0,4 ml Puffer suspendiert war, zugegeben. Das Gemisch wurde 6 h bei Raumtemperatur rotiert und anschliessend zentrifugiert und die Enzymaktivität in der überstehenden Flüssigkeit bestimmt. A dilution series was made with digoxin in 0.1 M phosphate buffer at pH 7.5 containing 0.9% NaCl, 0.5% Tween-20 and 1.0% BSA. The dilution range went from 0.1 to 100 ng / ml. 1 ml of a digoxin solution was mixed with 0.1 ml of digoxin HRP in a suitable dilution and then 2 mg of antidigoxin cellulose, which was suspended in 0.4 ml of buffer, were added. The mixture was rotated at room temperature for 6 h and then centrifuged and the enzyme activity in the supernatant liquid was determined.

Zugabe von 0,8 ng Digoxin führte zu einer messbaren Zunahme der Enzymaktivität in der überstehenden Flüssigkeit. Digoxin allein zeigte eine geringe Kreuzreaktion in dem System während Cholesterin, Cortisol, Östradiol, Testosteron und Progesteron keine Kreuzreaktion in dem System zeigten. The addition of 0.8 ng digoxin led to a measurable increase in the enzyme activity in the supernatant. Digoxin alone showed little cross reaction in the system while cholesterol, cortisol, estradiol, testosterone and progesterone showed no cross reaction in the system.

Beispiel 6 Example 6

Bestimmung von Cortisol Determination of cortisol

A) Herstellung von Cortisol-21-galactose-oxidase A) Preparation of cortisol-21-galactose oxidase

50 mgCortisol-21-hemisuccinatund 100 mg Galactoseoxi-dase wurden nach dem in Beispiel 1 A) beschriebenen gemischten Anhydridverfahren hergestellt. 50 mg of cortisol-21-hemisuccinate and 100 mg of galactoseoxy-dase were prepared according to the mixed anhydride method described in Example 1A).

B) Herstellung von unlöslichem Transcortin B) Preparation of Insoluble Transcortin

100 mg Transcortin, das durch Chromatographie mit DEAE, Cellulose bzw. Hydroxylapatit gereinigt worden war, wurden folgendermassen mit Hilfe des CNBr-Verfahrens an 3 g Sepharose 4 B gekoppelt: 3 g Sepharose 4 B-Suspension wurden aktiviert durch Vermischen mit 4 ml einer 2,5-prozentigen (Gew./Vol.) CNBr-Lösung in destilliertem Wasser und anschliessend wurde der pH-Wert mit 1 n NaOH auf 10 bis 11 eingestellt und 6 min auf diesem Wert gehalten. Die Sepharose wurde mit Eiswasser und 0,1 m NaHC03 gewaschen. Dann 100 mg transcortin, which had been purified by chromatography with DEAE, cellulose or hydroxyapatite, were coupled to 3 g of Sepharose 4 B using the CNBr method as follows: 3 g of Sepharose 4 B suspension were activated by mixing with 4 ml of a 2nd , 5 percent (w / v) CNBr solution in distilled water and then the pH was adjusted to 10 to 11 with 1N NaOH and kept at this value for 6 min. The Sepharose was washed with ice water and 0.1 m NaHC03. Then

5 5

10 10th

1^ 1 ^

211 211

25 25th

_■=() _ ■ = ()

35 35

40 40

45 45

50 50

55 55

60 60

65 65

617 774 617 774

6 6

wurden 100 mg Transcortin in 20 ml 0,1 m NaHC03 zugegeben und die Suspension 24 h bei 4° C geschüttelt. Dann wurde nacheinander mit 0,5 m NaHC03,0,05 m Citratpuffer mit einem pH-Wert von 1,1 und 0,05 m Phosphatpuffer mit einem pH-Wert von 6 gewaschen und die Sepharose in dem letzten Puffer gelassen, zu dem 0,1 % Merthiolat zugegeben worden war. 100 mg of transcortin in 20 ml of 0.1 M NaHC03 were added and the suspension was shaken at 4 ° C. for 24 h. Then it was washed successively with 0.5 M NaHC03.0.05 M citrate buffer with a pH of 1.1 and 0.05 M phosphate buffer with a pH of 6 and the Sepharose was left in the last buffer to which 0 , 1% merthiolate had been added.

C) Bestimmung von Cortisol C) Determination of cortisol

0,5 ml einer cortisolhaltigen Probe (Standard, Plasma oder Urin) wurden zweimal mit Methylenchlorid extrahiert (2X3 ml). Die vereinigten Auszüge wurden zur Trockne eingedampft. Der Rückstand wurde in 0,5 ml physiologischer Kochsalzlösung aufgenommen und mit 0,2 ml Cortisol-21-galactose-oxidase in einer geeigneten Konzentration und 0,3 ml Transcor-tin-Sepharose-Suspension (5 mg/ml) vermischt. Das Gemisch wurde 15 min bei 4" C rotiert und zentrifugiert. Anschliessend wurde die Enzymaktivität in der überstehenden Flüssigkeit durch Zugabe von 0,5 ml dieser Flüssigkeit zu 1,5 ml eines Substrats bestimmt. Das Substrat bestand aus 100 mg D-Galac-tose, 20 mg 5-Amino-salicylsäure und 10 (xg Peroxidase in 150 ml 0,02 m Phosphatpuffer mit einem pH-Wert von 6,0. 30 min später wurde die Extinktion bei 460 nm gemessen. 0.5 ml of a sample containing cortisol (standard, plasma or urine) was extracted twice with methylene chloride (2X3 ml). The combined extracts were evaporated to dryness. The residue was taken up in 0.5 ml of physiological saline and mixed with 0.2 ml of cortisol-21-galactose oxidase in a suitable concentration and 0.3 ml of transcorcinol-Sepharose suspension (5 mg / ml). The mixture was rotated for 15 min at 4 ° C. and centrifuged. The enzyme activity in the supernatant liquid was then determined by adding 0.5 ml of this liquid to 1.5 ml of a substrate. The substrate consisted of 100 mg of D-galactose , 20 mg of 5-amino-salicylic acid and 10 (xg peroxidase in 150 ml of 0.02 m phosphate buffer with a pH of 6.0. 30 min later, the absorbance was measured at 460 nm.

5 ng/ml Cortisol in der Probe führten zu einer messbaren Zunahme der Enzymaktivität in der überstehenden Flüssigkeit. Corticosteron und Progesteron beeinflussen das System nur, wenn grössere Mengen zugegeben wurden. Testosteron und s Aldosteron besassen kaum einen Einfluss. 5 ng / ml cortisol in the sample led to a measurable increase in enzyme activity in the supernatant. Corticosterone and progesterone only affect the system when larger amounts have been added. Testosterone and s aldosterone had little influence.

Beispiel 7 Bestimmung von Transcortin Example 7 Determination of transcortin

Die zur Bestimmung von Cortisol, wie in Beispiel 6 m beschrieben, verwendeten Reagentien wurden ebenso zur Bestimmung von Transcortin verwendet. The reagents used to determine cortisol as described in Example 6 m were also used to determine transcortin.

Von einer Verdünnungsreihe von Transcortin von 0 bis 1280 ng/ml wurden 0,5 ml 15 min bei 4" C mit 0,2 ml Cortisol-21 -galactose-oxidase in einer entsprechenden Verdünnung is inkubiert. Zu dieser Verdünnungsreihe wurden 0,3 ml Trans-cortin-Sepharose (15 mg/ml) zugegeben und das Gemisch 15 min bei 4" C rotiert. Die Aktivität der überstehenden Flüssigkeit wurde, wie in Beispiel 6 beschrieben, gemessen. From a dilution series of transcortin from 0 to 1280 ng / ml, 0.5 ml was incubated for 15 min at 4 ° C. with 0.2 ml cortisol-21-galactose oxidase in a corresponding dilution. 0.3 ml was added to this dilution series Trans-cortin-Sepharose (15 mg / ml) was added and the mixture was rotated at 4 "C for 15 min. The activity of the supernatant was measured as described in Example 6.

Eine Probe, enthaltend 40 ng/ml Transcortin, zeigte eine messbare Zunahme der Enzymaktivität in der überstehenden Flüssigkeit, während Sich bei Gegenwart von 320 ng/ml die gesamte Enzymaktivität in der überstehenden Flüssigkeit fand. A sample containing 40 ng / ml transcortin showed a measurable increase in enzyme activity in the supernatant liquid, whereas in the presence of 320 ng / ml all enzyme activity was found in the supernatant liquid.

C C.

3 Blatt Zeichnungen 3 sheets of drawings

CH1621671A 1970-11-10 1971-11-08 CH617774A5 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL707016396A NL154598B (en) 1970-11-10 1970-11-10 PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.

Publications (1)

Publication Number Publication Date
CH617774A5 true CH617774A5 (en) 1980-06-13

Family

ID=19811504

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1621671A CH617774A5 (en) 1970-11-10 1971-11-08

Country Status (16)

Country Link
US (1) US3850752A (en)
AU (1) AU468060B2 (en)
BE (1) BE775187A (en)
BR (1) BR7107459D0 (en)
CA (1) CA967464A (en)
CH (1) CH617774A5 (en)
DE (1) DE2155658C3 (en)
DK (1) DK140268B (en)
ES (1) ES396741A1 (en)
FI (1) FI54033C (en)
FR (1) FR2113733A5 (en)
GB (1) GB1348935A (en)
IT (1) IT986829B (en)
NL (1) NL154598B (en)
SE (1) SE451162B (en)
ZA (1) ZA717192B (en)

Families Citing this family (1630)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630328B2 (en) 1909-07-15 2003-10-07 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4191613A (en) * 1971-05-14 1980-03-04 Syva Company Malate dehydrogenase conjugates for enzyme immunoassays
US4282325A (en) * 1971-05-14 1981-08-04 Syva Company Enzyme bound corticosteroids
US3905871A (en) * 1971-05-14 1975-09-16 Syva Co Lactam conjugates to enzymes
US4203802A (en) * 1971-05-14 1980-05-20 Syva Company Inhibitable enzyme amplification assay
US4046636A (en) * 1974-06-20 1977-09-06 Syva Company Diazepam enzyme conjugates
US4039385A (en) * 1972-05-08 1977-08-02 Syva Company Cardiac glycoside enzyme conjugates
NL171930C (en) * 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3790447A (en) * 1972-07-05 1974-02-05 Abbott Lab Streptococci diagnostic method
US3966556A (en) * 1972-11-06 1976-06-29 Syva Company Compounds for enzyme amplification assay methadone analogs
US3975237A (en) * 1972-11-06 1976-08-17 Syva Company Compounds for enzyme amplification assay - - ecgonine analogs
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
NL7501215A (en) * 1975-02-01 1976-08-03 Akzo Nv METHOD FOR DETERMINING AND DETERMINING AN ANTIGEN OR ANTIBODY.
US4043872A (en) * 1975-02-20 1977-08-23 Syva Company Polyiodothyronine immunoassay
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4096138A (en) * 1975-12-08 1978-06-20 Scherr George H Immunological test procedure
US4166767A (en) * 1976-03-25 1979-09-04 Dainippon Pharmaceutical Co., Ltd. Insolubilized antibody
JPS5341420A (en) * 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
GB1572220A (en) * 1976-10-07 1980-07-30 Mochida Pharm Co Ltd Immunochemical process of measuring physiologically active substances
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
IT1153999B (en) * 1977-03-15 1987-01-21 Snam Progetti COMPOSITION SUITABLE FOR DETERMINING TRIIODOTHYRONIN AND DIAGNOSTIC METHOD USING THE SAME
IL51667A (en) * 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
US4156081A (en) * 1977-04-15 1979-05-22 Syva Company Theophylline antigens and antibodies
IT1114861B (en) * 1977-05-12 1986-01-27 Sclavo Inst Sieroterapeut METHOD FOR DETERMINING THE CONTENT OF CONSTITUENTS OF BIOLOGICAL FLUIDS AND MEANS SUITABLE FOR THE PURPOSE
FR2422956A1 (en) * 1978-04-13 1979-11-09 Pasteur Institut METHOD OF DETECTION AND CHARACTERIZATION OF A NUCLEIC ACID OR OF A SEQUENCE OF THE SAME, AND ENZYMATIC REAGENT FOR THE IMPLEMENTATION OF THIS PROCESS
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
DE2825650C3 (en) * 1978-06-12 1981-02-05 Boehringer Mannheim Gmbh, 6800 Mannheim Method for determining the thyroxine binding index in serum
US4269938A (en) * 1979-03-08 1981-05-26 Eastman Kodak Company Assay of peroxidatively active materials
US4376825A (en) * 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
JPS55152459A (en) * 1979-05-18 1980-11-27 Yamasa Shoyu Co Ltd Method and reagent for measuring quantity of cyclic nucleotide
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4347312A (en) * 1980-03-20 1982-08-31 Research Triangle Institute Detection of antibiotics in milk
JPS5714748A (en) * 1980-07-01 1982-01-26 Dainippon Pharmaceut Co Ltd Kit for quantitative determination of valproic acid and its method for quantitative determination
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
WO1982004323A1 (en) * 1981-06-02 1982-12-09 O Neill Sean Immunoprecipitation assay
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
US4419453A (en) * 1981-09-28 1983-12-06 The Dow Chemical Company Immunological agglutination assays with dyed or colored latex and kits
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
US4535057A (en) * 1982-07-26 1985-08-13 Amf Incorporated Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4530900A (en) * 1982-09-13 1985-07-23 Seragen Diagnostics Inc. Soluble insoluble polymers in enzymeimmunoassay
ZA841924B (en) * 1983-07-25 1984-10-31 Becton Dickinson Co Chromogenic tracers for use in an assay
WO1985000605A1 (en) * 1983-07-27 1985-02-14 American Hospital Supply Corporation Process for selective nitrile reduction
FR2550799B1 (en) * 1983-08-17 1986-02-21 Commissariat Energie Atomique COMPOUND MARKED BY AN ENZYME, ITS PREPARATION METHOD AND ITS USE IN ENZYMOIMMUNOLOGY
DE3433652A1 (en) * 1984-09-13 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim IMMUNCHEMICAL MEASUREMENT METHOD FOR HAPTENES AND PROTEINS
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
US4786594A (en) * 1986-05-14 1988-11-22 Syntex (U.S.A.) Inc. Enzyme immunoassay
DE68928124T2 (en) * 1988-09-02 1997-10-16 Chiron Corp., Emeryville, Calif. MACROPHAGE DERIVED IGNITION MEDIATOR (MIP-2)
ATE133714T1 (en) 1988-09-29 1996-02-15 Chiron Corp POLYNUCLEOTIDE DETERMINATION WITH SELECTABLE CLEAVAGE SITES
CA2029006C (en) * 1990-07-27 2001-07-17 Michael R. Detty Dicarboxylic acid oxidation products
CA2031109C (en) * 1990-07-27 1992-01-28 Susan J. Danielson Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5268298A (en) * 1991-04-26 1993-12-07 Life Technologies, Inc. System for delivering oxygen to a cell culture medium
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
JP3183666B2 (en) * 1991-07-19 2001-07-09 アツセイ・リサーチ・インコーポレーテツド Method and kit for measuring endogenous cytokines
US5464749A (en) 1991-07-22 1995-11-07 Bayer Corporation Immunoassay of free substances in biological fluids
US5939524A (en) * 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US7060283B1 (en) 1992-09-15 2006-06-13 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US7326535B2 (en) * 1993-09-15 2008-02-05 Ortho Diagnostic Systems Inc. Immunoreactive peptides from Epstein-Barr virus
US5637467A (en) * 1992-10-13 1997-06-10 Behringwerke Ag Heterogeneous assay using a pendulous drop
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6638905B2 (en) * 1993-06-18 2003-10-28 The Salk Institute For Biological Studies Cloning and recombinant production of CFR receptor(s)
US6495343B1 (en) 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US5684144A (en) * 1993-07-28 1997-11-04 University Of North Texas Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
CA2189774A1 (en) * 1994-05-10 1995-11-16 Donald J. Tindall Recombinant hk2 polypeptide
WO1995034640A1 (en) * 1994-06-13 1995-12-21 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
US5589344A (en) * 1994-06-15 1996-12-31 Johnson & Johnson Clinical Diagnostics, Inc. Test kit and method for competitive specific binding assay
CA2196790C (en) 1994-08-12 2000-10-10 Mark H. Skolnick 17q-linked breast and ovarian cancer susceptibility gene
DE69521002T3 (en) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutations of the 17q associated ovarian and breast cancer susceptibility gene
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US8236493B2 (en) 1994-10-21 2012-08-07 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US6974666B1 (en) * 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US7005509B1 (en) 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
US6506553B1 (en) 1995-03-30 2003-01-14 Ortho Diagnostics Systems, Inc. Method for diagnosis of Epstein-Barr virus associated disease
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
GB0112226D0 (en) * 2001-05-18 2001-07-11 Danisco Method of improving dough and bread quality
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
EP0785216B2 (en) 1995-12-18 2006-06-07 The University of Utah Research Foundation Chomosome 13-linked breast cancer susceptibility gene BRCA2
US7282327B2 (en) * 1996-01-23 2007-10-16 Affymetrix, Inc. Nucleic acid labeling compounds
US6864059B2 (en) * 1996-01-23 2005-03-08 Affymetrix, Inc. Biotin containing C-glycoside nucleic acid labeling compounds
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US20040210045A1 (en) * 1996-01-23 2004-10-21 Mcgall Glenn Nucleic acid labeling compounds
US7423143B2 (en) * 1996-01-23 2008-09-09 Affymetrix. Inc. Nucleic acid labeling compounds
US20010018514A1 (en) * 1998-07-31 2001-08-30 Mcgall Glenn H. Nucleic acid labeling compounds
US6965020B2 (en) 1996-01-23 2005-11-15 Affymetrix, Inc. Nucleic acid labeling compounds
US7291463B2 (en) 1996-01-23 2007-11-06 Affymetrix, Inc. Nucleic acid labeling compounds
US6924094B1 (en) * 1996-02-08 2005-08-02 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
EP1728875A3 (en) 1996-02-08 2007-05-09 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US6129917A (en) * 1996-03-22 2000-10-10 The University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
NZ332566A (en) * 1996-05-22 2000-08-25 Novopharm Biotech Inc Antigen binding fragments that specifically detect cancer cells
EP0918845A4 (en) 1996-07-08 2000-08-30 Burstein Lab Inc Cleavable signal element device and method
US6331275B1 (en) 1996-07-08 2001-12-18 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US20050214827A1 (en) * 1996-07-08 2005-09-29 Burstein Technologies, Inc. Assay device and method
US6342349B1 (en) 1996-07-08 2002-01-29 Burstein Technologies, Inc. Optical disk-based assay devices and methods
US20050069923A1 (en) * 1996-07-08 2005-03-31 Mullis Kary Banks Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
DK0920505T3 (en) 1996-08-16 2008-09-08 Schering Corp Mammalian cell surface antigens and associated reagents
PT932678E (en) 1996-09-24 2006-07-31 Tanox Inc A family of genes that encode apoptosis-related, peptide-encoded peptides and methods for their use
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
EP0954585B1 (en) 1996-10-01 2009-11-25 Geron Corporation Human telomerase reverse transcriptase promoter
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6808880B2 (en) * 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
CA2272850C (en) 1996-11-15 2009-02-24 Board Of Regents, The University Of Texas System Genetic test for equine severe combined immunodeficiency disease
DE122010000046I1 (en) 1996-12-13 2011-05-05 Schering Corp Surface antigens from mammals
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
CA2279231C (en) 1997-02-07 2013-11-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Activity dependent neurotrophic factor iii (adnf iii)
US6268165B1 (en) 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US6127338A (en) 1997-04-01 2000-10-03 Calyx Therapeutics, Inc. Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
PT1798288E (en) 1997-05-07 2009-12-23 Schering Corp Human toll-like receptor proteins, related reagents and methods
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
WO1998059073A1 (en) 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Method for detection of breast cancer
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
CN1493597A (en) 1997-07-09 2004-05-05 ���鹫˾ Isolation of dendritic cell membrane protein genes
JP2001500391A (en) * 1997-07-11 2001-01-16 ユニバーシティ オブ ノース テキサス Escherichia coli csrB gene, RNA encoded thereby, and methods of use
US6723550B1 (en) * 1997-07-15 2004-04-20 Genencor International, Inc. Proteases from gram-positive organisms
US6506579B1 (en) 1997-07-15 2003-01-14 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms using SecG
US6762039B2 (en) * 1997-07-15 2004-07-13 Genencor International, Inc. Bacillus subtillis with an inactivated cysteine protease-1
US20030157642A1 (en) 1997-07-15 2003-08-21 Caldwell Robert M. Increasing production of proteins in gram-positive microorganisms
US6521421B1 (en) 1997-07-16 2003-02-18 Genencor International, Inc. Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
PE20000183A1 (en) 1997-07-25 2000-03-11 Schering Corp MAMMAL CYTOKINES AND RELATED REAGENTS
US6180411B1 (en) 1997-08-01 2001-01-30 The Regents Of The University Of California Light-triggered indicators that memorize analyte concentrations
PT1003861E (en) 1997-08-01 2007-01-31 Schering Corp Mammalian cell membrane proteins; related reagents
US7252950B1 (en) * 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US6521440B1 (en) * 1997-09-15 2003-02-18 Genencor International, Inc. Proteases from gram-positive organisms
US6300117B1 (en) * 1997-09-15 2001-10-09 Genencor International, Inc. Proteases from gram-positive organisms
US7378244B2 (en) * 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
US6482389B1 (en) 1997-10-17 2002-11-19 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
GB9724629D0 (en) * 1997-11-20 1998-01-21 Genencor Int Bv Alpha/beta hydrolase-fold enzymes
US6316241B1 (en) * 1997-11-20 2001-11-13 Genencor International, Inc. Alpha/beta hydrolase-fold enzymes
US6465186B1 (en) * 1997-12-30 2002-10-15 Genecor International, Inc. Proteases from gram positive organisms
GB9727470D0 (en) * 1997-12-30 1998-02-25 Genencor Int Bv Proteases from gram positive organisms
US6599731B1 (en) * 1997-12-30 2003-07-29 Genencor International, Inc. Proteases from gram positive organisms
US6528255B1 (en) * 1997-12-30 2003-03-04 Genencor International, Inc. Proteases from gram positive organisms
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
US6060260A (en) * 1998-02-27 2000-05-09 Dade Behring Inc. Methods for reducing adsorption in an assay
JP2002505108A (en) 1998-03-04 2002-02-19 ジェネンコア インターナショナル インコーポレーテッド Modified form of pullulanase
US6869770B1 (en) 1998-03-20 2005-03-22 The Curators Of The University Of Missouri Compositions and methods for early pregnancy diagnosis
DK1696236T3 (en) * 1998-03-30 2014-08-18 Orasure Technologies Inc Collection device for analysis of oral fluids
US6303081B1 (en) 1998-03-30 2001-10-16 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US8062908B2 (en) * 1999-03-29 2011-11-22 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
ATE546544T1 (en) * 1998-03-31 2012-03-15 Esoterix Genetic Lab Llc METHOD FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
US7108968B2 (en) * 1998-04-03 2006-09-19 Affymetrix, Inc. Mycobacterial rpoB sequences
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
AU3745799A (en) 1998-04-14 1999-11-01 Regents Of The University Of California, The Assays for the detection of microtubule depolymerization inhibitors
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
WO2000002561A1 (en) 1998-07-13 2000-01-20 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
JP2002521666A (en) * 1998-07-21 2002-07-16 バースタイン テクノロジーズ,インコーポレイティド Optical disc based assay device and method
ES2188190T5 (en) 1998-07-21 2007-11-16 Danisco A/S FOOD PRODUCT.
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
SE9803099D0 (en) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
CA2343320A1 (en) * 1998-09-18 2000-03-30 The Rockefeller University Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
JP2002526079A (en) 1998-09-21 2002-08-20 シェーリング コーポレイション Human interleukin-B50, therapeutic use
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
JP2003523166A (en) 1998-09-29 2003-08-05 ガミダ セル リミテッド Methods for controlling proliferation and differentiation of stem and progenitor cells
ES2333694T3 (en) 1999-01-11 2010-02-26 Schering Corporation CYTOKINES OF MAMMALS RELATED TO INTERLEUQUINA-17.POLINUCLEOTIDO THAT CODIFY THEM AND ITS FACILITIES.
JP4523169B2 (en) 1999-02-04 2010-08-11 プルリステム リミテッド Method and apparatus for maintaining and increasing hematopoietic stem cells and / or progenitor cells
US6156515A (en) * 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
AR022890A1 (en) 1999-03-11 2002-09-04 Schering Corp MAMMARY CYTOKINS; RELATED REAGENTS AND METHODS
MXPA01011519A (en) 1999-05-13 2003-08-20 Medical Res Council Ox2 receptor homologs.
WO2000069898A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in allergy cells
US6440682B1 (en) * 1999-05-28 2002-08-27 Detroit R&D Inc. Detection of hypertension using immunoreactive metabolic products
ES2322791T5 (en) 1999-06-01 2013-11-29 Merck Sharp & Dohme Corp. Mammalian receptor proteins; reagents and related methods
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
GB9914210D0 (en) 1999-06-17 1999-08-18 Danisco Promoter
EP1190082A4 (en) * 1999-06-25 2003-07-02 Yissum Res Dev Co Method of inducing angiogenesis by micro-organs
US6531130B1 (en) 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
DE60042827D1 (en) 1999-07-30 2009-10-08 Schering Corp CYTOKINS FROM MAMMALS AND ASSOCIATED REAGENTS
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
EP1905832A3 (en) 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
DE60041821D1 (en) 1999-09-24 2009-04-30 Cybios Llc PLURIPOTENT EMBRYONAL STEM CELL-SIMILAR CELLS, COMPOSITIONS, AND ITS CONDITIONS
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
NZ519043A (en) 1999-11-19 2006-12-22 Yissum Res Dev Co Nucleic acid comprising a gene derived from Aspergillus niger that encodes a polypeptide that has a beta-glucosidase catalytic activity
EP2261256A3 (en) 1999-11-24 2011-03-02 Schering Corporation Methods of inhibiting metastasis
EP1247095B1 (en) 1999-12-06 2008-10-15 Board Of Trustees Of The University Of Illinois High affinity tcr proteins and methods
US6544792B1 (en) 1999-12-21 2003-04-08 Genencor International, Inc. Production of secreted polypeptides
US6544506B2 (en) * 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
AU2001225441A1 (en) * 2000-01-24 2001-07-31 Agricultural Research Organization The Volcani Center Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
DE10003734A1 (en) * 2000-01-28 2001-08-02 Bosch Gmbh Robert Detection method and device
EP1259626B1 (en) * 2000-02-25 2007-10-31 Ludwig Institute For Cancer Research Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins and screening methods for modulators
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US8288128B2 (en) * 2004-11-18 2012-10-16 Eppendorf Array Technologies S.A. Real-time quantification of multiple targets on a micro-array
US7829313B2 (en) * 2000-03-24 2010-11-09 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US7875442B2 (en) * 2000-03-24 2011-01-25 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2316950A1 (en) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP1274834B1 (en) 2000-03-31 2010-07-07 The Scripps Research Institute HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US20030108927A1 (en) * 2000-04-03 2003-06-12 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
PT1274450E (en) 2000-04-18 2009-03-06 Schering Corp Medical uses of agonsist and antagonists of il-174
IL135884A (en) * 2000-04-30 2005-08-31 Yissum Res Dev Co Method for measuring non-transferrin bound iron
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PL209128B1 (en) 2000-05-10 2011-07-29 Schering Corp Mammalian cytokine receptor subunit proteins, related reagents and methods
MXPA02011618A (en) 2000-05-25 2003-03-10 Schering Corp Human receptor proteins; related reagents and methods.
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
HUP0300810A2 (en) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Artifical vascular grafts, and methods of producing and using same
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1320542B9 (en) 2000-08-08 2007-09-12 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
DK1315519T3 (en) 2000-08-08 2011-04-11 Technion Res & Dev Foundation Pharmaceutical compositions and methods that can be used to treat cancer or liver fibrosis
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
EP1683874A3 (en) 2000-08-29 2006-10-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
CA2419979A1 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
EP1315965A4 (en) 2000-09-08 2006-04-05 Univ Texas Methods and compositions for in vitro targeting
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
DE60115958T2 (en) * 2000-09-18 2006-08-03 Genencor International, Inc., Palo Alto TWIN ARGININE TRANSLOCATION IN BACILLUS
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US7632522B2 (en) * 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
EP1379127B1 (en) * 2000-09-28 2013-04-17 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7018812B2 (en) 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
US7163800B2 (en) * 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050136431A1 (en) * 2000-11-03 2005-06-23 Oakley Robert H. Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
PT2186530E (en) 2000-11-17 2013-08-02 Vascular Biogenics Ltd Promoters exhibiting endothelial cell specificity and methods of using same
WO2002041827A2 (en) 2000-11-24 2002-05-30 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20020172980A1 (en) * 2000-11-27 2002-11-21 Phan Brigitte Chau Methods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20030003464A1 (en) * 2000-11-27 2003-01-02 Phan Brigitte C. Dual bead assays including optical biodiscs and methods relating thereto
US20040248093A1 (en) * 2000-11-27 2004-12-09 Coombs James Howard Magneto-optical bio-discs and systems including related methods
CA2430082A1 (en) * 2000-11-29 2002-06-06 Lynkeus Biotech Gmbh Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
JP2004524010A (en) 2000-11-30 2004-08-12 モルキューラー スキンケア リミテッド Diagnosis and treatment of disease
IL155941A0 (en) * 2000-11-30 2003-12-23 Yeda Res & Dev Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
US7087395B1 (en) 2001-01-16 2006-08-08 Quest Diagnostics Investments Incorporated Vitamin D assay
GB0101762D0 (en) * 2001-01-23 2001-03-07 Medical Res Council Method
US20050202098A1 (en) 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
US20050031618A1 (en) * 2001-01-31 2005-02-10 Dror Mevorach Induction of tolerance by apoptotic and/or necrotic cells
JP2004537506A (en) 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド Use of certain steroids to treat blood cell deficiency
AU2002258502A1 (en) 2001-03-12 2002-09-24 Affymetrix, Inc. Nucleic acid labeling compounds
US20030104410A1 (en) * 2001-03-16 2003-06-05 Affymetrix, Inc. Human microarray
US20030003454A1 (en) 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
US20030220475A1 (en) * 2001-04-03 2003-11-27 Fields Howard A. Neutralizing immunogenic hev polypepetides
WO2002081630A2 (en) * 2001-04-06 2002-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of semenogelin in the diagnosis, prognosis and treatment of cancer
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
MXPA03010511A (en) 2001-05-18 2004-03-02 Danisco Method of improving dough and bread quality.
CA2448142A1 (en) 2001-05-22 2002-11-28 Merck & Co., Inc. Beta-secretase substrates and uses thereof
WO2002099069A2 (en) * 2001-06-05 2002-12-12 The Regents Of The University Of California Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20090324612A1 (en) * 2001-06-05 2009-12-31 Kaufman Daniel L Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US20070190534A1 (en) * 2001-06-11 2007-08-16 Genesis Genomics Inc. Mitochondrial sites and genes associated with prostate cancer
US20050022269A1 (en) * 2001-07-19 2005-01-27 Joseph Hirschberg Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
JP2004536614A (en) * 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ PDE3 cyclic nucleotide phosphodiesterase isoform-selective inhibitors and activators
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20030082596A1 (en) * 2001-08-08 2003-05-01 Michael Mittmann Methods of genetic analysis of probes: test3
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US7442781B2 (en) 2001-08-16 2008-10-28 Urifer Ltd. Diagnosis, prevention and treatment of cancer
US7138144B2 (en) * 2001-09-07 2006-11-21 Nadir Askenasy Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US20040136972A1 (en) 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
JP4424987B2 (en) 2001-09-20 2010-03-03 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム Measurement of circulating therapeutic antibodies, antigens and antigen / antibody complexes using an ELISA assay
WO2003028582A2 (en) 2001-09-28 2003-04-10 Aspenbio, Inc. Bovine pregnancy test
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2003030835A2 (en) 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
JP4173446B2 (en) 2001-10-19 2008-10-29 ヴァスキュラー バイオジェニックス リミテッド Polynucleotide constructs and pharmaceutical compositions and methods for targeted down-regulation of angiogenesis and anti-cancer therapy
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
MXPA04004880A (en) 2001-11-20 2004-09-03 Monsanto Technology Llc Compositions and methods for accurate early pregnancy diagnosis.
US6952704B2 (en) * 2001-11-26 2005-10-04 Microsoft Corporation Extending a directory schema independent of schema modification
WO2003048298A2 (en) * 2001-12-05 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
WO2003054155A2 (en) * 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US20050085432A1 (en) * 2001-12-26 2005-04-21 Aviva Lapidot Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
WO2003063110A1 (en) * 2002-01-16 2003-07-31 Regents Of The University Of Minnesota Marker for psychiatric conditions
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062278A1 (en) 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
DK2311869T3 (en) 2002-02-01 2013-03-18 Merck Sharp & Dohme Use of mammalian cytokine-related reagents
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) * 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
AU2003225589A1 (en) 2002-02-22 2003-09-09 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Brother of the regulator of imprinted sites (boris)
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
EP1485464A4 (en) * 2002-03-18 2006-11-29 Gamida Cell Ltd Methods of inducing differentiation in ex vivo expanded stem cells
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
IL164191A0 (en) * 2002-03-26 2005-12-18 Nanocyte Inc Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc.
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US7534580B2 (en) * 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US20040121442A1 (en) * 2002-05-05 2004-06-24 Ilan Chet Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
WO2003101386A2 (en) 2002-05-30 2003-12-11 Memorial Sloan-Kettering Cancer Center Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
NZ537328A (en) * 2002-05-31 2008-04-30 Genetic Technologies Ltd Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
JP2005533102A (en) * 2002-07-12 2005-11-04 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム Method and apparatus for inducing biological processes by micro-organs
DK1537146T3 (en) 2002-07-15 2011-04-04 Univ Texas Antibodies that bind to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections
AU2003304195B8 (en) 2002-07-15 2008-08-28 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
ES2449115T3 (en) 2002-08-01 2014-03-18 Yeda Research And Development Co., Ltd. Method and composition to protect neuronal tissue from lesions induced by elevated glutamate levels
DE60332842D1 (en) 2002-08-10 2010-07-15 Univ Yale ANTAGONISTS OF NOGO RECEPTOR
EP1539183A4 (en) 2002-08-28 2007-04-25 Hollis Eden Pharmaceuticals Therapeutic treatment methods
CN1695058B (en) 2002-09-09 2011-04-13 生命树股份有限公司 Methods of diagnosing cervical cancer
EP2371955A1 (en) 2002-09-26 2011-10-05 K.U. Leuven Research & Development Integrase cofactor
US7267981B2 (en) 2002-10-07 2007-09-11 Technion Research & Development Foundation Ltd. Human foreskin fibroblasts for culturing ES cells
MXPA05004434A (en) 2002-10-24 2005-07-26 Sterix Ltd Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2.
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
AU2003278578A1 (en) 2002-10-30 2004-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Molecules and methods using same for measuring non-transferrin bound iron
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
CN100536836C (en) * 2002-11-26 2009-09-09 芝加哥大学 Materials and methods for preventing and treating microbe-mediated epithelial disorders
US7947499B2 (en) * 2002-11-29 2011-05-24 Technion Research & Development Foundation Ltd. Method of dynamically culturing embryonic stem cells
JP2006508662A (en) 2002-12-04 2006-03-16 アプレラ コーポレイション Multiplex amplification of polynucleotides
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
CN101297789B (en) 2002-12-12 2013-01-02 R.B.T.(洛东生物科技)有限公司 Methods of producing lignin peroxidase and use thereof in skin and hair lightening
PT2457999T (en) 2002-12-16 2019-01-28 Technion Res & Dev Foundation Culture medium for pluripotent stem cells
AU2002953431A0 (en) * 2002-12-19 2003-01-09 Murdoch University BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof
CN1780921B (en) 2003-01-02 2010-12-08 拉帕波特家族医学研究院 Reagent and kit for detecting haptogiobin phenotype, and uses thereof
US20040229245A1 (en) * 2003-01-06 2004-11-18 Anton Bittner Methods and algorithms for performing quality control during gene expression profiling on DNA microarray technology
EP1583713B1 (en) * 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US7955814B2 (en) 2003-01-17 2011-06-07 Danisco A/S Method
US20050196766A1 (en) 2003-12-24 2005-09-08 Soe Jorn B. Proteins
MXPA05007653A (en) 2003-01-17 2005-09-30 Danisco Method.
BR122016015076B1 (en) 2003-01-17 2017-05-16 Dupont Nutrition Biosci Aps method of producing a carbohydrate ester and using a lipid acyltransferase enzyme to produce a carbohydrate ester
EP1590438A2 (en) * 2003-01-24 2005-11-02 Duke University Modified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera
US20050032126A1 (en) * 2003-03-03 2005-02-10 Coombs James H. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US7786071B2 (en) 2003-03-04 2010-08-31 Yeda Research And Development Co. Ltd. Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same
EP1599608A4 (en) * 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal dna and fetal cell markers in maternal plasma or serum
KR20130026513A (en) 2003-03-07 2013-03-13 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 Treatment of iga1 deposition diseases
CA2517959A1 (en) * 2003-03-07 2004-09-16 Gamida-Cell Ltd. Expansion of renewable stem cell populations using modulators of pi 3-kinase
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US7524938B2 (en) 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
AU2004227204B2 (en) 2003-04-08 2010-06-03 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
FR2853551B1 (en) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM
US20040209246A1 (en) * 2003-04-15 2004-10-21 Agouron Pharmaceuticals, Inc. Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
BRPI0409562A (en) * 2003-04-16 2006-04-18 Univ Yale treatment of conditions involving amyloid plaques
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7554007B2 (en) * 2003-05-22 2009-06-30 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants
AU2005234725B2 (en) 2003-05-22 2012-02-23 Evogene Ltd. Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby
CA2978152C (en) 2003-05-22 2021-01-26 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20050020499A1 (en) * 2003-05-27 2005-01-27 Bar Ilan University Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US8129514B2 (en) * 2003-06-19 2012-03-06 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
WO2004111183A2 (en) * 2003-06-19 2004-12-23 Evogene Ltd. Plant trichome-specific promoter and leucoplast signal sequence
WO2005014795A2 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
US20050064479A1 (en) * 2003-08-12 2005-03-24 Affymetrix, Inc. Compounds and methods for post incorporation labeling of nucleic acids
US20080050313A1 (en) 2003-08-14 2008-02-28 Exelixis, Inc. Sulfs as Modifiers of the Beta-Catenin Pathway and Methods of Use
JP2007518394A (en) * 2003-08-14 2007-07-12 ザ バイオ バランス コーポレイション Bacterial strain, composition containing the bacterial strain, and use of probiotics thereof
CA2537818A1 (en) 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
US20050064435A1 (en) * 2003-09-24 2005-03-24 Xing Su Programmable molecular barcodes
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
CA2541535C (en) 2003-10-07 2013-12-10 Yeda Research And Development Co. Ltd. Antibodies to nik, their preparation and use
CN1918281A (en) * 2003-10-23 2007-02-21 辉瑞产品公司 Vaccine for periodontal disease
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
PE20090047A1 (en) 2003-11-10 2009-01-26 Schering Corp RECOMBINANT ANTI-INTERLEUQUIN HUMANIZED ANTIBODY 10
WO2005051423A2 (en) 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
WO2005060368A2 (en) 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
US20100221233A1 (en) * 2003-12-15 2010-09-02 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
WO2005061018A1 (en) 2003-12-22 2005-07-07 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring protein backbone
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
EP2119771B1 (en) 2003-12-24 2018-08-22 DuPont Nutrition Biosciences ApS Proteins
US7718408B2 (en) * 2003-12-24 2010-05-18 Danisco A/S Method
GB0716126D0 (en) * 2007-08-17 2007-09-26 Danisco Process
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050186646A1 (en) * 2004-01-26 2005-08-25 Cruz Miguel A. Rapid assay to detect ADAMTS-13 activity
AU2005206388A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
CA2555208A1 (en) * 2004-02-18 2005-09-01 Merck & Co., Inc. Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1721011A1 (en) 2004-03-01 2006-11-15 Applera Corporation Methods, compositions and kits for use in polynucleotide amplification
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
NZ549787A (en) 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
GB0405637D0 (en) 2004-03-12 2004-04-21 Danisco Protein
BRPI0510004A (en) * 2004-04-20 2007-09-18 Univ Chicago article of manufacture, methods for administering a therapeutic composition to an individual's epithelium, to treat a microbe-mediated condition of an individual's epithelium, to ameliorate a symptom of a condition and to prevent a condition, and to use compound type peg pma
US8586294B2 (en) 2004-05-18 2013-11-19 The Board Of Trustees Of The Leland Stanford Junior University Detection of protein translocation by beta-galactosidase reporter fragment complementation
WO2005118864A2 (en) 2004-05-28 2005-12-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
EP1766058A4 (en) 2004-06-14 2008-05-21 Evogene Ltd Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
ITBO20040412A1 (en) * 2004-07-01 2004-10-01 Eurodent Spa DENTAL LAMP PARTICULARLY FOR MEDICAL-DENTAL AMBULATORS
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
PL1791933T3 (en) 2004-07-16 2011-12-30 Dupont Nutrition Biosci Aps Enzymatic oil-degumming method
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
US20090035784A1 (en) * 2004-07-30 2009-02-05 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof
US20060073168A1 (en) * 2004-08-11 2006-04-06 Stephens David S Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
DK2386640T3 (en) 2004-08-26 2015-04-27 Engeneic Molecular Delivery Pty Ltd The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells
FI20050753A (en) 2004-09-03 2006-03-04 Licentia Oy New peptides
JP4933435B2 (en) 2004-09-14 2012-05-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト Bucindolol treatment method based on gene targeting
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
ATE487484T1 (en) 2004-09-18 2010-11-15 Univ Maryland THERAPEUTIC AGENTS FOR TARGETING THE NC CA ATP CHANNEL AND METHOD OF USE THEREOF
WO2006036278A2 (en) 2004-09-18 2006-04-06 University Of Maryland, Baltimore THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
CN101103045B (en) * 2004-09-24 2015-11-25 安姆根有限公司 The Fc molecule modified
JP5069562B2 (en) * 2004-09-29 2012-11-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム Recombinant human T2RNase and uses thereof
EP1809751B1 (en) 2004-09-29 2010-09-01 CollPlant Ltd. Collagen producing plants and methods of generating and using same
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
US7390489B2 (en) * 2004-10-08 2008-06-24 Komed Co., Ltd. Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
EP1809374A4 (en) * 2004-10-12 2008-09-10 Closed Loop Therapies Ltd Methods and implantable devices for treating supraventricular arrhythmias
GB0423139D0 (en) 2004-10-18 2004-11-17 Danisco Enzymes
AU2005302291B2 (en) * 2004-11-02 2011-02-10 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
GB0424940D0 (en) 2004-11-11 2004-12-15 Danisco Transcription factors
EP2302072B1 (en) 2004-11-18 2012-03-14 Eppendorf Array Technologies S.A. Real time-PCR of targets on a micro-array
MX2007006640A (en) 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.
US7504769B2 (en) * 2004-12-16 2009-03-17 E. I. Du Pont De Nemours + Company Aromatic chalcogen compounds and their use
US20060134680A1 (en) * 2004-12-22 2006-06-22 Alexander Kotlyar Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US8375327B2 (en) 2005-01-16 2013-02-12 Zlango Ltd. Iconic communication
EP1872604A4 (en) * 2005-01-16 2010-01-20 Zlango Ltd Communications network system and methods for using same
US8019818B2 (en) * 2005-01-18 2011-09-13 Zlango Ltd. Communications network system and methods for using same
ES2562406T3 (en) 2005-01-31 2016-03-04 Realbio Technologies Ltd. Multi-stage reaction lateral flow capillary device
CN103497993A (en) 2005-02-07 2014-01-08 基因信息公司 Mild osteoarthritis biomarkers and uses thereof
ES2366654T3 (en) 2005-02-17 2011-10-24 HADASIT MEDICAL RESEARCH SERVICES &amp; DEVELOPMENT CO., LTD. BIOPHOSPHONATES TO TREAT ENDOMETRIOSIS.
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
JP5432455B2 (en) 2005-02-25 2014-03-05 ザ ステート オブ イスラエル、ミニストリー オブ アグリカルチャー アンド ルーラル ディベロップメント、アグリカルチュラル リサーチ オーガナイゼイション、(エー.アール.オー.)、ボルカニ センター Fruit cell culture extract for inflammation treatment
US7695927B2 (en) * 2005-03-18 2010-04-13 Detroit R & D Detection of hypertension using glucuronidated metabolic products
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
WO2006107962A2 (en) 2005-04-04 2006-10-12 Biogen Idec Ma Inc Methods and products for evaluating an immune response to a therapeutic protein
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
EP1877559B1 (en) 2005-04-18 2010-10-13 Mitomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20130022979A1 (en) 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
EP2224008A3 (en) 2005-05-12 2010-12-01 Murdoch University Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
US9943481B2 (en) 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
ES2524996T3 (en) 2005-06-16 2014-12-16 Ramot At Tel Aviv University Ltd. Isolated cells and populations that comprise them for the treatment of CNS diseases
EP2711434B1 (en) 2005-06-20 2016-09-14 Advanced Cell Diagnostics, Inc. Multiplex detection of nucleic acids
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US9051379B2 (en) 2005-07-07 2015-06-09 Fulcrum Sp Ltd. Sp1 polypeptides, modified Sp1 polypeptides and uses thereof
CN101273130B (en) * 2005-07-07 2012-05-30 耶路撒冷希伯来大学伊森姆研究发展公司 Nucleic acid agents for downregulation of H19 and methods of use thereof
CA2615218A1 (en) 2005-07-18 2007-01-25 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
ES2534428T3 (en) 2005-07-26 2015-04-22 Rutgers, The State University Of New Jersey Profiles of antibodies specific for a tuberculous state
WO2007019541A2 (en) * 2005-08-08 2007-02-15 Onconon, Llc. Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1928479B1 (en) 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
SG177946A1 (en) 2005-08-29 2012-02-28 Technion Res & Dev Foundation Media for culturing stem cells
EP1931710B1 (en) 2005-08-31 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
DE602006014009D1 (en) * 2005-09-22 2010-06-10 Yissum Res Dev Co NUCLEIC ACID CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2007041340A2 (en) * 2005-09-30 2007-04-12 The Trustees Of Columbia University In The City Of New York Microfluidic cells with parallel arrays of individual dna molecules
WO2007047408A2 (en) * 2005-10-12 2007-04-26 Pathologica, Llc. Promac signature application
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
EP1945816B1 (en) 2005-10-21 2011-07-27 GeneNews Inc. Method and apparatus for correlating levels of biomarker products with disease
EP1940217A4 (en) 2005-10-24 2009-11-11 Evogene Ltd Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US7842823B2 (en) * 2005-10-27 2010-11-30 The Regents Of The University Of California Fluorogenic probes for reactive oxygen species
JP5336853B2 (en) 2005-11-02 2013-11-06 プロチバ バイオセラピューティクス インコーポレイティッド Modified siRNA molecules and methods of use thereof
NZ568762A (en) 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
DE212006000071U1 (en) 2005-11-18 2008-07-24 Board of Regents, The University of Texas System, Austin Quantification of fusion proteins and their activity as a result of chromosomal translocation
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
KR20080072748A (en) 2005-11-29 2008-08-06 가미다-셀 리미티드 Methods of improving stem cell homing and engraftment
KR20080080525A (en) 2005-12-08 2008-09-04 노파르티스 아게 Effects of inhibitors of fgfr3 on gene transcription
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CN101374860A (en) 2005-12-23 2009-02-25 技术转让合伙人公司 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US7465544B2 (en) * 2006-01-11 2008-12-16 Wisconsin Alumni Research Foundation Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
WO2007080559A2 (en) 2006-01-16 2007-07-19 Zlango Ltd. Iconic communication
BRPI0707276B1 (en) 2006-01-27 2021-08-31 Biogen Ma Inc NOGO RECEPTOR ANTAGONIST FUSION POLYPEPTIDE
TW200738752A (en) 2006-01-31 2007-10-16 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EP1989554A1 (en) 2006-02-06 2008-11-12 Rappaport Family Institute For Research in the Medical Sciences Methods and kit for diagnosing t1dm
BRPI0707590A2 (en) 2006-02-08 2011-05-10 Genzyme Corp niemann-pick gene therapy for type a disease
EP1996940B1 (en) 2006-02-09 2011-12-21 University of South Florida Detection of cancer by elevated levels of bcl-2
JP2009528359A (en) 2006-02-28 2009-08-06 エラン ファーマシューティカルズ,インコーポレイテッド Methods of treating inflammatory and autoimmune diseases with natalizumab
US20070231319A1 (en) 2006-03-03 2007-10-04 Yednock Theodore A Methods of treating inflammatory and autoimmune diseases with natalizumab
EP1991852B1 (en) 2006-03-06 2015-07-01 Zetiq Technologies Ltd. Methods for identifying a cell phenotype
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
CA2646384C (en) 2006-03-23 2020-03-24 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2004858A4 (en) 2006-03-28 2009-12-09 Tel Hashomer Medical Res Infrastructure & Services Ltd Methods and kits for determining predisposition to warfarin resistance
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
JP2009533028A (en) * 2006-04-07 2009-09-17 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antibody compositions and methods for the treatment of neoplastic diseases
CA2648481C (en) 2006-04-21 2017-03-07 Melinda Jane Frost Pestivirus species
FR2900341B1 (en) * 2006-04-27 2012-09-14 Centre Nat Rech Scient USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR THE TREATMENT OF CANCER
EP2021495A4 (en) * 2006-05-09 2009-06-24 Musc Found For Res Dev Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
CA2652538C (en) * 2006-05-19 2016-06-28 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
CA2656347A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
US20080026394A1 (en) * 2006-07-11 2008-01-31 Antara Biosciences Inc. Methods of detecting one or more cancer markers
US8445222B2 (en) * 2006-07-11 2013-05-21 Musc Foundation For Research Development Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
KR101433392B1 (en) 2006-07-14 2014-08-29 케모센트릭스, 인크. Triazolyl phenyl benzenesulfonamides
EP2046109A4 (en) 2006-07-20 2010-01-06 Yeda Res & Dev Photosyntheticorganisms and compositions and methods of generating same
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
JP2008043332A (en) 2006-08-17 2008-02-28 Panomics Inc Quantitative determination of nucleic acid from tissue slide
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
EP2423333A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008026198A2 (en) 2006-08-28 2008-03-06 Yeda Research And Development Co. Ltd. Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
JP2008111824A (en) * 2006-09-01 2008-05-15 Nox Technologies Inc NEOPLASM SPECIFIC tNOX ISOFORM AND METHOD THEREFOR
US7985542B2 (en) * 2006-09-07 2011-07-26 Institut Pasteur Genomic morse code
EP2067043B1 (en) 2006-09-08 2013-07-17 University of Oxford Clinical diagnosis of hepatic fibrosis using inter-alpha-trypsin inhibitor heavy chain h4
US8050516B2 (en) * 2006-09-13 2011-11-01 Fluidigm Corporation Methods and systems for determining a baseline during image processing
US8055034B2 (en) 2006-09-13 2011-11-08 Fluidigm Corporation Methods and systems for image processing of microfluidic devices
US7888059B2 (en) * 2006-10-05 2011-02-15 Yeda Research And Development Co. Ltd. Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
CN101595251B (en) 2006-10-05 2014-06-11 技术研究及发展基金有限公司 Microtubes and methods of producing same
EP2074230B1 (en) 2006-10-11 2012-11-28 Janssen Pharmaceutica NV Compositions and methods for treating and diagnosing irritable bowel syndrome
EP1912067A1 (en) * 2006-10-12 2008-04-16 Eppendorf Array Technologies S.A. Method for quantification of a target compound obtained from a biological sample upon chips
EP2426199A3 (en) 2006-10-20 2012-08-22 Danisco US Inc. Polyol oxidases
JP5057402B2 (en) * 2006-10-26 2012-10-24 アボット・ラボラトリーズ Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
WO2008049930A2 (en) 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv A method for profiling kinase inhibitors
CA2668235A1 (en) 2006-11-02 2008-06-05 Yale University Assessment of oocyte competence
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
ATE555128T1 (en) 2006-11-30 2012-05-15 Res Dev Foundation IMPROVED IMMUNOLOBULIN LIBRARIES
WO2008067552A2 (en) * 2006-11-30 2008-06-05 Fluidigm Corporation Method and apparatus for biological sample analysis
EP2129690A1 (en) 2006-12-14 2009-12-09 Schering Corporation Engineered anti-tslp antibody
CA2672756C (en) 2006-12-20 2018-11-20 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8506499B2 (en) * 2007-01-04 2013-08-13 Musc Foundation For Research Development Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
ES2634266T3 (en) * 2007-01-11 2017-09-27 Erasmus University Medical Center Capture of circular chromosomal conformation (4C)
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
WO2008087641A2 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
MX2009008021A (en) 2007-01-25 2009-08-07 Danisco Production of a lipid acyltransferase from transformed bacillus licheniformis cells.
WO2008092094A2 (en) * 2007-01-26 2008-07-31 University Of South Florida Method and materials for detection, diagnosis and management of ovarian cancer
AU2008207746B2 (en) 2007-01-26 2013-09-05 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
EP2117616A2 (en) 2007-01-31 2009-11-18 Technion Research & Development Foundation Ltd. Electrospun scaffolds and methods of generating and using same
AU2008211549B2 (en) 2007-02-01 2012-12-06 Abraham Katzir Albumin fibers and fabrics and methods of generating and using same
CL2008000278A1 (en) 2007-02-02 2008-09-26 Amgen Inc HUMAN ANTI-HEPCIDINE MONOCLONAL ANTIBODY; NUCLEIC ACID THAT CODIFIES IT; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; COMPOSITION THAT UNDERSTANDS IT; IMMUNO TEST KIT THAT UNDERSTANDS IT; METHOD FOR DIAGNOSING AND TREATING A RELATED DISORDER
US8143046B2 (en) * 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
US20080220498A1 (en) * 2007-03-06 2008-09-11 Cervin Marguerite A Variant Buttiauxella sp. phytases having altered properties
KR100855299B1 (en) * 2007-02-16 2008-08-29 건국대학교 산학협력단 Monoclonal antibodies specific against il-32 antigens, hybridoma producing the monoclonal antibodies and diagnostic systems using the monoclonal antibodies
JP2008203195A (en) * 2007-02-22 2008-09-04 Japan Science & Technology Agency Bsh immunoassay kit and bsh measuring method
MX2009009079A (en) 2007-02-23 2009-08-31 Schering Corp Engineered anti-il-23p19 antibodies.
CN101663320A (en) 2007-02-23 2010-03-03 先灵公司 engineered anti-il-23p19 antibodies
KR20100014568A (en) 2007-02-28 2010-02-10 쉐링 코포레이션 Engineered anti-il-23r antibodies
US8748371B2 (en) 2007-02-28 2014-06-10 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
WO2008106149A1 (en) * 2007-02-28 2008-09-04 Children's Medical Center Corporation Methods for predicting the onset of menarche
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008110006A1 (en) 2007-03-12 2008-09-18 Miraculins Inc. Biomarkers of prostate cancer and uses thereof
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
EP2514766A3 (en) 2007-03-29 2013-06-05 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
PT2865755T (en) 2007-03-30 2017-05-26 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells encompassing regulatory rna
EP2142661B1 (en) 2007-04-02 2012-08-29 Ramot at Tel-Aviv University Ltd. Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
EP2132333B1 (en) 2007-04-06 2011-11-23 Becton, Dickinson and Company Compositions and methods for the identification of a carbapenemase gene
CN101854798B (en) 2007-04-09 2013-04-03 伊沃基因有限公司 Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
JP5926487B2 (en) 2007-04-13 2016-05-25 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Method for treating cancer resistant to ErbB therapy
US8003314B2 (en) 2007-04-16 2011-08-23 Diagnostic Hybrids, Inc. Methods for direct fluorescent antibody virus detection in liquids
PT2144633E (en) * 2007-04-23 2014-10-27 Deliversir Ltd A system for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US8338113B2 (en) 2007-05-01 2012-12-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods for detecting fetal cells in the maternal blood
EP2155789B1 (en) 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
CA2688548A1 (en) * 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
CA2685954A1 (en) 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
US10364413B2 (en) 2007-05-07 2019-07-30 Protalix Ltd. Large scale disposable bioreactor
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US9102754B2 (en) * 2007-06-28 2015-08-11 University Of Saskatchewan Immunomodulatory compositions and methods for treating disease with modified host defense peptides
WO2009009662A1 (en) * 2007-07-10 2009-01-15 University Of South Florida Method of predicting non-response to first line chemotherapy
WO2009007980A1 (en) 2007-07-11 2009-01-15 Yeda Research And Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
KR101969689B1 (en) 2007-07-12 2019-04-16 케모센트릭스, 인크. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
CA2696833A1 (en) 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2685631T3 (en) 2007-07-24 2018-10-10 Evogene Ltd. Polynucleotides, polypeptides encoded by them, and methods of using them to increase tolerance to abiotic stress and / or biomass and / or yield in plants that express them
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EP2543389A3 (en) 2007-08-02 2013-04-24 Gilead Biologics, Inc. Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8715743B2 (en) 2007-08-03 2014-05-06 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
US8992938B2 (en) 2007-08-03 2015-03-31 Matthew Bellgard Genes and proteins of Brachyspira hyodysenteriae and uses thereof
EP2185726B1 (en) 2007-08-06 2014-01-08 Orion Genomics, LLC Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
CN102264755A (en) 2007-08-08 2011-11-30 得克萨斯大学体系董事会 Vegfr-1/nrp-1 targeting peptides
WO2009023676A1 (en) 2007-08-12 2009-02-19 Integrated Dna Technologies, Inc. Microarray system with improved sequence specificity
US20090136916A1 (en) * 2007-08-13 2009-05-28 Trustees Of Tufts College Methods and microarrays for detecting enteric viruses
US20110052572A1 (en) 2007-08-15 2011-03-03 Yeda Research And Development Co. Ltd Regulators of mmp-9 and uses therof
WO2009072001A2 (en) * 2007-09-12 2009-06-11 Aurelium Biopharma Inc. Slc9a3r1 directed diagnostics for neoplastic disease
AU2008299318A1 (en) 2007-09-12 2009-03-19 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating tumors in immune-privileged sites
PT2200622E (en) 2007-09-19 2012-11-06 Pluristem Ltd Adherent cells from adipose or placenta tissues and use thereof in therapy
EP3136103B1 (en) 2007-10-05 2018-08-29 Affymetrix, Inc. Highly multiplexed assays
ES2505440T3 (en) 2007-10-19 2014-10-09 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaforins for the treatment of diseases related to angiogenesis and their selection procedures
EP2220112B1 (en) 2007-11-26 2015-08-26 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions comprising fibrous polypeptides and polysaccharides
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US20110119791A1 (en) 2007-12-27 2011-05-19 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
ES2500066T3 (en) 2008-01-25 2014-09-30 Amgen, Inc Ferroportin antibodies and methods of use
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
DK2252312T3 (en) 2008-02-07 2014-06-16 Univ Cornell Methods for preventing or treating insulin resistance
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
EP2254911B1 (en) * 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
US9297094B2 (en) 2008-02-21 2016-03-29 Technion Research & Development Foundation Ltd. Use of electrospun microtubes for drug delivery
EP2363407A1 (en) 2008-02-28 2011-09-07 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
US20090311695A1 (en) * 2008-03-12 2009-12-17 Talat Nasim Method
EP2530087B1 (en) 2008-03-27 2018-05-02 Murdoch University Sequences of brachyspira, immunogenic composition, methods for preparation and use thereof
KR101819852B1 (en) * 2008-03-28 2018-02-28 엠디엔에이 라이프 사이언시즈 인코퍼레이티드 Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
EP2107125A1 (en) 2008-03-31 2009-10-07 Eppendorf Array Technologies SA (EAT) Real-time PCR of targets on a micro-array
EP2297200A1 (en) * 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
EP2280731A1 (en) * 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
CN102083615B (en) * 2008-04-10 2014-08-13 战略系统有限公司 System and method for three dimensional model printing
HUE034483T2 (en) 2008-04-15 2018-02-28 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
CA2721380A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
CN104491845A (en) 2008-04-18 2015-04-08 科尔普兰特有限公司 Methods Of Generating And Using Procollagen
GB0807161D0 (en) * 2008-04-18 2008-05-21 Danisco Process
EP2268129B1 (en) 2008-04-21 2015-06-17 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
WO2009132100A2 (en) * 2008-04-23 2009-10-29 Luminex Corporation Method for creating a standard for multiple analytes found in a starting material of biological origin
CN102066579A (en) 2008-04-24 2011-05-18 纽约市哥伦比亚大学理事会 Geometric patterns and lipid bilayers for DNA molecule organization and uses thereof
WO2009133464A2 (en) 2008-04-30 2009-11-05 Danisco A/S Oxidation process
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US9243030B2 (en) * 2008-05-22 2016-01-26 Centre National De La Recherche Scientifique (Cnrs) Optically pure compounds for improved therapeutic efficiency
MX367882B (en) 2008-05-22 2019-09-10 Evogene Ltd Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility.
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2009144718A1 (en) 2008-05-28 2009-12-03 Ramot At Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
WO2009152102A2 (en) * 2008-06-10 2009-12-17 The Regents Of The University Of California Pro-fluorescent probes
EP2326419B1 (en) 2008-06-29 2021-04-07 Realbio Technologies Ltd. Liquid transfer device particularly useful as a capturing device in a biological assay process
CN102176914B (en) 2008-08-08 2014-12-17 新加坡科技研究局 VHZ for diagnosis and treatment of cancers
EP2657342B1 (en) 2008-08-08 2015-11-18 Genisphere, LLC DNA dendrimers protected against nuclease degradation
EP4079146A3 (en) 2008-08-18 2023-01-25 Evogene Ltd. Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
US8524496B2 (en) 2008-09-02 2013-09-03 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US8367392B2 (en) * 2008-09-05 2013-02-05 Transalgae Ltd. Genetic transformation of algal and cyanobacteria cells by microporation
US20110305682A1 (en) 2008-09-11 2011-12-15 Ben Gurion University Of The Negev Research And Development Authority Compositions and Methods for Treating S. Pneumonia Infection
WO2010031006A1 (en) 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
EP2789626B1 (en) 2008-09-24 2018-07-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010036323A1 (en) 2008-09-25 2010-04-01 University Of Massachusetts Medical School Method of identifing interactions between genomic loci
US20110178024A1 (en) 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010049897A2 (en) * 2008-10-30 2010-05-06 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
CA2743057C (en) 2008-11-07 2019-11-26 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
US20110229892A1 (en) 2008-11-17 2011-09-22 Yehuda G Assaraf Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010061383A1 (en) 2008-11-26 2010-06-03 Biodalia Microbiological Technologies Ltd. A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en) 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
US20120014927A1 (en) 2008-12-03 2012-01-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
CA2745111A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8734759B2 (en) 2008-12-05 2014-05-27 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
CN104174025B (en) 2008-12-05 2017-01-11 阿布拉西斯生物科学有限责任公司 SPARC binding peptides and uses thereof
US20120003664A1 (en) 2008-12-09 2012-01-05 Uffe Lovborg Method for evaluating pre-treatment
WO2010068757A1 (en) 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
CA2748121C (en) 2008-12-29 2017-12-12 Tel Hashomer Medical Research, Infrastructure And Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010076788A2 (en) 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
MX340023B (en) 2008-12-29 2016-06-22 Evogene Ltd Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same.
WO2010076794A1 (en) 2008-12-31 2010-07-08 Technion Research & Development Foundation Ltd. Method of denitrifying brine and systems capable of same
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
IL196820A0 (en) 2009-02-01 2009-11-18 Yissum Res Dev Co Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells
US8691760B2 (en) 2009-02-02 2014-04-08 Ramot At Tel-Aviv University Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1 (en) 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
US20120165340A1 (en) 2009-02-11 2012-06-28 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
CN102439454B (en) 2009-02-11 2015-05-13 卡里斯Mpi公司 Molecular profiling of tumors
JP5748672B2 (en) 2009-02-11 2015-07-15 オリオン ゲノミクス エルエルシー Combination of polymorphisms to determine allele-specific expression of IGF2
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
EP2401362B1 (en) 2009-02-26 2017-04-12 Tel HaShomer Medical Research Infrastructure and Services Ltd. Isolated populations of renal stem cells and methods of isolating and using same
CA2753616C (en) 2009-03-02 2018-07-17 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103515A2 (en) 2009-03-09 2010-09-16 Ramot At Tel Aviv University Ltd. Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
US20100240065A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Prolyl Hydroxylase Compositions and Methods of Use Thereof
US8481698B2 (en) * 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
KR101720555B1 (en) 2009-03-27 2017-03-29 엠디엔에이 라이프 사이언시즈 인코퍼레이티드 Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor
PT2411410E (en) * 2009-03-27 2015-10-09 Gojo Ind Inc Compositions and methods for screening and using compounds antagonizing spore-surface interactions
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
JP2012522762A (en) 2009-04-01 2012-09-27 ザ メディカル リサーチ, インフラストラクチャー, アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター Methods for regulating keratinocyte proliferation and differentiation
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
US9447467B2 (en) 2009-04-21 2016-09-20 Genetic Technologies Limited Methods for obtaining fetal genetic material
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
KR20180077322A (en) 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드. Anti ceacam1 antibodies and methods of using same
EP2425253B1 (en) 2009-05-01 2017-03-22 Dako Denmark A/S New antibody cocktail
CN105866423A (en) * 2009-05-14 2016-08-17 牛津大学之校长及学者 Clinical diagnosis of hepatic fibrosis using novel panel of low abundant human plasma protein biomarkers
CA2761767A1 (en) 2009-05-19 2010-11-25 Danisco A/S Use of amylase and lipolytic enzyme in bread
US9182403B2 (en) 2009-05-19 2015-11-10 Zetiq Technologies Ltd. Kits for and methods of differential staining of cervical cancer cells and/or tissues
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
US20120083477A1 (en) 2009-05-27 2012-04-05 Yeda Research And Development Co. Ltd. Proteasome inhibitors and uses thereof
WO2010137013A1 (en) 2009-05-27 2010-12-02 Ramot At Tel Aviv University Ltd. Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137021A2 (en) 2009-05-27 2010-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
EP2438444A1 (en) 2009-06-02 2012-04-11 The Board of Regents of The University of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
ES2773985T3 (en) 2009-06-10 2020-07-16 Evogene Ltd Isolated polynucleotides and polypeptides, and methods of using them to increase nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and / or tolerance to abiotic stress
EP2446267A1 (en) 2009-06-24 2012-05-02 Health Corporation - Rambam Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
CN102459581B (en) 2009-06-25 2014-10-29 杜邦营养生物科学有限公司 Protein
IN2012DN00403A (en) 2009-06-29 2015-08-21 Univ Western Australia
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
HUE029328T2 (en) 2009-07-17 2017-02-28 Bioatla Llc Simulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
ES2753986T3 (en) 2009-07-21 2020-04-15 Tel Hashomer Medical Res Infrastructure & Services Ltd A method of diagnosing cancer
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US20120148546A1 (en) 2009-08-17 2012-06-14 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
US20120157512A1 (en) 2009-08-21 2012-06-21 Monsanto Technology Llc Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
KR20120063488A (en) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. Catalytic domains from lysyl oxidase and loxl2
CN106619515A (en) 2009-08-27 2017-05-10 工业研究与发展基金会有限公司 Liposomal compositions and uses of same
ES2788869T3 (en) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anti-GITR antibodies
EP2475381A2 (en) 2009-09-08 2012-07-18 Yeda Research and Development Co. Ltd. Methods for hematopoietic precursor mobilization
EP2475784A1 (en) 2009-09-08 2012-07-18 Ramot at Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
US20120171213A1 (en) 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2477652B1 (en) 2009-09-16 2015-04-15 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
US8735124B2 (en) 2009-09-17 2014-05-27 Yeda Research And Development Co. Ltd. Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2478093A2 (en) 2009-09-17 2012-07-25 Yeda Research and Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
BR112012006005A2 (en) 2009-09-17 2017-09-19 Univ Ramot "peptides in the treatment of oxidative stress disorder"
US9222086B2 (en) 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
US20130023433A1 (en) 2009-09-28 2013-01-24 Yuling Luo Methods of detecting nucleic acid sequences with high specificity
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
CN102906263B (en) 2009-10-14 2017-05-31 耶路撒冷希伯来大学伊森姆研究发展公司 Composition for controlling watt mite in honeybee
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
CA2777663A1 (en) 2009-10-16 2011-04-21 University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
WO2011056688A2 (en) 2009-10-27 2011-05-12 Caris Life Sciences, Inc. Molecular profiling for personalized medicine
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel Knock-out mouse of the mo-1 gene, a gene associated with morbid obesity
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
ES2932664T3 (en) 2009-11-12 2023-01-23 Technion Res & Dev Foundation Culture media, cell cultures and methods of culturing pluripotent stem cells in the undifferentiated state
WO2011058557A1 (en) 2009-11-12 2011-05-19 Ramot At Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
GB0920089D0 (en) 2009-11-17 2009-12-30 Danisco Method
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US8592151B2 (en) * 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
WO2011064773A1 (en) 2009-11-24 2011-06-03 Collplant Ltd. Method of generating collagen fibers
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
EP2507362A2 (en) 2009-11-30 2012-10-10 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
US8835120B2 (en) 2009-12-02 2014-09-16 Abbott Laboratories Assay for cardiac troponin-T (cTnT)
US8652788B2 (en) * 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US8183002B2 (en) * 2009-12-03 2012-05-22 Abbott Laboratories Autoantibody enhanced immunoassays and kits
US20110136141A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
WO2011067745A2 (en) 2009-12-06 2011-06-09 Rosetta Green Ltd. Compositions and methods for enhancing plants resistance to abiotic stress
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
GB0922377D0 (en) 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
AR081095A1 (en) 2009-12-28 2012-06-13 Evogene Ltd POLINUCLEOTIDES AND ISOLATED POLYPEPTIDES AND METHODS TO USE THEM TO INCREASE THE PERFORMANCE OF THE PLANT, BIOMASS, GROWTH RATE, VIGOR, OIL CONTENT, TOLERANCE TO THE ABIOTIC STRESS AND EFFECTIVENESS IN THE USE OF NITROG NITROG
BR112012016203A2 (en) 2009-12-29 2019-09-24 Gamida Cell Ltd "methods for enhancing the proliferation and activity of natural killer cells"
AU2011204405B2 (en) 2010-01-05 2015-06-18 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
WO2011084882A2 (en) 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
RS63744B1 (en) 2010-01-11 2022-12-30 Biogen Ma Inc Assay for jc virus antibodies
EP2523681A1 (en) 2010-01-12 2012-11-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
EA201270701A1 (en) 2010-01-27 2013-01-30 Йеда Рисеч Энд Девелопмент Ко. Лтд. INHIBITING METAL PROTEINS ANTIBODIES
EP2529030B1 (en) 2010-01-29 2019-03-13 Advanced Cell Diagnostics, Inc. Methods of in situ detection of nucleic acids
US8574832B2 (en) 2010-02-03 2013-11-05 Massachusetts Institute Of Technology Methods for preparing sequencing libraries
AU2011212830B2 (en) 2010-02-04 2014-05-22 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
EP2533804B1 (en) 2010-02-08 2018-04-11 Agensys, Inc. Antibody drug conjugates (adc) that bind to 161p2f10b proteins
WO2011099006A2 (en) 2010-02-11 2011-08-18 Yeda Research And Development Co. Ltd. Enzymatic systems for carbon fixation and methods of generating same
AU2011219426A1 (en) 2010-02-24 2012-10-04 Ben Gurion University Of The Negev Research And Development Authority Methods for inhibiting necrosis
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en) 2010-03-04 2011-09-09 Yeda Research And Development Co. Ltd. Methods of measuring protein stability
PE20130649A1 (en) 2010-03-08 2013-07-13 Monsanto Technology Llc POLYNUCLEOTIDE MOLECULES FOR GENETIC REGULATION IN PLANTS
US9267142B2 (en) 2010-03-08 2016-02-23 Yeda Research And Development Co. Ltd. Recombinant protein production in heterologous systems
WO2011111050A2 (en) 2010-03-11 2011-09-15 Jacob Edrei Methods of generating hydrogen
WO2011114251A1 (en) 2010-03-18 2011-09-22 Danisco A/S Foodstuff
US9073990B2 (en) 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
EP2556185B1 (en) 2010-04-06 2021-02-10 Massachusetts Institute of Technology Gene-expression profiling with reduced numbers of transcript measurements
US9125931B2 (en) 2010-04-06 2015-09-08 Massachusetts Institute Of Technology Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
US8927274B2 (en) 2010-04-12 2015-01-06 Technion Research & Development Foundation Limited Populations of pancreatic progenitor cells and methods of isolating and using same
US9458438B2 (en) 2010-04-12 2016-10-04 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
WO2011129382A1 (en) 2010-04-16 2011-10-20 Abbott Japan Co. Ltd. Methods and reagents for diagnosing rheumatoid arthritis
IN2012MN02247A (en) 2010-04-18 2015-06-12 Yeda Res & Dev
BR122021002337B1 (en) 2010-04-28 2022-03-22 Evogene Ltd Method of increasing yield, biomass, growth rate, vigor, oil content, fiber yield fiber quality, abiotic stress tolerance and/or nitrogen use efficiency of a plant, and isolated nucleic acid construct
WO2011138778A2 (en) 2010-05-04 2011-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
EP2566500B1 (en) 2010-05-05 2017-04-12 Rappaport Family Institute for Research in the Medical Sciences Ccl1 for use in therapy
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
US20120190563A1 (en) 2010-05-07 2012-07-26 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
CA2798441A1 (en) 2010-05-07 2011-11-10 Abbvie Inc. Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
ES2672918T3 (en) 2010-05-13 2018-06-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Isolated populations of adult renal cells and methods to isolate and use them
WO2011146479A1 (en) 2010-05-18 2011-11-24 The Texas A&M University System Method and composition for the diagnosis and monitoring of inflammatory diseases
JP2013534515A (en) 2010-06-01 2013-09-05 モナシュ ユニバーシティ Antibody to unprocessed receptor tyrosine kinase c-MET
CN103037891A (en) 2010-06-03 2013-04-10 雷蒙特亚特特拉维夫大学有限公司 Methods of treating diabetes and compositions capable of same
WO2011154940A1 (en) 2010-06-07 2011-12-15 Osnat Ashur-Fabian Methods and kits for diagnosing conditions related to hypoxia
US9187787B2 (en) 2010-06-16 2015-11-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of diagnosing and treating cancer
WO2011158242A2 (en) 2010-06-16 2011-12-22 Futuragene Israel Ltd. Pest -resistant plants containing a combination of a spider toxin and a chitinase
US20130316338A1 (en) 2010-06-29 2013-11-28 The United States Government As Represented By The Department Of Veterans Affairs CCR6 As A Biomarker of Alzheimer's Disease
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
ES2817780T3 (en) 2010-07-12 2021-04-08 The State Of Israel Ministry Of Agriculture And Rural Development Agricultural Res Organization A R Isolated polynucleotides and methods and plants that use them to regulate the acidity of plants
EP2407242A1 (en) 2010-07-13 2012-01-18 Dublin City University Direct clone analysis and selection technology
CN103108955B (en) 2010-07-15 2015-11-25 工业研究与发展基金会有限公司 For improving the nucleic acid construct of abiotic stress tolerance in plant
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
EP2593480A2 (en) 2010-07-15 2013-05-22 Technion Research & Development Foundation Ltd. Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
US9677979B2 (en) 2010-07-16 2017-06-13 Vanderbilt University Low resource processor using surface tension valves for extracting, concentrating and detecting molecular species
ES2966088T3 (en) 2010-07-16 2024-04-18 Bioatla Inc New methods of protein evolution
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
CA2806306A1 (en) 2010-07-23 2012-01-26 Luminex Corporation Co-coupling to control reactivity of reagents in immunoassays
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
US20130130311A1 (en) 2010-07-27 2013-05-23 Yeda Research And Development Co., Ltd. Methods and systems for assessing clonality of cell cultures
US9144585B2 (en) 2010-07-27 2015-09-29 Technion Research & Development Foundation Limited Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
SG187830A1 (en) 2010-08-22 2013-03-28 Univ Ramot Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
US10457954B2 (en) 2010-08-30 2019-10-29 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
SG10202109393RA (en) 2010-09-07 2021-10-28 Technion Res & Dev Foundation Novel Methods And Culture Media For Culturing Pluripotent Stem Cells
WO2012032510A1 (en) 2010-09-07 2012-03-15 Yeda Research And Development Co. Ltd. Primers for amplifying dna and methods of selecting same
WO2012032519A2 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing parkinson's disease
US20130164288A1 (en) 2010-09-07 2013-06-27 Protalix Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
CN103270050A (en) 2010-09-08 2013-08-28 耶达研究及发展有限公司 An immunosuppressive drug combination for a stable and long term engraftment
JP5977238B2 (en) 2010-09-08 2016-08-24 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Use of anti-third party central memory T cells for anti-leukemia / lymphoma treatment
CN103210082A (en) 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 Methods of expanding and redifferentiating islet beta cells
US20130210901A1 (en) 2010-09-20 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
WO2012040168A2 (en) 2010-09-20 2012-03-29 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
HUE038908T2 (en) 2010-09-29 2018-12-28 Agensys Inc Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US9487559B2 (en) 2010-10-04 2016-11-08 Elro Pharma Sarl Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
EP2441520A1 (en) 2010-10-12 2012-04-18 Eppendorf AG Real-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2627766B1 (en) 2010-10-17 2016-05-25 Yeda Research and Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
CN107365847A (en) 2010-10-21 2017-11-21 领先细胞医疗诊断有限公司 Ultrasensitive method in situ detection nucleic acid
US20130216603A1 (en) 2010-10-27 2013-08-22 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en) 2010-10-28 2012-05-03 Yeda Research And Development Co. Ltd. Methods of generating antibodies to metalloenzymes
US20130227724A1 (en) 2010-11-03 2013-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Transgenic plants with improved saccharification yields and methods of generating same
US9410132B2 (en) 2010-11-04 2016-08-09 Ben-Gurion University Of The Negev Research And Development Authority Acyl-CoA: diacylglycerol acyltransferase 1-like gene (PtDGAT1) and uses thereof
CA2817830A1 (en) 2010-11-15 2012-05-24 Ramot At Tel Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
US10117895B2 (en) 2010-11-17 2018-11-06 Ben-Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
JP6139410B2 (en) 2010-12-02 2017-05-31 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Method for producing corneal cell and cell population containing the corneal cell
EP2463382A1 (en) 2010-12-07 2012-06-13 Enterologics, Inc. Method for identifying E. Coli M-17
US9404087B2 (en) 2010-12-15 2016-08-02 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
AR084511A1 (en) 2010-12-22 2013-05-22 Evogene Ltd POLINUCLEOTIDES AND ISOLATED POLYPEPTIDES, AND METHODS TO USE THEM TO INCREASE TOLERANCE TO ABIOTIC STRESS, PERFORMANCE, GROWTH RATE, VIGOR, BIOMASS, OIL CONTENT AND / OR EFFECTIVENESS IN THE USE OF NITROGEN
AR084358A1 (en) 2010-12-27 2013-05-08 Lilly Co Eli COMPOSITIONS AND METHODS FOR IDENTIFYING AND DIFFERING VIRAL COMPONENTS OF MULTIVALENT VACCINES OF THE “BOILING FEVER” (BOVINE RESPIRATORY DISEASE COMPLEX (BRDC))
CN103533947A (en) 2010-12-28 2014-01-22 卡梅迪斯有限公司 Plant extracts for the treatment and prevention of infections
CA2822969C (en) 2010-12-31 2018-03-13 Jay M. Short Comprehensive monoclonal antibody generation
EP3567121B1 (en) 2011-01-17 2023-08-30 Life Technologies Corporation Workflow for detection of ligands using nucleic acids
PL3272861T3 (en) 2011-01-20 2020-07-13 Protalix Ltd. Alpha-galactosidase compositions
CN103476948A (en) 2011-01-28 2013-12-25 领先细胞医疗诊断有限公司 RNAscop (TM) HPV assay for determining HPV status in head and neck cancers and cervical lesions
WO2012104851A1 (en) 2011-01-31 2012-08-09 Yeda Research And Development Co. Ltd. Methods of diagnosing disease using overlap extension pcr
JP5804395B2 (en) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー Systems and methods for diagnosis and treatment
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
US20130330349A1 (en) 2011-02-23 2013-12-12 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
US9212258B2 (en) 2011-02-23 2015-12-15 The Board Of Trustees Of The University Of Illinois Amphiphilic dendron-coils, micelles thereof and uses
BR112013022331B1 (en) 2011-03-02 2021-01-26 Futuragene Israel Ltd. nucleic acid expression vector, and method for generating a plant that comprises enhanced resistance to a bacterial pathogen
WO2012117373A1 (en) 2011-03-03 2012-09-07 Ramot At Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
CA2829110C (en) 2011-03-06 2019-01-15 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012120518A1 (en) 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
AU2012226530B2 (en) 2011-03-08 2016-12-01 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
WO2012125582A1 (en) 2011-03-11 2012-09-20 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
CN103533934B (en) 2011-03-17 2016-03-30 特尔汗什莫尔医学基础设施研究和服务公司 Be used for the treatment of the quinolone analogs of autoimmune disease
IN2013MN01438A (en) 2011-03-17 2015-06-12 Univ Ramot
EP2689033B1 (en) 2011-03-22 2017-02-01 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
WO2012127320A1 (en) 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
US20140045764A1 (en) 2011-03-24 2014-02-13 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN103476949A (en) 2011-03-28 2013-12-25 诺瓦提斯公司 Markers associated with cyclin-dependent kinase inhibitors
CA2831426C (en) 2011-04-01 2023-02-21 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
DK2694962T3 (en) 2011-04-06 2017-06-12 Ramot At Tel-Aviv Univ Ltd PROCEDURES FOR MONITORING AND ANALYSIS OF METABOLIC ACTIVITY PROFILES AND DIAGNOSTIC AND THERAPEUTICAL APPLICATIONS THEREOF
EP2694537A1 (en) 2011-04-08 2014-02-12 Danisco US Inc. Compositions
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
AU2012241521B2 (en) 2011-04-15 2016-07-14 Pluri Biotech Ltd Methods and systems for harvesting cells
WO2012145630A2 (en) 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
AR086243A1 (en) 2011-05-03 2013-11-27 Evogene Ltd POLYPEPTIDES AND POLINUCLEOTIDES ISOLATED AND METHODS FOR USE, TO INCREASE PERFORMANCE, BIOMASS, GROWTH INDEX, VIGOR, OIL CONTENT, TOLERANCE TO THE ABIOTIC STRESS OF PLANTS AND EFFICIENCY IN THE USE OF THE NITER
WO2012150600A2 (en) 2011-05-04 2012-11-08 Ramot At Tel-Aviv University Ltd. Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
CN107102135A (en) 2011-05-20 2017-08-29 阿波特日本有限公司 Immunity inspection method and reagent for reducing non-specific binding
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
HUE043339T2 (en) 2011-05-31 2019-08-28 Biogen Ma Inc Method of assessing risk of pml
CN107325164A (en) 2011-05-31 2017-11-07 和黄生物膜医疗解决方案有限公司 The scattered and disengaging of cell aggregation
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
WO2012168199A1 (en) 2011-06-06 2012-12-13 Novo Nordisk A/S Therapeutic antibodies
EP2720720B1 (en) 2011-06-14 2018-02-28 Yeda Research and Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
US20140130199A1 (en) 2011-06-23 2014-05-08 Kaiima Bio Agritech Ltd. Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
WO2013010170A1 (en) 2011-07-14 2013-01-17 Lovell Mark A Process for detection of alzheimer's disease from a serum sample
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
RU2014106125A (en) 2011-07-20 2015-08-27 Каиима Био Агритех Лтд. CORN PLANTS WITH PARTIALLY OR FULLY REPRODUCED GENOMES AND THEIR APPLICATIONS
EP2550982A1 (en) 2011-07-27 2013-01-30 Technion Research & Development Foundation Ltd. Devices for surgical applications
HUE044154T2 (en) 2011-08-04 2019-09-30 Yeda Res & Dev Micro-rna mir-15 and compositions comprising same for the treatment of corticotropin-releasing hormone- associated medical conditions
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
US20140212568A1 (en) 2011-08-14 2014-07-31 Kaiimam Bio Agritech Ltd. Durum wheat plants having a partially or fully multiplied genome and uses thereof
JP6317670B2 (en) 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
WO2013025479A1 (en) 2011-08-16 2013-02-21 Emory University Jaml specific binding agents, antibodies, and uses related thereto
EP2753367A4 (en) 2011-09-07 2015-10-14 Yeda Res & Dev Olfactory signature and odorant mixture having the same
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
ES2657552T3 (en) 2011-09-08 2018-03-05 Yeda Research And Development Co. Ltd. New risk biomarkers for lung cancer
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
WO2013040033A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
CN107739737A (en) 2011-09-13 2018-02-27 孟山都技术公司 Method and composition for Weeds distribution
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
CA2848695A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and composition for weed control comprising inhibiting ppg oxidase
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US9249467B2 (en) 2011-09-16 2016-02-02 Steven Goodison Bladder cancer detection composition, kit and associated methods
ES2683035T3 (en) 2011-10-05 2018-09-24 The Rockefeller University Dimeric bacteriophage lysines
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US10132806B2 (en) 2011-10-21 2018-11-20 Augurex Life Sciences Corp. Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
WO2013064163A1 (en) 2011-11-01 2013-05-10 Academisch Medisch Centrum Methylation markers for colorectal cancer
US9422560B2 (en) 2011-11-03 2016-08-23 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US9736998B2 (en) 2011-11-23 2017-08-22 Danziger Dan Flower Farm Otomeria plants
US9617331B2 (en) 2011-11-27 2017-04-11 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide
CN104105493A (en) 2011-12-08 2014-10-15 耶达研究及发展有限公司 Mammalian fetal pulmonary cells and therapeutic use of same
EP2795295B1 (en) 2011-12-12 2017-10-11 Step Ahead Innovations, Inc. Water-quality monitoring system
WO2013093921A1 (en) 2011-12-20 2013-06-27 Collplant Ltd. Collagen coated synthetic polymer fibers
CN105833925B (en) 2011-12-22 2018-11-13 瑞尔比奥技术有限公司 sequential lateral flow capillary device for analyte determination
US10434121B2 (en) 2011-12-22 2019-10-08 Yeda Research And Development Co. Ltd. Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2013098820A1 (en) 2011-12-28 2013-07-04 Kaiima Bio Agritech Ltd. Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013101758A1 (en) 2011-12-29 2013-07-04 Baylor Research Institute Biomarkers for kawasaki disease
US20150216998A1 (en) 2012-01-01 2015-08-06 Ramot At Tel-Aviv University Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
CA2862499C (en) 2012-01-24 2020-10-27 Cd Diagnostics, Inc. System for detecting infection in synovial fluid
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2013118120A2 (en) 2012-02-06 2013-08-15 Rosetta Green Ltd. Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
SG11201404836QA (en) 2012-02-14 2014-12-30 Opko Biolog Ltd Long-acting coagulation factors and methods of producing same
WO2013121405A1 (en) 2012-02-19 2013-08-22 Protalix Ltd. Oral unit dosage forms and uses of same for the treatment of gaucher disease
EP3401394A1 (en) 2012-02-22 2018-11-14 Exostem Biotec Ltd Generation of neural stem cells
EP2844744A2 (en) 2012-02-22 2015-03-11 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
ES2702874T3 (en) 2012-02-24 2019-03-06 Arbutus Biopharma Corp Cationic trialkyl lipids and methods for their use
JP6249966B2 (en) 2012-02-29 2017-12-20 ケモセントリックス, インコーポレイテッド Aza-aryl 1H-pyrazol-1-ylbenzenesulfonamide
WO2013128454A1 (en) 2012-03-01 2013-09-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Male sterile garlic plants, hybrid offspring of same and methods of generating and using same
CA2865486C (en) 2012-03-07 2021-03-30 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
EP2828284B1 (en) 2012-03-20 2019-05-08 Biogen MA Inc. Jcv neutralizing antibodies
EP2828280B1 (en) 2012-03-22 2018-05-02 Ramot at Tel-Aviv University Ltd. Plif multimeric peptides and uses thereof
EP2830663B1 (en) 2012-03-30 2019-02-06 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US20140178869A1 (en) 2012-04-05 2014-06-26 Advanced Cell Diagnostics, Inc. Detection of immunoglobulin light chain restriction by rna in situ hybridization
IN2014MN01886A (en) 2012-04-18 2015-07-10 Univ Ramot
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
US20130280696A1 (en) 2012-04-23 2013-10-24 Elliott Millenson Devices and methods for detecting analyte in bodily fluid
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
JP6181158B2 (en) 2012-05-09 2017-08-16 イェダ リサーチ アンド デベロップメント カンパニー リミテッド TACE prodomain variants as TNF-α inhibitors and their medical use
KR102089526B1 (en) 2012-05-10 2020-03-17 바이오아트라, 엘엘씨 Multi-specific monoclonal antibodies
US8865158B2 (en) 2012-05-22 2014-10-21 Ramot At Tel-Aviv University Ltd. Bacteriophages for reducing toxicity of bacteria
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
CA2873828A1 (en) 2012-05-24 2013-11-28 A.B. Seeds Ltd. Naked dsrna for silencing target molecules in plant seeds
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
EP2855507B1 (en) 2012-06-03 2018-01-03 Ben-Gurion University of The Negev Research and Development Authority Functionalized titanium binding peptides and implants coated with same
SG11201408054RA (en) 2012-06-04 2015-01-29 Opko Biolog Ltd Pegylated oxm variants
CN109503714A (en) 2012-06-21 2019-03-22 索伦托治疗有限公司 Antigen-binding proteins in conjunction with c-Met
EP2864358B1 (en) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
AU2013277971B2 (en) 2012-06-22 2018-11-15 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
EP2870110A1 (en) 2012-07-03 2015-05-13 Nanospun Technologies Ltd. Methods and devices for adsorption and biodegradation of petroleum
EP2870261B1 (en) 2012-07-09 2017-12-06 Novartis AG Biomarkers associated with cdk inhibitors
CA3176706A1 (en) 2012-07-11 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US20150173883A1 (en) 2012-07-18 2015-06-25 President And Fellows Of Harvard College Modification of surfaces for simultaneous repellency and targeted binding of desired moieties
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
KR102250696B1 (en) 2012-07-27 2021-05-12 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Engineering t-cell receptors
EP3594331A1 (en) 2012-07-29 2020-01-15 Yeda Research and Development Co. Ltd. Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
PL2880447T3 (en) 2012-07-31 2019-10-31 Novartis Ag Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
CN104684558A (en) 2012-07-31 2015-06-03 耶达研究及发展有限公司 Methods of diagnosing and treating motor neuron diseases
JP6362596B2 (en) 2012-08-06 2018-07-25 ブレインストーム セル セラペウティクス リミテッド Method for producing mesenchymal stem cells secreting neurotrophic factor
KR102433282B1 (en) 2012-08-23 2022-08-16 어젠시스 인코포레이티드 Antibody binding to 158p1d7 proteins
US20140068814A1 (en) 2012-09-03 2014-03-06 A.B. Seeds Ltd. Method of improving abiotic stress tolerance of plants and plants generated thereby
EP2895197B1 (en) 2012-09-12 2020-02-26 Ramot at Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
ES2776029T3 (en) 2012-10-08 2020-07-28 St Jude Childrens Res Hospital Therapies based on the control of the stability and function of regulatory T cells by means of a neuropilin-1 axis: semaphorin
WO2014057490A1 (en) 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
CA2887933A1 (en) 2012-10-12 2014-04-17 Arizona Board Of Agents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
CA2888264A1 (en) 2012-10-18 2014-04-24 Monsanto Technology Llc Methods and compositions for plant pest control
US20150354006A1 (en) 2012-10-19 2015-12-10 Novartis Ag Markers for acute lymphoblastic leukemia
US10226744B2 (en) 2012-10-19 2019-03-12 Danisco Us Inc Stabilization of biomimetic membranes
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
AU2013336237A1 (en) 2012-10-22 2015-06-11 Sabag-Rfa Ltd A system for delivering therapeutic agents into living cells and cells nuclei
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
EP3584259A1 (en) 2012-10-24 2019-12-25 Yeda Research and Development Co., Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en) 2012-10-29 2014-05-08 Yeda Research And Development Co. Ltd. Aptamers, multimeric aptamers and uses thereof
EP2922867B1 (en) 2012-11-20 2021-07-21 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2015079413A2 (en) 2013-11-28 2015-06-04 Yeda Research And Development Co. Ltd. Synaptojanin-2 inhibitors and uses thereof
IN2014MN02655A (en) 2012-11-29 2015-08-21 Yeda Res & Dev
EA032406B1 (en) 2013-01-01 2019-05-31 Эй.Би. СИДЗ ЛТД. METHODS OF INTRODUCING dsRNA TO PLANT SEEDS FOR MODULATING GENE EXPRESSION
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10047399B2 (en) 2013-01-07 2018-08-14 The Cleveland Clinic Foundation ABCA1 downregulation in prostate cancer
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014108850A2 (en) 2013-01-09 2014-07-17 Yeda Research And Development Co. Ltd. High throughput transcriptome analysis
WO2014111936A1 (en) 2013-01-17 2014-07-24 Novellusdx Ltd. Methods and systems for identifying patient specific driver mutations
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
US9411930B2 (en) 2013-02-01 2016-08-09 The Regents Of The University Of California Methods for genome assembly and haplotype phasing
WO2014121077A2 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
GB2519255B (en) 2013-02-01 2016-01-06 Univ California Methods for genome assembly and haplotype phasing
EP2950808B1 (en) 2013-02-04 2019-08-21 Ramot at Tel-Aviv University Ltd. Generation of cytotoxic tumor specific cell lines and uses thereof
US20160008282A1 (en) 2013-02-22 2016-01-14 The Board Of Trustees Of The Universityof Illinois Transdermal Drug Delivery Using Amphiphilic Dendron-Coil Micelles
US10087232B2 (en) 2013-03-06 2018-10-02 Protalix Ltd. Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
WO2014136114A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
TWI582239B (en) 2013-03-11 2017-05-11 諾華公司 Markers associated with wnt inhibitors
AR095232A1 (en) 2013-03-13 2015-09-30 Monsanto Technology Llc METHODS AND COMPOSITIONS FOR WEED CONTROL
UY35385A (en) 2013-03-13 2014-09-30 Monsanto Technology Llc ? METHODS AND COMPOSITIONS FOR WEED CONTROL ?.
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
PE20151893A1 (en) 2013-03-14 2015-12-30 Parkash Gill TREATMENT OF CANCER USING ANTIBODIES THAT BIND GRP78 ON THE CELLULAR SURFACE
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
MY193211A (en) 2013-03-15 2022-09-26 Bayer Healthcare Llc Gla domains as targeting agents
WO2014144170A1 (en) 2013-03-15 2014-09-18 The Cleveland Clinic Foundation In-vitro method for monoclonal antibody production using non-human act1 -deficient mice
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc Peptides comprising non-natural amino acids and methods of making and using the same
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US10493134B2 (en) 2013-03-21 2019-12-03 Collplant Ltd. Compositions comprising collagen and PRP for tissue regeneration
CA2906314A1 (en) 2013-03-24 2014-10-02 Biolinerx Ltd. Methods of treating myeloid leukemia
EP2978440B1 (en) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
RU2015149680A (en) 2013-04-21 2017-05-24 Йеда Ресеарч Энд Девелопмент Ко. Лтд. AGENTS TO SUPPRESS ACTIVITY AND / OR REDUCE THE NUMBER OF BCL-XL AND / OR BCL-W
WO2014174470A1 (en) 2013-04-23 2014-10-30 Yeda Research And Development Co. Ltd. Isolated naive pluripotent stem cells and methods of generating same
US9714268B2 (en) 2013-04-25 2017-07-25 Yeda Research And Development Co. Ltd. Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014176047A1 (en) 2013-04-25 2014-10-30 Novartis Ag Markers for ezh2 inhibitors
EP3848044A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
US20160115231A1 (en) 2013-05-21 2016-04-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
EP3626310A1 (en) 2013-05-27 2020-03-25 Rakuto Bio Technologies Ltd. Enzymatic system containing cosmetic compositions
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
WO2014200767A1 (en) 2013-06-12 2014-12-18 The General Hospital Corporation Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
SG10201710528WA (en) 2013-06-18 2018-01-30 Dnatrix Inc Treatment of brain cancer with oncolytic adenovirus
US9784686B2 (en) 2013-06-19 2017-10-10 Step Ahead Innovations, Inc. Aquatic environment water parameter testing systems and methods
WO2014207744A1 (en) 2013-06-24 2014-12-31 Ramot At Tel-Aviv University Ltd. Omentum based scaffold and delivery system
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
BR112016000555B1 (en) 2013-07-19 2022-12-27 Monsanto Technology Llc METHOD FOR CONTROLLING AN INFESTATION OF THE LEPTINOTARSA SPECIES IN A PLANT, INSECTICIDAL COMPOSITION AND CONSTRUCTION OF RECOMBINANT DNA
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
WO2015015489A1 (en) 2013-07-30 2015-02-05 Biolinerx Ltd. Antibody for treating diabetes and autoimmune diseases
JP6510518B2 (en) 2013-08-01 2019-05-08 アジェンシス,インコーポレイテッド Antibody-drug conjugate (ADC) that binds to the CD37 protein
CN114621346A (en) 2013-08-21 2022-06-14 德克萨斯州大学系统董事会 Compositions and methods for targeting connexin hemichannels
CN105849117B (en) 2013-08-29 2017-12-12 耶达研究及发展有限公司 The selective depressant of the hypotypes of α 2 of Na, K ATP enzyme and the purposes for reducing intraocular pressure
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
IL228284A (en) 2013-09-03 2016-12-29 Technion Res & Dev Foundation Implants composed of cellular scaffolds and a vascular pedicle
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en) 2013-09-16 2015-03-19 Plexicure Ltd. Isolated proteins capable of binding plexin-a4 and methods of producing and using same
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
WO2015049677A1 (en) 2013-10-01 2015-04-09 Kadimastem Ltd. Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
CA2925004C (en) 2013-10-03 2019-04-30 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US9476884B2 (en) 2013-10-04 2016-10-25 University Of Massachusetts Hybridization- independent labeling of repetitive DNA sequence in human chromosomes
TW201536312A (en) 2013-10-21 2015-10-01 Opko Biolog Ltd Long-acting polypeptides and methods of producing and administering same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
EP3062809B1 (en) 2013-10-31 2020-07-08 Biokine Therapeutics Ltd. A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
AR098295A1 (en) 2013-11-04 2016-05-26 Monsanto Technology Llc COMPOSITIONS AND METHODS TO CONTROL INFESTATIONS OF PESTS AND PARASITES OF THE ARTHROPODS
US20170002064A1 (en) 2013-11-08 2017-01-05 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
JP6592435B2 (en) 2013-11-20 2019-10-16 ユニバーシティー オブ アイオワ リサーチ ファウンデーション Methods and compositions for treating amyloid deposition
DK3071593T3 (en) 2013-11-22 2019-06-11 The Board Of Trustees Of The Univ Of Illionis MODIFIED HIGH AFFINITY HUMAN T-CELLE RECEPTORS
EP3074391B1 (en) 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
UA119253C2 (en) 2013-12-10 2019-05-27 Біолоджикс, Інк. Compositions and methods for virus control in varroa mite and bees
DK3080243T3 (en) 2013-12-10 2019-01-07 Yeda Res & Dev USE OF ENZYMES THAT CATALYZE PYRUVATH SYNTHESIS FROM FORMIATE AND ACETYL COA, AND BACTERIES THAT EXPRESS THIS
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
US9982229B2 (en) 2013-12-19 2018-05-29 Danisco Us Inc. Use of hydrophobins to increase gas transfer in aerobic fermentation processes
ES2709388T3 (en) 2014-01-07 2019-04-16 Bioatla Llc Protein targeting orthologs
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
MX368629B (en) 2014-01-15 2019-10-08 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides.
CN106132992B (en) 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 Antibodies against MUC 1-C/extracellular domain (MUC1-C/ECD)
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
CN106715695B (en) 2014-02-05 2020-07-31 耶达研究及发展有限公司 micro-RNAs for therapy and diagnosis and compositions comprising same
US10066014B2 (en) 2014-02-06 2018-09-04 Yeda Research And Development Co. Ltd. Anti CD84 antibodies, compositions comprising same and uses thereof
WO2015120273A1 (en) 2014-02-07 2015-08-13 The General Hospital Corporation Differential diagnosis of hepatic neoplasms
US20170101633A1 (en) 2014-02-10 2017-04-13 Protalix Ltd. Method of maintaining disease stability in a subject having gaucher's disease
JP6628253B2 (en) 2014-02-11 2020-01-08 ブレインストーム セル セラペウティクス リミテッド Method for determining cell suitability
US20150232935A1 (en) 2014-02-14 2015-08-20 The General Hospital Corporation Methods for diagnosing igg4-related disease
US20150247205A1 (en) 2014-02-28 2015-09-03 The General Hospital Corporation Diagnosis of multiple myeloma and lymphoma
CN106255882A (en) 2014-03-03 2016-12-21 耶路撒冷希伯来大学伊森姆研究发展公司 For the method and apparatus detecting Pseudomonas aeruginosa
EP2923709A1 (en) 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
BR112016022711A2 (en) 2014-04-01 2017-10-31 Monsanto Technology Llc compositions and methods for insect pest control
CA2945438C (en) 2014-04-10 2023-08-22 Bonus Therapeutics Ltd. Bone repair compositions
FI4026917T3 (en) 2014-04-14 2024-02-14 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd A method and kit for determining the death of cells or tissue or the tissue or cell origin of dna by dna methylation analysis
US10590467B2 (en) 2014-04-17 2020-03-17 Yeda Research And Development Co. Ltd. Methods and kits for analyzing DNA binding moieties attached to DNA
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
EP3137502B1 (en) 2014-04-27 2020-07-29 FameWave Ltd. Humanized antibodies against ceacam1
WO2015166492A2 (en) 2014-04-28 2015-11-05 Yeda Research And Development Co. Ltd. Microbiome response to agents
EP3140401A2 (en) 2014-05-04 2017-03-15 Forrest Innovations Ltd. Compositions for mosquito control and uses of same
EP3502698A1 (en) 2014-05-05 2019-06-26 MicroBPlex, Inc. Media elaborated with newly synthesized antibodies and uses thereof
JP6875129B2 (en) 2014-05-08 2021-05-19 ノボダイアックス, インコーポレイテッド Direct immunohistochemical assay
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US10294482B2 (en) 2014-05-22 2019-05-21 Yeda Research And Development Co. Ltd. Recombinant microorganisms capable of carbon fixation
WO2015186128A1 (en) 2014-06-02 2015-12-10 Kadimastem Ltd. Methods of inducing myelination and maturation of oligodendrocytes
US20170253881A1 (en) 2014-06-02 2017-09-07 Technion Research & Development Foundation Limited Compositions and methods of selectively inhibiting irp1 and treating inflammation
AU2015280252A1 (en) 2014-06-23 2017-01-12 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
ES2791199T3 (en) 2014-06-25 2020-11-03 Tel Hashomer Medical Res Infrastructure & Services Ltd Identification of cancer stem cell markers and their use for diagnosis and treatment
WO2015200539A1 (en) 2014-06-25 2015-12-30 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
WO2015198326A1 (en) 2014-06-26 2015-12-30 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
EP3169343B1 (en) 2014-07-15 2020-03-25 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
WO2016013008A1 (en) 2014-07-21 2016-01-28 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
CN106715719B (en) 2014-07-21 2022-08-02 福尔生物治疗有限公司 Method for determining drug response to patient specific mutations
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
AU2015296029B2 (en) 2014-08-01 2022-01-27 Dovetail Genomics, Llc Tagging nucleic acids for sequence assembly
CN111624346A (en) 2014-08-14 2020-09-04 米密德诊断学有限公司 Kit for predicting and/or determining prognosis
EA201790437A1 (en) 2014-08-22 2017-08-31 Сорренто Терапьютикс, Инк. ANTIGEN-BINDING PROTEINS CONNECTING WITH CXCR3
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev Nmda receptor antagonists for treating gaucher disease
US10759860B2 (en) 2014-09-16 2020-09-01 Synermore Biologics Co., Ltd. Anti-EGFR antibody and uses of same
WO2016042561A2 (en) 2014-09-21 2016-03-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Downregulating mir-132 for the treatment of lipid related disorders
RU2713653C2 (en) 2014-10-06 2020-02-06 Кемосентрикс, Инк. COMBINED THERAPY WITH INHIBITORS OF C-CHEMOKINE RECEPTOR 9 (CCR9) AND ANTIBODIES BLOCKING α4β7-INTEGRIN
EP3207156A1 (en) 2014-10-13 2017-08-23 Life Technologies Corporation Methods, kits & compositions for determining gene copy numbers
WO2016064887A1 (en) 2014-10-20 2016-04-28 Gen-Probe Incorporated Red blood cell lysis solution
WO2016062855A1 (en) 2014-10-24 2016-04-28 Dupont Nutrition Biosciences Aps Proline tolerant tripeptidyl peptidases and uses thereof
CN107075534A (en) 2014-10-24 2017-08-18 丹尼斯科美国公司 The method that alcohol is prepared using three peptidyl peptidases
US10570368B2 (en) 2014-11-13 2020-02-25 Enzootic Holdings Ltd. Functional sex-reversal of decapod crustacean females
EP3220945A2 (en) 2014-11-17 2017-09-27 Yeda Research and Development Co., Ltd. Methods of treating diseases related to mitochondrial function
CA2967233A1 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Method of analyzing microbiome
RU2758608C2 (en) 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Diagnostics method using hnl
EA038931B9 (en) 2014-11-20 2022-02-18 Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
JP6860483B2 (en) 2014-11-26 2021-04-14 テクノロジー イノベーション モメンタム ファンド(イスラエル)リミテッド パートナーシップTechnology Innovation Momentum Fund(israel)Limited Partnership Bacterial gene targeting reduction
EP3224363B1 (en) 2014-11-27 2021-11-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid constructs for genome editing
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US11279974B2 (en) 2014-12-01 2022-03-22 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
AU2015360694B2 (en) 2014-12-08 2021-10-14 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016092555A2 (en) 2014-12-11 2016-06-16 Yeda Research And Development Co. Ltd. Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
KR101942955B1 (en) 2014-12-23 2019-01-28 4디 파마 리서치 리미티드 Immune modulation
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
EA035925B1 (en) 2014-12-23 2020-09-01 4Д Фарма Рисерч Лимитед Polypeptide and immune modulation
AU2015373051B2 (en) 2014-12-30 2022-10-06 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
DK3240612T3 (en) 2014-12-30 2021-01-18 Cell Cure Neurosciences Ltd PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
BR112017014345A2 (en) 2014-12-30 2018-01-02 Cell Cure Neurosciences Ltd. rpe cell populations and methods of generating them
RU2017125957A (en) 2015-01-04 2019-02-04 Проталикс Лтд. MODIFIED DNA AND ITS APPLICATIONS
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
PL3256589T3 (en) 2015-01-22 2022-02-21 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US10457737B2 (en) 2015-02-09 2019-10-29 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
EP4151231A1 (en) 2015-02-13 2023-03-22 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
EP3259696A1 (en) 2015-02-17 2017-12-27 Dovetail Genomics LLC Nucleic acid sequence assembly
DK3262411T3 (en) 2015-02-25 2022-04-19 Univ Vanderbilt ANTIBODY-MEDIATED NEUTRALIZATION OF MARBURG VIRUS
WO2016135732A1 (en) 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth
AR103896A1 (en) 2015-03-09 2017-06-14 Agensys Inc ANTI-PROTEIN FLT3 ANTI-PROTEIN DRUGS (ADC)
US10781445B2 (en) 2015-03-11 2020-09-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
EP3268462B1 (en) 2015-03-11 2021-08-11 The Broad Institute, Inc. Genotype and phenotype coupling
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Anti amphiregulin antibodies, compositions comprising same and uses thereof
US11807896B2 (en) 2015-03-26 2023-11-07 Dovetail Genomics, Llc Physical linkage preservation in DNA storage
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
US9612534B2 (en) 2015-03-31 2017-04-04 Tokyo Electron Limited Exposure dose homogenization through rotation, translation, and variable processing conditions
JP2018511325A (en) 2015-03-31 2018-04-26 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. Glutamate oxaloacetate transaminase 1 (GOT1), its preparation and production method and use thereof
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
HUE057044T2 (en) 2015-04-07 2022-04-28 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
US9951144B2 (en) 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
IL255290B2 (en) 2015-04-27 2024-01-01 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
ES2911341T3 (en) 2015-04-29 2022-05-18 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Antiphytopathogenic compositions
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
EP3292219B9 (en) 2015-05-04 2022-05-18 Ramot at Tel-Aviv University Ltd. Methods and kits for fragmenting dna
CN106117288B (en) 2015-05-08 2019-10-15 生捷科技控股公司 The reversible terminator of disulfide bond connection
EP3294280A1 (en) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrin inhibitors for the treatment of cancer
US11219636B2 (en) 2015-05-17 2022-01-11 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Compositions and methods for treating cancer
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
US10849985B2 (en) 2015-05-20 2020-12-01 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
CN107847531A (en) 2015-05-21 2018-03-27 耶达研究及发展有限公司 For sanatory bacterial flora
AU2016273045B2 (en) 2015-05-29 2020-11-26 Opko Biologics Ltd. Pegylated oxyntomodulin variants
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
CN108024517A (en) 2015-06-03 2018-05-11 孟山都技术公司 For the method and composition introducing nucleic acid in plant
US10711064B2 (en) 2015-06-04 2020-07-14 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
NZ777234A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3307288B1 (en) 2015-06-15 2019-07-24 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
LT3240554T (en) 2015-06-15 2019-11-11 4D Pharma Res Ltd Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
WO2016203476A1 (en) 2015-06-18 2016-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for diagnosing and treating urothelial cancer
US10668109B2 (en) 2015-06-18 2020-06-02 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
PL3310347T3 (en) 2015-06-19 2021-12-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2016210395A1 (en) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases for protein hydrlyzates
CA2992139A1 (en) 2015-07-10 2017-01-19 West Virginia University Markers of stroke and stroke severity
DK3322425T3 (en) 2015-07-16 2023-06-12 Yeda Res & Dev GENETICLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND THE USE OF THE SAME IN IMMUNE THERAPY
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
WO2017013648A1 (en) 2015-07-19 2017-01-26 Yeda Research And Development Co. Ltd. SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
BR112018001310A2 (en) 2015-07-22 2018-09-11 Phytopharma Int Ltd bee-ingestible compositions, methods of use thereof for the production of honey and honey produced by these
EP3328995B1 (en) 2015-07-29 2021-03-31 Hadasit Medical Research Services And Development Large scale production of retinal pigment epithelial cells
EP3331546B1 (en) 2015-08-03 2023-10-04 Biokine Therapeutics Ltd. Cxcr4 inhibitor for the treatment of cancer
WO2017023929A1 (en) 2015-08-04 2017-02-09 Cd Diagnostics, Inc. Methods for detecting adverse local tissue reaction (altr) necrosis
WO2017021961A1 (en) 2015-08-04 2017-02-09 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
CN108138144A (en) 2015-08-05 2018-06-08 细胞治疗神经科学有限公司 The preparation of retinal pigment epithelium
AU2016303631B2 (en) 2015-08-05 2022-07-28 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
US10639350B2 (en) 2015-08-10 2020-05-05 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using CD24
US20180237790A1 (en) 2015-08-13 2018-08-23 Forrest Innovation Ltd. Formulations and compositions for delivery of nucleic acids to plant cells
AU2016308339A1 (en) 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017033188A1 (en) 2015-08-24 2017-03-02 Yeda Research And Development Co. Ltd. Algal oil and biofuel and methods of producing same
ES2890073T3 (en) 2015-08-25 2022-01-17 Prothena Biosciences Ltd Methods to detect phosphorylated alpha-synuclein
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
CA3035810A1 (en) 2015-09-02 2017-03-09 University Of Massachusetts Detection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids
US10765706B2 (en) 2015-09-03 2020-09-08 University Of South Florida Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
EP3347464B1 (en) 2015-09-08 2024-01-24 University of Massachusetts Dnase h activity of neisseria meningitidis cas9
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
EP3353547A1 (en) 2015-09-22 2018-08-01 Delta TM Technologies Designing customized protein-specific buffer systems
EP3356554B1 (en) 2015-09-29 2019-10-30 HTG Molecular Diagnostics, Inc. Methods for subtyping diffuse b-cell lymphoma (dlbcl)
EP3347373A1 (en) 2015-10-10 2018-07-18 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017066211A1 (en) 2015-10-12 2017-04-20 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
CA3002740A1 (en) 2015-10-19 2017-04-27 Dovetail Genomics, Llc Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection
EP3365376A1 (en) 2015-10-25 2018-08-29 Yeda Research and Development Co., Ltd. Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
US20180312805A1 (en) 2015-10-26 2018-11-01 Cell Cure Neurosciences Ltd. Preparation of Retinal Pigment Epithelium Cells
CA3002767C (en) 2015-10-27 2023-03-14 Zvi VOGEL Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
IL242380A0 (en) 2015-10-29 2016-02-01 Yeda Res & Dev A method of inducing cardiomyocytes proliferation and treating heart diseases
US20180303974A1 (en) 2015-11-03 2018-10-25 Ariel-University Research And Development Company Ltd. Compositions for regeneration and repair of neural tissue
CA3004438A1 (en) 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
WO2017081689A1 (en) 2015-11-11 2017-05-18 Ramot At Tel-Aviv University Ltd. Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2662617T3 (en) 2015-11-20 2018-04-09 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
BR112018010946A2 (en) 2015-11-30 2018-12-04 Kadimastem Ltd pancreatic endocrine cell enrichment method, pancreatic endocrine cell enriched population, diabetes treatment method and insulin production beta cell preparation method
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383418B1 (en) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2 peptides for immunotherapy
EP4059507B1 (en) 2015-12-16 2024-06-05 Ramot at Tel-Aviv University Ltd. Particles comprising decellularized omentum
JOP20200228A1 (en) 2015-12-21 2017-06-16 Novartis Ag Compositions and methods for decreasing tau expression
EP3393524B1 (en) 2015-12-22 2022-04-06 The Regents of The University of Colorado, A Body Corporate Protecting rnas from degradation using engineered viral rnas
IL260331B2 (en) 2015-12-28 2024-10-01 B G Negev Technologies And Applications Ltd At Ben Gurion Univ Composition and method for treating amyotrophic lateral sclerosis
US10828318B2 (en) 2016-01-06 2020-11-10 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017122203A1 (en) 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
CN109068605B (en) 2016-01-21 2022-11-11 以色列国家农业和农村发展农业研究组织沃尔坎尼中心 Parthenocarpic plants and methods of producing the same
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive yarn
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd Composition comprising sp1 and carbon based nanoparticles and uses thereof
CN109715821B (en) 2016-01-29 2022-09-06 索伦托药业有限公司 Antigen binding proteins that bind to PD-L1
EP3408376A1 (en) 2016-01-31 2018-12-05 Hadasit Medical Research Services and Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
WO2017134671A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US10337050B2 (en) 2016-02-11 2019-07-02 Qiagen Sciences, Llc Polyphenolic additives in sequencing by synthesis
US10036011B2 (en) 2016-02-11 2018-07-31 Qiagen Waltham, Inc. Scavenger compounds for improved sequencing-by-synthesis
WO2017138007A1 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Microbiome-based diagnosis, prediction and treatment of relapsing obesity
US20190046497A1 (en) 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
AU2017220830A1 (en) 2016-02-16 2018-09-06 Yeda Research And Development Co. Ltd. Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
US20200200735A9 (en) 2016-02-22 2020-06-25 Ursure, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
CA3014911A1 (en) 2016-02-23 2017-08-31 Dovetail Genomics, Llc Generation of phased read-sets for genome assembly and haplotype phasing
EP3420075A4 (en) 2016-02-23 2019-10-16 Chaya Brodie Generation of cancer stem cells and use thereof
BR112018015589A2 (en) 2016-02-25 2019-10-01 Dupont Nutrition Biosci Aps A method for producing protein hydrolyzate employing an aspergillus fumigatus tripeptidyl peptidase
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
KR20180133399A (en) 2016-03-01 2018-12-14 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Antibodies specific for the human polyoviral receptor (PVR)
CN114959084A (en) 2016-03-03 2022-08-30 米密德诊断学有限公司 Analysis of RNA for diagnosis of infection type
CN108883139B (en) 2016-03-04 2022-04-26 4D制药有限公司 Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
IL244649A0 (en) 2016-03-17 2016-06-30 Yeda Res & Dev Methods of isolating barrel-like proteases and identifying peptides processed thereby
CN118773299A (en) 2016-03-17 2024-10-15 西达-赛奈医疗中心 Method for diagnosing inflammatory bowel disease by RNASET2
EP3433262A4 (en) 2016-03-25 2019-11-20 Muralidhar Reddy Moola Combinatorial synthesis and biomarker development
WO2017172518A1 (en) 2016-03-29 2017-10-05 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
CN109195990A (en) 2016-03-30 2019-01-11 Musc研究发展基金会 Immunodominant proteins (GARP) treatment and diagnosis cancer are repeated by targeting glycoprotein A and the method for effective immunotherapy is provided alone or in combination
WO2017189746A1 (en) 2016-04-27 2017-11-02 Gen-Probe Incorporated Blood cell lysis reagent
WO2017194589A1 (en) 2016-05-10 2017-11-16 Vib Vzw Inhibition of tau-mediated early synaptic dysfunction
DK3455356T3 (en) 2016-05-13 2021-11-01 Dovetail Genomics Llc RECOVERY OF LONG-TERM BINDING INFORMATION FROM PRESERVED SAMPLES
CN109476764A (en) 2016-05-16 2019-03-15 哈佛大学校长及研究员协会 It is coupled at through CO2Aqueous biological molecule on plasma-activated surface
EP3463402B1 (en) 2016-05-22 2021-06-23 Yeda Research and Development Co. Ltd. Methods of using pulmonary cells for transplantation and induction of tolerance
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of agents for treating drug resistant tumors
US20190100732A1 (en) 2016-06-02 2019-04-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
EP3465200A4 (en) 2016-06-05 2020-07-08 Berg LLC Systems and methods for patient stratification and identification of potential biomarkers
WO2017212476A1 (en) 2016-06-05 2017-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Novel molecules for the treatment of inflammation
EP3468610A1 (en) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
EP3472342A1 (en) 2016-06-19 2019-04-24 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Screening for chemotherapy resistance in human haploid cells
JP7334043B2 (en) 2016-06-27 2023-08-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド Vet cells made from memory T cells
JP7112966B2 (en) 2016-06-30 2022-08-04 シーメンス ヘルシニアーズ ネイザランド ビー.ブイ. Apparatus, system and method for detecting an analyte within a bodily fluid sample containing a plurality of cells
EP4184167A1 (en) 2016-07-10 2023-05-24 MeMed Diagnostics Ltd. Early diagnosis of infections
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
US20200080050A1 (en) 2016-07-11 2020-03-12 Yaakov Nahmias Systems and methods for growing cells in vitro
IL246722A0 (en) 2016-07-11 2016-09-29 Yeda Res & Dev Combination therapy to increase endogenous nitric oxide (no) synthesis
JP7268943B2 (en) 2016-07-11 2023-05-08 ボーナス セラピューティックス リミテッド Cell composition for tissue regeneration
TW201821093A (en) 2016-07-13 2018-06-16 英商4D製藥有限公司 Compositions comprising bacterial strains
EP3484517A4 (en) 2016-07-18 2020-04-15 Ramot at Tel-Aviv University Ltd. Modular platform for targeted therapeutics
US10829528B2 (en) 2016-07-20 2020-11-10 Vib Vzw Therapeutic agents for neurological and psychiatric disorders
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
WO2018020489A1 (en) 2016-07-24 2018-02-01 Yeda Research And Development Co. Ltd. Methods and kits for analyzing dna binding moieties attached to dna
US10982252B2 (en) 2016-08-08 2021-04-20 Technology Innovation Momentum Fund (Israel) Limited Partnership Bacterial systems for analyzing ubiquitylated polypeptides
EP4033248B1 (en) 2016-08-10 2024-04-10 MeMed Diagnostics Ltd. System and method for analysis of mx1 and crp in blood
EP3497239A4 (en) 2016-08-10 2020-02-26 Ramot at Tel-Aviv University Ltd. Analysis of methylation status and copy number
IL264825B (en) 2016-08-14 2022-08-01 Univ Ramot Mesenchymal cell-derived exosomes to treat neurological disorders
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
WO2018047154A1 (en) 2016-09-07 2018-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same
EP3512943B1 (en) 2016-09-14 2023-04-12 Yeda Research and Development Co. Ltd. Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
IL248468A0 (en) 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
IL248385A0 (en) 2016-10-18 2017-02-01 Yeda Res & Dev Treatment of a circadian rhythm disorder
EP3535409B1 (en) 2016-11-04 2024-03-20 CD Diagnostics, Inc. Direct detection of microorganisms in patient samples by immunoassay
US11162129B2 (en) 2016-11-09 2021-11-02 IsoPlexis Corporation Photoprotective mixtures as imaging reagents in sequencing-by-synthesis
US20190359956A1 (en) 2016-11-10 2019-11-28 Yeda Research And Development Co. Ltd. Phosphotriesterases for treating or preventing organophosphate exposure associated damage
KR20240130832A (en) 2016-11-23 2024-08-29 케모센트릭스, 인크. Method of treating focal segmental glomerulosclerosis
US11542508B2 (en) 2016-11-28 2023-01-03 Yeda Research And Development Co. Ltd. Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
CN110199031A (en) 2016-11-29 2019-09-03 基因组影像公司 Method designed for analyzing one group of polynucleotide sequence of the particular event in interested genetic region
EP3548015A1 (en) 2016-11-30 2019-10-09 Yeda Research and Development Co. Ltd. Methods of treating liver toxicity and disorders
AU2017368911B2 (en) 2016-12-01 2022-03-10 Ramot At Tel-Aviv University Ltd. Combined treatment for nerve injuries
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
AU2017373651B2 (en) 2016-12-05 2022-03-10 Nuritas Limited Compositions comprising peptide wkdeagkplvk
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
WO2018137705A1 (en) 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof
US20190390278A1 (en) 2017-01-26 2019-12-26 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
EP3576758A4 (en) 2017-01-31 2020-12-09 Vanderbilt University Generation of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same
WO2018146162A1 (en) 2017-02-07 2018-08-16 Academisch Medisch Centrum Molecular biomarker for prognosis of sepsis patients
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods of culturing t cells and uses of same
EP3592868B1 (en) 2017-03-06 2022-11-23 Novartis AG Methods of treatment of cancer with reduced ubb expression
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US20200150125A1 (en) 2017-03-12 2020-05-14 Yeda Research And Development Co., Ltd. Methods of diagnosing and prognosing cancer
EP3595687A1 (en) 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
BR112019020953A2 (en) 2017-04-05 2020-05-05 Yeda Res & Dev ex vivo culture system and methods of using it
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Methods of treating psychiatric stress disorders
CN110831966A (en) 2017-05-10 2020-02-21 阿里埃勒科学创新有限公司 Method for purifying antibodies
ES2939298T3 (en) 2017-05-21 2023-04-20 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Combination of markers for cancer diagnosis
CN110913878A (en) 2017-05-22 2020-03-24 4D制药研究有限公司 Compositions comprising bacterial strains
WO2018216011A1 (en) 2017-05-23 2018-11-29 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
US20200109408A1 (en) 2017-05-31 2020-04-09 Tropic Biosciences UK Limited Methods of selecting cells comprising genome editing events
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
GB201708662D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing shelf-life of banana
GB201708665D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing extractability of solids from coffee beans
KR20200024158A (en) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that immunospecifically bind to BTN1A1
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
PT3638271T (en) 2017-06-14 2021-01-05 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2018229189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
DK3804737T3 (en) 2017-06-14 2022-07-25 4D Pharma Res Ltd COMPOSITIONS COMPRISING BACTERIAL STRAINS
US20200165671A1 (en) 2017-07-13 2020-05-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detecting tissue-specific dna
US11466323B2 (en) 2017-07-13 2022-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules
EP3652344A1 (en) 2017-07-13 2020-05-20 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Dna targets as tissue-specific methylation markers
WO2019018747A1 (en) 2017-07-20 2019-01-24 Trustees Of Boston University Tenofovir detection assay
EP4085919A3 (en) 2017-07-21 2023-02-08 Novartis AG Compositions and methods to treat cancer
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combination therapy for the treatment of cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses
WO2019038771A1 (en) 2017-08-23 2019-02-28 Technion Research & Development Foundation Limited Compositions and methods for improving alcohol tolerance in yeast
UA128472C2 (en) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 antibodies and methods of use thereof
WO2019042153A1 (en) 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 Recombinant bispecific antibody
JP2020533976A (en) 2017-09-05 2020-11-26 グラディエーター バイオサイエンシーズ インコーポレイテッド How to target exosomes
DE112018005145T5 (en) 2017-09-15 2020-07-23 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN TREATMENT OF CANCER
US11555199B2 (en) 2017-09-19 2023-01-17 Tropic Biosciences UK Limited Modifying the specificity of plant non-coding RNA molecules for silencing gene expression
EP3692152A4 (en) 2017-10-04 2021-12-01 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
EP3694504A4 (en) 2017-10-11 2021-07-14 ChemoCentryx, Inc. Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
CA3082365A1 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with improved properties
AR114936A1 (en) 2017-11-29 2020-11-11 Weedout Ltd COMPOSITIONS, KITS AND METHODS FOR CONTROLLING THE AMARANTHUS WEED
IL274979B2 (en) 2017-11-29 2024-07-01 Univ Ramot Methods of preventing or treating neurogenic shock
WO2019106680A1 (en) 2017-12-03 2019-06-06 Yeda Research And Development Co. Ltd. Treatment of an ischemic heart disease
CN109870581B (en) 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 Kit and method for quantitatively detecting HBsAg
CN111465406A (en) 2017-12-15 2020-07-28 先正达参股股份有限公司 Non-antibody ligands for detecting target proteins
EP3723785A1 (en) 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2019130313A1 (en) 2017-12-28 2019-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method to reproduce circadian rhythms on a microfluidic chip
WO2019156758A2 (en) 2018-01-05 2019-08-15 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
IL257269A (en) 2018-01-31 2018-04-09 Olender Tsviya Endoplasmic reticulum targeting signal
WO2019155465A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
EP3749689A1 (en) 2018-02-08 2020-12-16 Yeda Research and Development Co. Ltd Inhibitors of the 20s proteasome
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019165217A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd153 and/or cd30 in infection
WO2019162945A1 (en) 2018-02-23 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Methods for treating memory impairment and cognitive dysfunction
US20200408761A1 (en) 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
MA52416A (en) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc B7-H4 ANTIBODIES AND PROCESSES FOR USE
EP3765034A1 (en) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Treatment of a heart disease
WO2019182896A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
IL314908A (en) 2018-03-29 2024-10-01 Technion Res & Dev Foundation Vesicles comprising a pten inhibitor and uses of same
WO2019186569A1 (en) 2018-03-29 2019-10-03 Yeda Research And Development Co. Ltd. Use of electric field gradients to control gene expression
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
CN112292457A (en) 2018-04-09 2021-01-29 领先细胞医疗诊断有限公司 Method for further enhancing signal amplification for in situ detection of nucleic acids
WO2019206095A1 (en) 2018-04-24 2019-10-31 安源医药科技(上海)有限公司 Antibody against tim-3 and application thereof
GB201807192D0 (en) 2018-05-01 2018-06-13 Tropic Biosciences Uk Ltd Compositions and methods for reducing caffeine content in coffee beans
EP3788138A1 (en) 2018-05-02 2021-03-10 Novartis AG Regulators of human pluripotent stem cells and uses thereof
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
WO2019220441A1 (en) 2018-05-15 2019-11-21 Hadasit Medical Research Services And Development Ltd. Compositions and methods for treating cancer resistant to an anti-cancer agent
JP2021525233A (en) 2018-05-27 2021-09-24 バイオラインアールエックス・リミテッドBioLineRx Ltd. AGI-134 in combination with checkpoint inhibitors to treat solid tumors
CN112424365A (en) 2018-06-07 2021-02-26 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 Nucleic acid constructs and methods of use thereof
US20210337753A1 (en) 2018-06-07 2021-11-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of regenerating and transforming cannabis
EP3820498A1 (en) 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide for disease treatment
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
WO2020003311A1 (en) 2018-06-25 2020-01-02 Yeda Research And Development Co. Ltd. Systems and methods for increasing efficiency of genome editing
US20210292381A1 (en) 2018-07-04 2021-09-23 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
EP3818529A2 (en) 2018-07-08 2021-05-12 Yeda Research and Development Co. Ltd Person-specific assessment of probiotics responsiveness
AU2019301316A1 (en) 2018-07-11 2021-02-18 Kahr Medical Ltd. Sirpalpha-4-1BBL variant fusion protein and methods of use thereof
WO2020012478A2 (en) 2018-07-11 2020-01-16 Immunity Pharma Ltd. Peptide compounds and therapeutic uses of same
AU2019315054A1 (en) 2018-07-31 2021-03-18 Collplant Ltd. Tobacco transgenic event and methods for detection and use thereof
IL261156A (en) 2018-08-14 2020-02-27 Fass Deborah Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
CN113227359A (en) 2018-08-24 2021-08-06 耶达研究及发展有限公司 Methods of modulating polarization of M2 macrophages and uses thereof in therapy
KR20210061341A (en) 2018-09-13 2021-05-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Novel LILRB4 antibodies and uses thereof
US20210353611A1 (en) 2018-09-20 2021-11-18 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
WO2020065647A1 (en) 2018-09-25 2020-04-02 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
EP3856753A4 (en) 2018-09-28 2022-11-16 Centrillion Technology Holdings Corporation Disulfide-linked reversible terminators
SG11202103722TA (en) 2018-10-15 2021-05-28 Univ Massachusetts Programmable dna base editing by nme2cas9-deaminase fusion proteins
KR102554477B1 (en) 2018-10-18 2023-07-11 오클라호마 메디컬 리써치 화운데이션 Biomarkers for Systemic Lupus Erythematosus (SLE) Disease Activity Immunity Index to Characterize Disease Activity
EP3872093A4 (en) 2018-10-22 2022-10-19 Shanghai Genbase Biotechnology Co., Ltd. Anti-cldn18.2 antibody and uses thereof
CA3115887A1 (en) 2018-10-23 2020-04-30 Glycardial Diagnostics, S.L. Antibodies specific for glycosylated apoj and uses thereof
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
CN111196851B (en) 2018-11-20 2021-11-16 厦门万泰凯瑞生物技术有限公司 Specific antibody aiming at human anti-mullerian hormone and application thereof
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
CN113423465A (en) 2018-11-28 2021-09-21 俄勒冈健康与科学大学 Therapeutic factor XII antibodies
AU2019389175A1 (en) 2018-11-30 2021-06-10 Caris Mpi, Inc. Next-generation molecular profiling
KR20210109520A (en) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Antibodies and their uses
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
WO2020185312A2 (en) 2019-01-25 2020-09-17 President And Fellows Of Harvard College Compositions and method for synthesizing nucleic acids
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
IL264854A (en) 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
WO2020168162A1 (en) 2019-02-15 2020-08-20 Bio-Techne Corporation Methods for multiplex detection of nucleic acids by in situ hybridization
EP3927807A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of generating organoids for high throughput screening of drugs
EP3927378A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
CN113692225B (en) 2019-03-05 2023-04-18 以色列农业和农村发展部农业研究组织(范卡尼中心) Genome-edited birds
US20220177581A1 (en) 2019-03-11 2022-06-09 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
WO2020202142A2 (en) 2019-03-31 2020-10-08 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
JP2022528595A (en) 2019-04-16 2022-06-15 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド Anti-FXI / FXIa antibody and its use
US20200377951A1 (en) 2019-04-30 2020-12-03 Chondrial Therapeutics, Inc. Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
IL266433B (en) 2019-05-02 2020-11-30 Sagi Irit Compositions comprising the propeptide of lysyl oxidase and uses thereof
EP3969619A1 (en) 2019-05-13 2022-03-23 Yeda Research and Development Co. Ltd Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutated neopeptides
US20220213445A1 (en) 2019-05-22 2022-07-07 Hadasit Medical Research Services And Development Ltd. Methods of culturing human pluripotent cells
IT201900007222A1 (en) 2019-05-24 2020-11-24 Univ Degli Studi Di Torino COMPOSITION OF LIPOSOMES AND METHOD OF DOSAGE BASED ON THE USE OF THE SAME
GB2598520B (en) 2019-05-28 2024-07-24 Univ Shanghai Technology Composition and methods to treat ectodermal dysplasia 2, Clouston type
CA3141995A1 (en) 2019-06-12 2020-12-17 Hadasit Medical Research Services And Development Ltd. Methods of generating oligodendrocytes
WO2020255124A1 (en) 2019-06-16 2020-12-24 Yeda Research And Development Co. Ltd. Method for stabilizing intracellular rna
US20220251193A1 (en) 2019-06-27 2022-08-11 Ramot At Tel-Aviv University Ltd. Semaphorin 3a antibodies and uses thereof
WO2020264185A1 (en) 2019-06-27 2020-12-30 Dovetail Genomics, Llc Methods and compositions for proximity ligation
JP2022538647A (en) 2019-07-04 2022-09-05 ウッコ インコーポレイテッド De-epitoped alpha gliadin and its use for the management of celiac disease and gluten sensitivity
CN114375310A (en) 2019-07-11 2022-04-19 卡尔医学有限公司 Several heterodimers and several methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
WO2021009740A1 (en) 2019-07-16 2021-01-21 Ramot At Tel-Aviv University Ltd. Compositions and methods for the treatment of tuberculosis
JP2022541538A (en) 2019-07-19 2022-09-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Chimeric antigen receptor containing glypican 2 binding domain
CA3145278A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
CA3147575A1 (en) 2019-07-29 2021-02-04 Yeda Research And Development Co. Ltd. Methods of treating and diagnosing lung cancer
US20220298522A1 (en) 2019-07-30 2022-09-22 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021028909A1 (en) 2019-08-12 2021-02-18 Yeda Research And Development Co. Ltd. Dna repair blood test for predicting response of lung cancer patients to immunotherapy
MX2022002116A (en) 2019-08-20 2022-03-17 Nuritas Ltd Peptides for treating muscle atrophy.
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
US20240140988A1 (en) 2019-08-22 2024-05-02 Ariel Scientific Innovations Ltd. Scaled-up methods for purifying antibodies
WO2021038569A1 (en) 2019-08-27 2021-03-04 Yeda Research And Development Co. Ltd. Treatment of bacterial vaginosis
WO2021048852A1 (en) 2019-09-11 2021-03-18 Yeda Research And Development Co. Ltd. Methods of treating breast cancer
US20220331363A1 (en) 2019-09-20 2022-10-20 Shanghai GenBase Biotechnology Co., Ltd. Bcma-targeted antibody and chimeric antigen receptor
IL269674B (en) 2019-09-25 2020-08-31 Roy Bar Ziv Assembly of protein complexes on a chip
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220070201A (en) 2019-09-30 2022-05-30 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Anti-PD-1 antibodies and uses thereof
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
AU2020370733A1 (en) 2019-10-22 2022-05-05 Nuritas Limited Treatment of non-alcoholic fatty liver disease
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
US20240117386A1 (en) 2019-10-31 2024-04-11 Yeda Research And Development Co. Ltd. Engineered autotrophic bacteria for co2 conversion to organic materials
MX2022005678A (en) 2019-11-11 2022-10-18 Ibi Ag Innovative Bio Insecticides Ltd Insect control nanobodies and uses thereof.
AU2019474716A1 (en) 2019-11-19 2022-07-07 Protalix Ltd. Removal of constructs from transformed cells
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev Method of treating alzheimer’s disease
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
CA3161183A1 (en) 2019-12-12 2021-06-17 President And Fellows Of Harvard College Compositions and methods for light-directed biomolecular barcoding
EP4047019A4 (en) 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev Systems and methods for identifying cells that have undergone genome editing
WO2021130753A1 (en) 2019-12-22 2021-07-01 Yeda Research And Development Co. Ltd. Diagnosis of frontotemporal dementia
EP3842452A1 (en) 2019-12-26 2021-06-30 Universitat Autònoma de Barcelona Scaffold proteins and therapeutic nanoconjugates based on nidogen
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods of treating atopic dermatitis
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
CN113061165A (en) 2020-01-02 2021-07-02 厦门大学 EB virus BNLF2b gene encoding polypeptide and detection use thereof
IL272074B1 (en) 2020-01-15 2024-08-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multispecific antibodies for use in treating diseases
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Methods of treating cancer
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
WO2021152586A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy
BR102020002165A2 (en) 2020-01-31 2021-11-30 Fundação Oswaldo Cruz ANTIBODY, ITS USE, PHARMACEUTICAL COMPOSITION INCLUDING IT, METHOD OF DIAGNOSING FUNGAL INFECTIONS, DIAGNOSIS KIT OF FUNGAL INFECTIONS AND METHOD FOR TREATMENT OF FUNGAL INFECTIONS.
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP3862014A1 (en) 2020-02-07 2021-08-11 Nuritas Limited Treatment of panx1 associated diseases
IL295500A (en) 2020-02-09 2022-10-01 Nlc Pharma Ltd Rapid detection test for sars-cov-2
IL272586A (en) 2020-02-10 2021-08-31 Yeda Res & Dev Method for analyzing cell clusters
KR20220140568A (en) 2020-02-11 2022-10-18 벤더르빌트 유니버시티 Human monoclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20230012464A (en) 2020-02-25 2023-01-26 브이아이비 브이지더블유 Leucine-rich repeat kinase 2 allosteric modulator
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
EP4121441A1 (en) 2020-03-16 2023-01-25 Yeda Research and Development Co. Ltd Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
KR20220154740A (en) 2020-03-17 2022-11-22 제네반트 사이언시즈 게엠베하 Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
DK4045533T5 (en) 2020-03-26 2024-07-29 Univ Vanderbilt HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
CA3174917A1 (en) 2020-03-29 2021-10-07 Yeda Research And Development Co. Ltd. Variants of beta-glucocerebrosidase for use in treating gaucher disease
EP4125440A1 (en) 2020-03-31 2023-02-08 Biomuse Ltd. Bacteria for the prevention and treatment of smoke-induced lung damage
TW202203916A (en) 2020-03-31 2022-02-01 美商卡默森屈有限公司 Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies
EP4133107A1 (en) 2020-04-06 2023-02-15 Yeda Research and Development Co. Ltd Methods of diagnosing cancer and predicting responsiveness to therapy
WO2021205459A1 (en) 2020-04-07 2021-10-14 Ramot At Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof
US20230135456A1 (en) 2020-04-13 2023-05-04 Exoprother Medical Ltd. Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
KR20230002943A9 (en) 2020-04-22 2024-04-26 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Isothermal methods, compositions, kits, and systems for nucleic acid detection
WO2021229577A1 (en) 2020-05-12 2021-11-18 Collplant Ltd. Collagen as a delivery tool for metal-based anti-viral agents
AU2021270940A1 (en) 2020-05-15 2022-12-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody drug conjugate, preparation method therefor and use thereof
IL274811B (en) 2020-05-20 2021-05-31 Yeda Res & Dev Indexing spatial information for a single-cell downstream applications
US20230235080A1 (en) 2020-06-03 2023-07-27 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
EP4168438A4 (en) 2020-06-22 2024-07-10 Univ Ramot Multi subunit protein modules, cells expressing same and uses thereof
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev Mage-a1 specific t cell receptor and uses thereof
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
WO2022038536A1 (en) 2020-08-18 2022-02-24 International Rice Research Institute Methods of increasing outcrossing rates in gramineae
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
AU2021337687A1 (en) 2020-09-04 2023-03-23 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
IL277488A (en) 2020-09-21 2022-04-01 Yeda Res & Dev Method for modulating weight
WO2022064494A2 (en) 2020-09-23 2022-03-31 Yeda Research And Development Co. Ltd. Methods and compositions for treating coronaviral infections
IL277743A (en) 2020-10-01 2022-04-01 Yeda Res & Dev Method of diagnosing breast cancer
US20230374447A1 (en) 2020-10-05 2023-11-23 Protalix Ltd. Dicer-like knock-out plant cells
CN116635056A (en) 2020-10-07 2023-08-22 波塔力克斯有限公司 Long-acting deoxyribonuclease
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for rna editing and methods of using same
IL302594A (en) 2020-11-09 2023-07-01 1E Therapeutics Ltd Catalytic sequence based methods of treating or preventing bacterial infections
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
US20230416314A1 (en) 2020-11-26 2023-12-28 Ukko Inc. Modified high molecular weight glutenin subunit and uses thereof
CA3200167A1 (en) 2020-12-04 2022-06-09 Jonathan S. Wall Method for diagnosing amyloid diseases
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
AU2021411103A1 (en) 2020-12-28 2023-07-13 1E Therapeutics, Ltd. P21 mrna target areas for silencing
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
CA3203886A1 (en) 2020-12-31 2022-07-07 Yanni CONG Human lifr antigen binding protein, preparation method therefor, and application thereof
EP4274886A2 (en) 2021-01-10 2023-11-15 Supermeat the Essence of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
US20240083843A1 (en) 2021-01-14 2024-03-14 Yeda Research And Development Co. Ltd. Methods of producing vitamin d
IL280340B (en) 2021-01-21 2022-04-01 Yeda Res & Dev Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
WO2022159984A1 (en) 2021-01-22 2022-07-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4257154A1 (en) 2021-02-09 2023-10-11 Medilink Therapeutics (Suzhou) Co., Ltd. Bioactive substance conjugate, preparation method therefor and use thereof
IL305315A (en) 2021-02-18 2023-10-01 Yeda res & development co ltd Method of generating vaccines
WO2022175951A1 (en) 2021-02-18 2022-08-25 Yeda Research And Development Co. Ltd. Genetically modified bacteria for generating vaccines
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022183502A1 (en) 2021-03-05 2022-09-09 上海吉倍生物技术有限公司 Anti-cldn6 antibody and use thereof
TW202302155A (en) 2021-03-08 2023-01-16 美商伊繆諾金公司 Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
CA3207635A1 (en) 2021-03-09 2022-09-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ror1 binding protein and use thereof
IL281561A (en) 2021-03-16 2022-10-01 Yeda Res & Dev Methods and devices for ex-utero mouse embryonic development
JP2024514252A (en) 2021-03-30 2024-03-29 バイオエムエックス・リミテッド PSEUDOMONAS bacteriophage and its use
IL307528A (en) 2021-04-06 2023-12-01 Bpgbio Inc Protein markers for the prognosis of breast cancer progression
EP4320440A1 (en) 2021-04-06 2024-02-14 BPGbio, Inc. Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
US20230059578A1 (en) 2021-04-06 2023-02-23 Berg Llc Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
JP2024514194A (en) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド,コーク PSG1 for use in the treatment of osteoarthritis
CA3214581A1 (en) 2021-04-14 2022-10-20 Tom Moore Treatment of cerebrovascular events and neurological disorders
JP2024515726A (en) 2021-04-19 2024-04-10 テンプル セラピューティクス ビーブイ Methods for detecting or treating endometrial and ovarian hyperproliferative disorders - Patents.com
EP4337764A1 (en) 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease
WO2022259242A1 (en) 2021-06-06 2022-12-15 Yeda Research And Development Co. Ltd. Combined treatment for cancer
AU2022294310A1 (en) 2021-06-13 2024-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming human cells
KR20240035997A (en) 2021-06-16 2024-03-19 시드엑스 테크놀로지스 인코포레이티드 Methods for selecting Matiola seeds
NL2028466B1 (en) 2021-06-16 2022-12-21 Sakata Holland B V Methods of sorting matthiola seeds
JP2024524924A (en) 2021-07-02 2024-07-09 トロピック バイオサイエンシーズ ユーケー リミテッド Delaying or preventing browning in banana fruit
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
EP4373919A1 (en) 2021-07-18 2024-05-29 Gamida-Cell Ltd. Therapeutic nk cell populations
WO2023002492A1 (en) 2021-07-22 2023-01-26 Yeda Research And Development Co. Ltd. Codon optimization of nucleic acids
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4380973A2 (en) 2021-08-02 2024-06-12 Yeda Research and Development Co. Ltd. Anti-matrix metalloproteinase-14 antibodies for the treatment of cancer
KR20240040770A (en) 2021-08-03 2024-03-28 제니시티 리미티드 Engineered TCR complexes and methods of using the same
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
US20240358828A1 (en) 2021-08-10 2024-10-31 Gamida Cell Ltd. Engineered nk cells, methods of their production and uses thereof
GB202112866D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to fusarium wilt in a banana
GB202112865D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to black sigatoka disease in banana
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in treating diseases
CA3236778A1 (en) 2021-11-02 2023-05-11 Erik SONTHEIMER Nme2cas9 inlaid domain fusion proteins
PE20241755A1 (en) 2021-11-19 2024-08-28 Mirobio Ltd ENGINEERED PD-1 ANTIBODIES AND THEIR USES
WO2023105526A1 (en) 2021-12-08 2023-06-15 Yeda Research And Development Co. Ltd. Multipotent lung progenitor cells for lung regeneration
KR20240137076A (en) 2022-01-25 2024-09-19 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 Antibodies, conjugates and uses thereof to Her3
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023144798A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
EP4238988A1 (en) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antibodies against sars-cov-2 and uses thereof
CN114853890B (en) 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 PRLR antigen binding protein and preparation method and application thereof
TW202405011A (en) 2022-04-01 2024-02-01 美國德州系統大學評議委員會 Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
WO2023196937A1 (en) 2022-04-06 2023-10-12 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin replacement therapy
WO2023196866A1 (en) 2022-04-06 2023-10-12 Mirobio Limited Engineered cd200r antibodies and uses thereof
WO2023209708A1 (en) 2022-04-25 2023-11-02 Yeda Research And Development Co. Ltd. Compositions for altering cyclic adp-ribose secondary messenger signalling
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2023239710A1 (en) 2022-06-08 2023-12-14 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024038160A1 (en) 2022-08-18 2024-02-22 Vib Vzw Means and methods to modulate neuron excitability
WO2024054469A1 (en) 2022-09-08 2024-03-14 Onkure, Inc. Isoquinolones as pi3k inhibitors
WO2024064024A1 (en) 2022-09-19 2024-03-28 Onkure, Inc. ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2024064002A1 (en) 2022-09-20 2024-03-28 Onkure, Inc. Hdac inhibitor oki-179 for the treatment of cancers resulting from a mapk pathway mutation
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024081345A1 (en) 2022-10-14 2024-04-18 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury
WO2024102466A2 (en) 2022-11-11 2024-05-16 Igan Biosciences Iga protease polypeptide agents
WO2024124041A1 (en) 2022-12-07 2024-06-13 Advanced Cell Diagnostics, Inc. Multiplexed detection of nucleic acid targets
WO2024178172A1 (en) 2023-02-23 2024-08-29 University Of Rochester Agents and methods for making closed-end dna thread molecules
WO2024213648A1 (en) 2023-04-11 2024-10-17 Sterling Ip Pte. Ltd. Treatment of haematological cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615222A (en) * 1968-09-04 1971-10-26 New England Nuclear Corp Method and apparatus for measuring the amount of a component in a biological fluid
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies

Also Published As

Publication number Publication date
FR2113733A5 (en) 1972-06-23
GB1348935A (en) 1974-03-27
SE451162B (en) 1987-09-07
BE775187A (en) 1972-03-01
AU3508271A (en) 1973-05-03
US3850752A (en) 1974-11-26
DE2155658B2 (en) 1976-08-05
NL154598B (en) 1977-09-15
FI54033B (en) 1978-05-31
AU468060B2 (en) 1975-12-18
CA967464A (en) 1975-05-13
NL7016396A (en) 1972-05-15
ES396741A1 (en) 1975-05-16
FI54033C (en) 1978-09-11
DK140268B (en) 1979-07-16
BR7107459D0 (en) 1973-06-21
ZA717192B (en) 1972-08-30
IT986829B (en) 1975-01-30
DE2155658A1 (en) 1972-05-18
DK140268C (en) 1979-12-10
DE2155658C3 (en) 1978-09-14

Similar Documents

Publication Publication Date Title
DE2155658C3 (en) Method for the detection and determination of a hapten or its antibody
DE2323467C2 (en) Methods for the detection and determination of haptens
DE2743444C3 (en) Immunochemical measuring method and reagent for its implementation
DE2164768B2 (en) METHOD OF DETECTION AND DETERMINATION OF A COMPONENT OF THE REACTION BETWEEN SPECIFIC BINDING PROTEINS AND BINDING SUBSTANCES
DE2206103A1 (en) Method for detecting and determining a component of the reaction between specifically binding proteins and the substances which are specifically bound by these proteins
EP0280211B1 (en) Method for determination of antibodies
DE3650513T2 (en) Delayed immunological test in solid phase
DE68910758T2 (en) Determination with affinity substances and HPLC step.
DE2902676C2 (en) Method of analyzing an antigen other than RF or C1q in serum using an immunoassay
CH645465A5 (en) IMMUNIOLOGICAL METHOD FOR QUANTITATIVE DETERMINATION OF HAPTENEN AND TEST EQUIPMENT FOR IMPLEMENTING THE METHOD.
DE3205849C2 (en) Reagent for immunological determination
DE3136579C2 (en)
DE2548427A1 (en) UNIT TRAINED IMMUNO ANALYSIS EQUIPMENT IN A FIXED PHASE AND PROCESS FOR ITS MANUFACTURING
EP0008432A1 (en) Immunological determination process
DE3224837A1 (en) CARRIER-TIED IMMUNOSORPTION AGENT
DE2744836A1 (en) IMMUNCHEMICAL MEASURING METHOD
DE2608667A1 (en) SOLIDS DIAGNOSTIC REAGENT AND METHOD FOR MANUFACTURING THEREOF
EP0001223A2 (en) Latex coated with a polyhydroxy compound, process for the preparation of this latex, immunological reagent containing this latex, process for the preparation of this reagent, application of this reagent, testing procedure utilising this reagent and reagent kit containing this reagent
DE69232801T2 (en) SEPARATION PROCESS
DE3433652A1 (en) IMMUNCHEMICAL MEASUREMENT METHOD FOR HAPTENES AND PROTEINS
DE3822750A1 (en) Method for determining a specific binding substance
DE69328727T2 (en) IMMUNOLOGICAL DETECTION METHOD USING TWO DETERMINABLE MARKERS
CN104031886B (en) A kind of immunomagnetic beads purification-enzyme linked immune assay detects method and the special monoclonal antibody thereof of monensin
DE3018593A1 (en) METHOD FOR THE QUANTITATIVE DETERMINATION OF CYCLIC NUCLEOTIDES
DE69008178T2 (en) ANALYSIS OF VITAMIN B12.

Legal Events

Date Code Title Description
PL Patent ceased